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Abstract 
Aberrant glycosylation in cancer cells can often lead to an increase in the exposure 
of unusual glycan structures. The presence of these structures can be exploited by 
engineering glycan-binding proteins as novel tools for the characterisation of 
glycoproteins bearing cancer-associated glycan structures. The carbohydrate-
recognition domain (CRD) of a rat serum mannose-binding protein (MBP) has been 
modified to mimic the glycan-specificity of a galactose-binding C-type lectin. Galactose-
binding MBP (GalMBP) binds selectively to cancer-associated glycan structures on an 
array of glycans, including Lewis-type structures and T antigen. 
GalMBP binding to breast cancer cell lines has been demonstrated and GalMBP 
ligands on these cell lines have been purified on affinity columns of immobilised GalMBP. 
Analysis and purification of GalMBP ligands from MCF7 cell membranes led to the 
identification of a restricted population of high molecular weight glycoproteins. 
Proteomic and glycomic analysis of these glycoproteins by mass spectrometry showed 
that they are forms of CD98hc that bear glycans displaying heavily fucosylated termini, 
including Lewisx and Lewisy structures.  Glycoproteomic analysis of a panel of commonly 
studied breast cancer cell lines reveals wide variations in the levels of Lewisx and the T 
antigen as well as the proteins that they are carried on. Proteins identified in multiple cell 
lines by GalMBP, including the mucin MUC-1 bearing T antigen and CD98hc, may 
represent common cancer-cell surface targets for GalMBP.  
The use of GalMBP as a proteomic tool for characterisation of glycoproteins bearing 
Lewisx has also been demonstrated on a panel of Hodgkin’s Reed-Sternberg cell lines. 
Identification of common protein carriers of Lewisx among different cell lines including 
CD98hc and ICAM-1 provides information about the likely role of these structures in the 
pathology of Hodgkin's Lymphomas and supports the previous finding that CD98hc is a 
novel protein carrier of Lewisx structures. 
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Chapter 1 
General introduction 
 
1.1 Biochemical, genetic and structural characterisation of mannose-binding 
proteins 
 
1.11 Introduction to mannose-binding protein 
Clearance of pathogens by the innate immune system of animals provides a 
vital initial defense against infection. Recognition of pathogens by innate immune 
molecules often involves the identification of distinct structural patterns present on 
their cell surface. One molecule that acts as a pattern recognition receptor is serum 
mannose binding protein (MBP), also referred to as mannose-binding lectin and 
mannan-binding lectin (Thiel, 2007).  
 MBP is a member of the C-type lectin family of sugar-binding proteins that 
contain one or more C-type lectin domains involved in Ca2+-dependent carbohydrate 
recognition (Drickamer and Taylor, 1993). MBP binds to appropriately spaced 
mannose and mannose-related sugars that are not commonly found on the cell 
surface of mammalian cells but are present on the cell surface of many 
microorganisms, such as bacteria and fungi, and are also present on non-self 
components such as apoptotic cells. Once bound, MBP targets pathogens for 
clearance by phagocytic cells of the innate immune system (Gadjeva et al., 2004a).  
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The C-type lectin family can be split into several subgroups that are 
distinguished by their domain architectures. MBP belongs to a subgroup of C-type 
lectins referred to as collectins (Gupta and Surolia, 2007; Holmskov et al., 1994). In 
addition to MBP, there are four other collectins found in humans, two surfactant 
proteins (SP-A and SP-D) and two less well characterised proteins referred to as 
collectins-L1 and K1 (CL-L1 and CL-K1) (Gupta and Surolia, 2007). An additional 
three members; conglutinin, CL-43 and CL-46, are found in Bovidae only (Holmskov 
et al., 1994). The C-type lectin receptor SRCL has been referred to as collectin P-1 
(CL-P1) but is more closely related to the scavenger family of proteins (Nakamura et 
al., 2001; Ohtani et al., 2001). MBP, SP-A and SP-D are all thought to have roles in 
innate immune defence against microorganisms, MBP as a molecule expressed in 
liver and secreted as a serum protein and SP-A and SP-D as components of 
pulmonary surfactant (Clark et al., 2000; Hickling et al., 2004; Weis et al., 1998). 
 
1.1.1 Expression of MBPs in mammals  
Two closely related mannose-binding proteins, known as MBP-A and MBP-C, 
have been identified in mammals. Both proteins are predominantly expressed in the 
liver (Ezekowitz, 1988). In rabbits and rodents both mannose-binding proteins are 
expressed with MBP-A the predominant form present in serum and MBP-C mostly 
retained in the liver (Kozutsumi et al., 1981). The expression profile differs in 
humans, where only MBP-C is expressed as a protein. Humans appear to produce 
both serum and liver-specific forms of MBP from one mRNA transcript through post-
translational modifications (Ma et al., 1997). The gene encoding human MBP-A is 
expressed as a pseudogene containing stop codons in the exon coding for the neck 
domain (Guo et al., 1998). 
The serum levels of MBP range broadly between 5 ng/ml and 10 µg/ml in the 
human population, with levels remaining relatively constant through life (Thiel et al., 
2006). Several responsive elements are present in the promoter region upstream of 
the human MBP gene including those found in genes encoding the acute-phase 
proteins serum amyloid protein and C-reactive protein, leading to the suggestion that 
MBP may act as an acute-phase response protein (Taylor et al., 1989). 
Experimentally, a three-fold increase in MBP levels was detected in patients following 
trauma or malarial infection (Thiel et al., 1992). This increase is considerably lower, 
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and the response much slower, than for other acute-phase proteins (Janeway et al., 
2001).  
 
1.1.2 MBP domain organisation 
The primary structure of an MBP polypeptide contains four discrete regions 
(Drickamer et al., 1986): an N-terminal cysteine-rich region, a collagenous region, a 
neck region and a C-type carbohydrate-recognition domain (CRD) (Figure 1.1A). 
Three MBP polypeptides oligomerise in a C-terminal to N-terminal direction through 
the formation of α-helical coiled coils in the three neck regions followed by assembly 
of the collagenous tails (Wallis and Drickamer, 1997). The resulting trimer forms the 
basic structural unit of mannose-binding proteins (Figure 1B). Formation of the 
collagen domain is initiated through interactions in the neck regions and is further 
stabilised by interchain disulphide bonds in the N-terminal cysteine-rich region (Wallis 
and Drickamer, 1997). The collagen domain of MBP contains several features and 
modifications typically found in vertebrate collagens. This region of each MBP 
polypeptide contains 18-20 repeats of the Gly-Xaa-Yaa consensus sequence 
commonly associated with collagens and is susceptible to enzymatic digestion with 
collagenase (Drickamer et al., 1986). Several proline and lysine residues within the 
collagen repeat sequence are hydroxylated post-translationally to hydroxyproline and 
hydroxylysine and the hydroxylysine residues undergo glycosylation to form 
hydroxylgalactosylhydroxylysine and most commonly glucosylgalactosyl- 
hydroxylysine (Colley and Baenziger, 1987a). Disruption of these modifications 
affects the stability of the collagen helix and the ability of serum MBP to form higher 
order oligomers (Colley and Baenziger, 1987b; Ma et al., 1997). 
Unlike liver-specific MBP-C, which consists exclusively as a single trimeric unit, 
serum MBPs adopt distinct higher order structures (Wallis and Drickamer, 1999). 
MBP trimers oligomerise through interchain disulphide bonds in the cysteine-rich N-
terminal domain and interactions in the N-terminal region of the collagen domain, that 
are thought to include electrostatic interactions between charged residues in the 
collagen helix (Wallis and Drickamer, 1999). The presence of glycosylated lysine 
residues in the collagen helix also influences the formation of higher order structures 
(Ma et al., 1997; Wallis and Cheng, 1999). Serum MBPs form a heterogeneous 
mixture of higher order oligomers. Analysis of rat MBP-A by SDS-PAGE reveals that 
the principal structures present consist of dimers and trimers of the trimeric subunit, 
3
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Figure 1.1 Primary structure and domain organisation of human MBP. A, The primary 
structure of human MBP with discrete regions indicated. Collagen repeat sequences are 
alternately coloured blue and purple, with the interruption to the sequence coloured orange. 
The sites of polymorphic variants are highlighted in yellow. B, Three polypeptide chains 
oligomerise through interactions between neck and collagen domains to form trimers, which 
are further stabilised by intrachain disulphide bonds. C, Trimers can further oligomerise 
through interchain disulphide-bonding, creating molecules containing between 6 and 18 
polypeptide chains and giving MBP a characteristic bouquet-like structure
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with lower levels of tetramer and monomer also present (Wallis and Cheng, 1999). 
SDS-PAGE and electron microscopy shows human serum MBP forms larger 
structures, up to hexamers of the trimeric subunit (Lu et al., 1990). The association of 
two or more MBP trimers creates a tertiary structure in which the collagen and neck 
domains of each trimeric subunit project away from the N-terminal domain, forming 
‘stalks’ with globular CRDs at the C termini (Figure 1C). An interruption in the Gly-X-
Y repeat sequence of the collagen domain of each MBP trimer induces a kink that 
projects the CRDs of MBP trimers away from each other and gives a bouquet-like 
structure to the molecule. 
The association of trimeric subunits occurs during assembly of the protein and is 
fixed when the protein is secreted; no self-association is evident at high protein 
concentrations (Wallis and Drickamer, 1999). Control of association may involve the 
derivitisation of free cysteine residues that have not participated in either intrachain 
or interchain disulphide bonding, fixing the protein in a particular composition. 
 
1.1.3 MBP polymorphisms 
Several allelic variants are present in the promoter region and the 5’ 
untranslated region of exon 1 of the gene encoding human MBP that are partially 
linked with variations in the level of expression of protein (Gadjeva et al., 2004b; 
Madsen et al., 1995). Single base mutations occur at positions -550, -221 and -66, 
which are referred to as H/L, X/Y and P/Q variants. HYP and LYQ haplotypes are 
associated with high MBP levels whereas LXP is associated with low levels of MBP. 
The variation in serum levels of MBP between individuals with identical haplotypes 
indicates that other unknown mechanisms also affect MBP levels.  
Three polymorphisms have also been identified at codons 52, 54 and 57 in exon 
1 of human MBP; which lead to amino acid changes in the collagen region of the 
protein. The mutation at codon 52 leads to the replacement of an arginine to a 
cysteine residue (Madsen et al., 1994) and G to A mutations at codons 54 and 57 
replace glycine residues with aspartic acid and glutamic acid residues respectively 
(Lipscombe et al., 1992; Sumiya et al., 1991). All three mutations have been 
associated with individuals who are immunodeficient (Summerfield et al., 1997; 
Turner, 1996).  
MBP variants all exhibit alterations in oligomeric structure (Wallis and Cheng, 
1999). The cysteine mutation severely disrupts the ability of MBP to form higher 
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order oligomers by affecting the pattern of intrachain disulphide bonds in MBP 
monomers (Wallis and Cheng, 1999). MBP variants containing the cysteine mutant 
predominantly form monomers and dimers of the trimeric unit. The two mutations of 
glycine residues affect the stability of the collagen helix (Wallis et al., 2004) and the 
interaction between rat MBP-A and its associated serine proteases (MASPs) (see 
Section 1.4) due to the introduction of bulky acidic side chains disrupting the collagen 
triple-helical structure. In addition to the reduced stability of the collagen region, the 
mutation at codon 57 affects the ability of MBP to activate MASPs. The mutation is 
thought to disrupt structural changes in the hinge region of the collagen domain that 
occur upon binding of MBP to surfaces which are proposed to be responsible for 
MASP activation (Wallis et al., 2004).  
Individuals either heterozygous or homozygous for MBP mutations have 
significantly lower levels of serum MBP, which has been attributed to impaired 
secretion and the increased rate of turnover of the protein (Heise et al., 2000; Naito 
et al., 1999). The disruption of post-translational modifications of lysine caused by the 
close proximity of the two glycine mutations to modified lysine residues has been 
proposed to disrupt the secretion of the protein. The rate of turnover for the glycine to 
aspartic acid variant in plasma was found to be twice that of wild-type MBP (Naito et 
al., 1999). This increased turnover is proposed to be due to increased susceptibility 
of mutant MBPs to protease degradation (Butler et al., 2002). However, the MBP-
specific antibodies used to detect serum levels of MBP in many studies show 
increased affinity toward higher order MBP oligomers, suggesting that the difference 
in MBP levels frequently detected may in part reflect the reduction in higher order 
oligomers present (Garred et al., 2003b).  
 
1.1.4 Structural analysis of the C-type lectin fold 
Members of the C-type lectin family of proteins contain one or more C-type 
lectin domains. These domains are composed of approximately 120 amino acids and 
are responsible for Ca2+-dependent carbohydrate binding. The crystal structure of the 
CRD from rat MBP-A was the first C-type lectin domain to be solved and has served 
as the archetypal member when describing CRDs in other proteins (Weis et al., 
1991). The domain has dimensions of approximately 40 by 25 by 25 Å and consists 
of two α helices, 5 β strands and four loop regions (Figure 1.2A). The fold is 
stabilised by two hydrophobic cores and two disulphide bonds formed from four 
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Figure 1.2 Crystal structure of the CRD of rat MBP-A. A, Overview of the complete structure 
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with helices, sheets and loops labelled. B, Detailed view of the Ca -binding sites, with amino 
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acids responsible for Ca  ligation labelled.This figure was prepared from entry 2MSB in the 
Protein Databank using PyMOL version 0.99.   
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conserved cysteine residues, one linking the first α helix to the last β strand and the 
other the third β strand to the loop following the fourth β strand. The loop regions are 
stabilised by residues contributing to one of the two hydrophobic cores and through 
binding to two Ca2+ ions, principally via side chain carboxylate groups. Ca2+ ions are 
ligated at one site (Ca2+ site 1) through interactions with Asp161 and Glu165 from 
loop 1 and Asp188 and Asp194 from loop 4. Ca2+ ions in the second binding site 
(Ca2+ site 2) are ligated to Glu185 from loop 3, Asn187 and Glu193 from loop 4 and 
Asn205 and Asp206 from the fourth β strand (Figure 1.2B).  
 Mutagenesis of residues directly involved in Ca2+ ligation eliminates sugar-
binding and mutagenesis of many hydrophobic residues involved in the formation of 
the hydrophobic cores alters the affinity for Ca2+, indicating their importance in 
stabilising the loop regions (Quesenberry and Drickamer, 1992). In general sugar 
binding and Ca2+ ligation are not affected by mutations to surface-exposed residues. 
Alignments of the primary structures of CRDs from other members of the C-type 
lectin family shows residues that are associated with Ca2+ ligation, disulphide bond 
formation and the formation of the two hydrophobic cores in MBP-A are conserved, 
highlighting their importance in the formation of the fold (Drickamer, 1993; Drickamer 
and Taylor, 1993). 
 
1.1.5 Carbohydrate-binding by MBP-A 
MBP binds hexoses containing equatorial hydroxyl substituents at the 3 and 4 
positions, including glucose, mannose, fucose and N-acetylglucosamine (GlcNAc). 
Structural analysis of the CRD of rat MBP-A in complex with an oligosaccharide 
consisting of five mannose units shows that only the terminal mannose residues of 
the glycan interacts with the protein (Weis et al., 1992). The remaining mannose 
residues project away from the CRD with no other significant interactions occurring. 
The key interaction between MBP-A and mannose consists of the direct ligation of 
the Ca2+ bound at Ca2+ site 2 of MBP-A with lone electron pairs from the 3- and 4-
hydroxyl groups of the sugar (Figure 1.3). Further direct interactions between protein 
and ligand involve Glu185, Asn187, Glu193 and Asn205, which are also Ca2+ ligands: 
the remaining lone electron pairs of the 3- and 4-hydroxyl groups accept hydrogen 
bonds from protons on asparagine side chain amides and the hydroxyl protons 
donate hydrogen bonds to the carboxylate oxygens from glutamic acid residues 
(Figure 1.3).  
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Figure 1.3 Structure of the sugar-binding site of rat MBP-A with bound mannose. Carbon, 
2+
nitrogen and oxygen atoms are outlined in green, blue and red respectively. Ca  is shown as a 
large light blue sphere. Solid lines represent coordination bonds with dashed lines representing 
hydrogen bonds. This figure is adapted from Taylor and Drickamer, 2003, which was prepared 
from entry 2MSB in the Protein Databank using Molscript (Kraulis, 1991). 
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Few other interactions between protein and ligand are visible in the crystal 
structure, with van der Waals interactions between the 4-carbon of mannose and the 
β-carbon of His189 being the only other interaction that contributes significantly to the 
energetics of binding (Iobst et al., 1994). The lack of other interactions between 
protein and sugar highlights the critical nature of Ca2+ in sugar ligation and explains 
the broad carbohydrate specificity of MBP-A.  
 
1.1.6 Structural analysis of the MBP trimers 
A fragment consisting of the CRD and C-terminal neck region of MBP forms a 
stable trimer, the structure of which has been determined for both the rat and human 
proteins (Sheriff et al., 1994; Weis and Drickamer, 1994) (Figure 1.4). Trimerisation is 
mediated through the formation of a parallel coiled coil of α helices in the neck 
region. However, the hydrophobic interface between the C-terminal region of the 
neck and residues from the CRD of an adjacent chain provides a large degree of 
stabilisation to the oligomer so that the neck region in isolation is unable to trimerise. 
This interaction between neck and CRD serves to lock the carbohydrate-binding 
domains in the fixed position that is required to generate the biological specificity 
observed.  
 
 
1.2 Carbohydrate binding by other C-type lectins 
Formation of a ternary complex of carbohydrate, Ca2+ and protein is the driving 
force for carbohydrate binding by all C-type lectins (Weis and Drickamer, 1996). 
Although Ca2+-dependent sugar binding is conserved, members of the C-type lectin 
family bind a wide array of carbohydrates due to subtle changes in the local 
environment of the binding site. Sugar specificity falls broadly into two groups: those 
that bind hexoses such as mannose, glucose and fucose, which contain 4-hydroxyl 
groups in the equatorial position, and those that bind hexoses such as galactose and 
N-acetylgalactosamine (GalNAc), which contain 4-hydroxyl groups in the axial 
position. Alignment of the amino acid sequences of C-type CRDs shows that the 
primary determinant of specificity lies in the two Ca2+-ligating residues involved in 
interactions with the 3-hydroxyl group (Figure 1.5). In galactose-binding C-type 
lectins, glutamine and aspartic acid residues replace the glutamic acid and 
asparagine residues found in mannose-binding C-type lectins such as MBP. This 
10
Figure 1.4 Crystal structure of a trimeric fragment of rat MBP-A in complex with mannose 
pentasaccharides. Interactions between neck and CRD regions fix the orientation of the CRDs 
and provide a strict distance requirement for binding of more than one CRD to ligands presented 
on a cell surface. This figure is adapted from Weis and Drickamer, 1994,  based on entry 1KX1 
in the Protein Databank.  
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type lectins. Proteins that bind mannose-type sugars are highlighted in blue, those that bind 
2+ 
galactose-type sugars in green and others in purple.  Residues that are involved in Ca ligation 
2+ 
at Ca site two, forming the carbohydrate-binding site, are highlighted in red.
12
  
switching of an amide and a carboxylate oxygen imposes a positioning requirement 
on the sugar ring that favours the orientation of 3- and 4-hydroxyl groups found in 
galactose. Binding of mannose in this arrangement would require rotation of the 3-
hydroxyl group into an unfavourable position (Kolatkar and Weis, 1996; Weis and 
Drickamer, 1996).   
The major subunit of the asialoglycoprotein receptor (ASGPR-1) is the 
prototypical member of the C-type lectin family that binds galactose-type ligands 
(Taylor and Drickamer, 2003). Comparison of the CRDs from rat ASGPR-1 and 
MBP-A shows that ASGPR-1 contains the galactose-binding glutamine and aspartic 
acid residues in Ca2+ site 2, in addition to a tryptophan residue at the equivalent 
position of His189, and a five amino acid glycine-rich inserted loop (Figure 1.5). The 
CRD of rat MBP-A has been mutated to bind galactose by the incorporation of the 
amino acid residues found in the binding site of ASGPR-1. The crystal structure of 
the mutant in complex with galactose shows that in addition to the coordination of the 
3- and 4-hydroxyl groups of the sugar, a significant interaction occurs with the apolar 
face of the galactose ring, which forms hydrophobic packing interactions with the 
aromatic ring of the tryptophan residue (Figure 1.6) (Kolatkar and Weis, 1996). The 
crystal structure of the CRD of ASGPR subsequently confirmed the validity of this 
mutant as a model for galactose binding by C-type lectins (Meier et al., 2000).  
MBP forms few secondary interactions outside of the primary sugar-binding site 
and consequently retains broad carbohydrate specificity, with the only principal 
requirement for binding being the presence of mannose-type sugars with free 3- and 
4-hydroxyl groups (Weis et al., 1992). There are several members of the C-type 
lectin family that contain an extended or secondary binding site, permitting additional 
interactions with other groups of the bound sugar unit or with other residues in an 
oligosaccharide (Coombs et al., 2005; Mitchell et al., 2001; Varki, 1994). The 
increased energy of binding associated with these interactions creates specificity for 
distinct subsets of carbohydrate structures in these proteins.  
The scavenger receptor C-type lectin (SRCL) is an example of a C-type lectin 
which has specificity for distinct carbohydrate structures. The CRD of the endothelial 
receptor SRCL binds with high selectivity to glycans containing the Lewisx 
trisaccharide Galβ1-4(Fucα1-3)GlcNAc or the closely related Lewisa trisaccharide 
Galβ1-3(Fucα1-4)GlcNAc (Coombs et al., 2005). The crystal structure of mouse 
SRCL CRD in complex with the oligosaccharide Lewisx reveals an interaction 
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Figure 1.6 Structure of a galactose-binding mutant of rat MBP-A with bound galactose. 
2+
Carbon, nitrogen and oxygen atoms are outlined in green, blue and red respectively. Ca  is 
shown as a large light blue sphere. Solid lines represent coordination bonds, with dashed lines 
representing hydrogen bonds. This figure is adapted from Taylor and Drickamer, 2003, which 
was prepared from entry 1AFA  in the Protein Databank using Molscript. 
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between galactose and protein in the primary site similar to other galactose-binding 
C-type lectins, involving coordination of the 3- and 4-hydroxyl groups of the sugar as 
well interaction of the apolar face of the galactose ring with the aromatic ring of 
tryptophan (Feinberg et al., 2007). Binding of galactose in the primary binding site 
orientates the trisaccharide so that the GlcNAc residue points away from the protein 
and the fucose residue forms contacts with the protein in a secondary binding site. 
The principal interactions at the secondary binding site are hydrogen bonds between 
a lysine residue and the 4-hydroxyl and ring oxygens of fucose as well as van der 
Waals interactions between the exocyclic methyl group of fucose and the Cδ1 of an 
isoleucine residue (Feinberg et al., 2007). 
 
 
1.3 The collectin family of C-type lectins 
As noted, MBP belongs to the collectin family of C-type lectins that contain C-
terminal CRDs and N-terminal collagenous regions that assemble into trimeric units 
through interactions between neck and collagen domains. Further higher order 
structures are created through disulphide bonding in an N-terminal cysteine-rich 
region in some members of the family. In addition to MBP, there are four other 
collectins found in humans: SP-A, SP-D, CL-L1 and CL-K1.  
SP-A is the major protein constituent of pulmonary surfactant, a complex 
mixture of lipid and protein that covers alveolar epithelium. Two SP-A genes are 
found in humans and mice, referred to as SP-A1 and SP-A2, with a pseudogene also 
identified (Kishore et al., 2006). SP-A assembles to form trimers consisting of one 
SP-A1 and two SP-A2 chains. SP-A trimers assemble into hexamers of trimers by 
disulphide bonding in the N-terminal regions (Kishore et al., 2006). SP-A, like MBP, 
belongs to a subgroup of collectins that contain short interrupted collagen sequences 
which results in the adoption of a bouquet-like structure (Figure 1.7B).  
SP-D is also a significant component of pulmonary surfactant. There is only one 
type of SP-D polypeptide that assembles into a trimeric subunit. Unlike SP-A and 
MBP, SP-D contains a longer collagen region without an interruption in the 
sequence. The N-terminal domains of four SP-D trimers interact to create a cruciform 
structure, with minor populations of low order oligomers also present (Holmskov et 
al., 2003) (Figure 1.7C). This tetrameric structure can further oligomerise with up to 8 
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Collectin K-1 Collectin L-1
SP-A
SP-D
A
B
C
Figure 1.7 Structures of members of the collectin family of C-type lectins. A, Collectins K-
1 and L-1 are thought to form simple trimers. B, SP-A adopts bouquet-like structures similar to 
MBP. C, In contrast, the longer collagen domain of SP-D leads to the formation of a cruciform 
structure, which can further oligomerise to generate complexes containing up to 96 polypeptide 
chains.
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other tetrameric units, generating large SP-D multimers with up to 96 individual 
polypeptide chains.  
Sequence alignment of SP-D and MBP shows that residues involved in Ca2+ 
ligation and sugar binding are conserved. The crystal structure of the CRD of SP-D 
complexed with maltose reveals a mechanism of monosaccharide binding similar to 
that observed for MBP (Shrive et al., 2003). An asparagine residue involved in Ca2+ 
ligation and sugar binding in SP-A is replaced with alanine in the rat protein. 
Consequently, the crystal structure of rat SP-A reveals differences in the residues 
involved in Ca2+ ligation and suggests that SP-A binds to carbohydrates in a different 
manner to MBP or SP-D (Kishore et al., 2006). The CRDs of SP-A and SP-D bind to 
carbohydrates and lipids on the surfaces of Gram-positive and Gram-negative 
bacteria, viruses and yeasts (Hartshorn et al., 1998). Binding of surfactant proteins 
causes agglutination of invading pathogens hindering movement through tissues or 
infection of host cells and can enhance phagocytosis and killing by phagocytes 
(Wright, 2005). The ability to bind to and aggregate allergens is also thought to play 
an important role in dampening hypersensitive responses in the lung (Wang et al., 
1996). 
Collectin K-1 has recently been identified and cloned from a cDNA library 
generated from kidney tissue (Keshi et al., 2006). Analysis of transcript levels in 
multiple tissues by PCR suggests that CL-K1 has a broad expression pattern, 
differing from the restricted expression of MBP and the surfactant proteins. 
Production of recombinant CL-K1 and analysis by polyacrylamide gel electrophoresis 
shows that the protein forms a simple trimer without the formation of higher order 
oligomers (Figure 1.7A). Analysis of monosaccharide binding reveals a preference 
for fucose with weak binding to mannose. CL-K1 has also been shown to bind 
mannans from yeast and lipopolysaccharides from several strains of E. coli. The 
biological roles of CL-K1 have yet to be elucidated 
Collectin L-1 (CL-L1) was cloned from a cDNA library generated from liver 
tissue (Ohtani et al., 1999). Analysis of transcript levels in multiple tissues by PCR 
suggests that CL-L1 has a broad expression pattern but northern blotting of a panel 
of tissues identified expression only in liver and placenta. Analysis of CL-L1 
demonstrates binding to galactose, mannose, fucose, GlcNAc and GalNAc only at 
high ligand levels. Sequence alignment of CL-L1 with other collectins reveals that an 
asparagine residue involved in Ca2+ ligation and in sugar binding is replaced with 
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serine, indicating a likely change in the mechanism for sugar binding by CL-L1. The 
orientation of sugar bound to CL-L1 and the biological function of CL-L1 are not 
known.  
 
 
1.4 MBP-associated serine proteases 
MBP present in serum exists as complexes with one or more members of a 
family of serine proteases referred to as MBP-associated serine proteases (MASPs). 
MASPs were originally identified as proteins associated with MBP that are able to 
activate the complement pathway of innate immune defense in response to MBP 
binding to pathogen surfaces (Ikeda et al., 1987; Matsushita and Fujita, 1992; Thiel 
et al., 1997). MASPs associate with MBP through a binding site in the collagen 
domain and serve as an important link between the carbohydrate-dependent 
pathogen recognition of MBP and the pathogen clearance by the innate and adaptive 
immune system. 
 MASPs contain six protein domains. The three N-terminal domains are a Ca2+-
binding epidermal growth factor domain (EGF) flanked by two CUB domains 
(domains found in complement subcomponents C1r/C1s, Uegf, and bone 
morphogenetic protein 1). The second CUB domain is followed by two complement 
control protein modules (CCP domains) that are attached by a short linker region to 
the C-terminal serine protease domain (Sim and Laich, 2000) (Figure 1.8A).  
Two MASP genes have been identified in mammals, each of which produces 
two mRNA transcripts through alternative splicing (Schwaeble et al., 2002). The gene 
encoding MASP1 has an alternative spliced form encoding a protein product that 
contains identical CUB1-EGF-CUB2-CCP1-CCP2 domains but a different serine 
protease domain and is referred to as MASP3 (Dahl et al., 2001). The gene encoding 
MASP2 also generates a short alternatively spliced product encoding a 19-kDa 
protein MAP19. MAP19 consists of the N-terminal CUB and EGF domains of MASP2 
followed by a short region of unique sequence (Stover et al., 1999). MASP3 and 
MAP19 can also associate with MBP.  
MASPs are synthesised as zymogens. Activation requires cleavage of the 
polypeptide chain in the linker region between the CCP2 domain and the serine 
protease domain (Matsushita and Fujita, 1992). The serine protease domain, referred 
to as the light chain, then forms a disulphide linkage with the CUB1-EGF-CUB2-
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B
Figure 1.8 MASP domain structure. A, MASP zymogens form dimers through interactions 
between EGF and CUB domains. B, MASP dimers associate with MBPs through interactions 
between the EGF and CUB domains of MASPs with the collagen domain of MBP.
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CCP1-CCP2 heavy chain forming the active MASP (Wong et al., 1999). MASPs form 
homodimers through interactions between EGF and CUB2 domains (Feinberg et al., 
2003; Wallis and Dodd, 2000) (Figure 1.8A). MASP dimers associate with MBP 
collagenous domains in the inactive zymogen form and are activated following 
binding of MBP to carbohydrate structures.  
Binding of MASPs to MBP is mediated through the CUB1-EGF-CUB2 region 
(Figure 1.8B) (Wallis and Dodd, 2000). Both CUB1 and CUB2 domains form the 
major sites of binding to MBP (Chen and Wallis, 2001). The presence of bound Ca2+ 
in the EGF domain stabilises the conformation of the MBP-binding region and is 
required for the interaction between MASPs and MBP (Chen and Wallis, 2001). The 
MASP-binding site on MBP has been mapped to a region C terminal to the 
interruption in the collagen sequence, corresponding to triplet number 9 of the 
collagen region of rat MBP-A (Wallis et al., 2004). Mutagenesis of human MBP and 
analysis of synthetic collagen-like peptides binding to rat MASPs have identified a 
conserved lysine as the principle residue involved in the binding of all MASPs and 
MAp19 to MBPs, with the surrounding residues having differing degrees of 
importance between MASPs (Teillet et al., 2007; Wallis et al., 2004).  
MASP binding is affected by the oligomeric structure of MBP. MASP dimers 
contain two MBP-binding sites and consequently MASP binds 1000-fold less well to 
monomeric MBP than to dimeric MBP (Wallis, 2002). MASP binds to trimeric and 
tetrameric MBP with higher affinity than for binding to dimeric MBP. Trimeric, 
tetrameric and other higher order MBP structures can bind up to two MASP dimers, 
although a stoichiometry of 1:1 is thought to be the most stable composition. 
The mechanism by which MBP binding to bacterial surfaces leads to MASP 
activation is not currently known. No major structural changes are observed upon 
sugar binding for either isolated CRD or for neck and CRD fragments of rat MBP-A, 
suggesting that any structural alteration is likely to involve a rearrangement between 
MBP subunits (Weis and Drickamer, 1994; Weis et al., 1992). The likely mode of 
activation is thought to involve structural changes in the collagen portion of MBP 
subunits leading to alignment of the serine protease domains of MASPs so that the 
catalytic site of one domain is in close proximity to the linker region of the other 
(Figure 1.9) (Chen and Wallis, 2004). This change would increase the ability of a 
transiently active form of one protease domain to cleave and activate the other serine 
20
C4
C2
C3
Pathogen
Figure 1.9 Proposed mechanism of MASP2 activation through MBP binding to 
carbohydrate structures. MBP binding to a pathogen surface alters the distance between 
collagen domains, bringing the serine protease domains of MASP2 dimers into close proximity 
and leading to activation. Once activated, MASP2 cleaves complement proteins C2 and C4, 
leading to the formation of C3 convertase that can deposit complement on the surface of the 
pathogen for detection by cells of the immune system or for the initiation of the terminal pathway 
of complement activation.
C3b
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protease domain to a permanently activated state. This permanently active MASP 
subunit can then fully activate the other subunit in the dimer (Wallis, 2007).   
Upon activation, both MASP1 and MASP2 are able to cleave a variety of natural 
and synthetic substrates (Wong et al., 1999). Analysis of natural substrates revealed 
that MASP2 can cleave both C2 and C4 complement proteins. MASP1 has no 
detectable activity towards C4 but does cleave C2 with a comparable activity to 
MASP2. MASP1 has also been suggested to cleave complement protein C3 
(Matsushita et al., 2000), although the low level of activity detected suggests this 
cleavage is not physiologically relevant. MASP1 has also been shown to cleave 
proteins involved in the coagulation of blood including fibrinogen and factor XIII 
(Krarup et al., 2008). The activation of the coagulation cascade of proteins is thought 
to hamper the ability of pathogens to move from the site of primary infection and in 
this respect MBP:MASP1 complexes may form a link between coagulation and the 
complement system (Hajela et al., 2002). No natural substrates for MASP3 have 
been reported. The lack of C4 convertase activity by MASP1 means that only 
complexes of MBP and MASP2 are capable of activating complement (see Section 
1.5). The C2 convertase activity of MASP1 may be important in aiding the deposition 
of complement onto a bacterial surface bound by both MBP:MASP2 and 
MBP:MASP1 complexes (Sim and Laich, 2000). 
 
 
1.5 Biological functions of human MBP 
MBP couples the recognition of carbohydrate structures on the surface of 
microorganisms to the activation of an immune response. These immune responses 
are mediated through the interactions of immune molecules with the N-terminal 
collagen domain of MBP, with the best characterised pathway involving the activation 
of the lectin pathway of complement activation through MBP-MASP2 complexes 
(Figure 1.9).  
 
1.5.1 The complement system 
The complement system forms an important mechanism for identification and 
clearance of microorganisms by both innate and adaptive immune systems. 
Complement consists of a series of plasma proteins that are activated in a cascade, 
ultimately resulting in the induction of an inflammatory response, which serves to 
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recruit phagocytes to the site of infection, and in opsonisation of pathogens for 
identification by phagocytes recruited to the area (Walport, 2001a; Walport, 2001b). 
There are three mechanisms that trigger the complement cascade, all of which 
converge with the formation of an enzymatic activity referred to as C3 convertase 
(Muller-Eberhard, 1988) (Figure 1.10). The classical pathway involves the 
identification of pathogen surfaces by the complement protein complex C1, either 
directly or by binding to antibodies produced by the adaptive immune system. The 
lectin pathway of complement activation is triggered by MBP binding to 
carbohydrates on the surface of microorganisms and the alternative pathway is 
triggered by spontaneous activation of complement components on the surface of a 
pathogen.  
The classical pathway is part of both adaptive and innate immune systems and 
is initiated by the C1 complex. The C1 complex consists of the recognition 
component C1q and the serine proteases C1r and C1s (Muller-Eberhard, 1988). 
Binding of C1q to antibodies in immune complexes activates the protease activity of 
C1r and C1s (Calcott and Mueller-Eberhard, 1972). Activated C1s cleaves the 
complement component C4 producing the small peptide C4a which acts as an 
anaphylatoxin and C4b, a protein containing a thioester bond that rapidly forms a 
covalent linkage to molecules on the surface of the pathogen (Law and Dodds, 
1997). C4b contains a binding site for the complement protein C2 and recruits C2 to 
the pathogen surface. C2 is then cleaved by C1s generating C2a and an active 
protease C2b, which in association with C4b forms the C3 convertase (Muller-
Eberhard, 1988) (Figure 1.10).   
The lectin pathway of complement activation is initiated by the binding of 
MBP:MASP2 complexes to carbohydrate structures on the surface of 
microorganisms. Binding of MBP leads to autoactivation of the associated MASP2 
protease. Activated MASP2 cleaves the complement components C4 and C2 in an 
analogous fashion to the classical pathway (Matsushita and Fujita, 1992). 
The alternative pathway is initiated by the spontaneous low level hydrolysis in 
plasma of complement component C3 to the C3b-like molecule C3(H2O) (Muller-
Eberhard, 1988). Complement component factor B binds to C3(H2O) and is 
subsequently cleaved and activated by the protease factor D generating a small 
peptide Ba and a protease Bb. C3(H2O)Bb is a plasma C3 convertase that cleaves 
C3 to C3b and C3a (Schreiber et al., 1978). C3b molecules can then attach to the 
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Figure 1.10 Pathways of complement activation. C1q or MBP binding to pathogen surfaces 
or the spontaneous hydrolysis of complement protein C3 can lead to the generation of protein 
complexes with C3 convertase activity. The cleavage of C3 by C3 convertases produces the 
small peptide mediator of inflammation C3a and C3b. A thioester bond in C3b rapidly forms a 
covalent linkage with molecules on the pathogen surface and thus serves as an opsonin. 
Membrane-bound C3b can combine with the C3 convertase C2bC4b to produce a C5 
convertase which cleaves complement protein C5 into C5a, a potent mediator of inflammation 
and C5b, which initiates the terminal pathway of complement activation.   
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surface of the microorganism where they can be bound by further molecules of factor 
B. Factor B can then be cleaved by factor D to produce a membrane-bound C3 
convertase C3bBb (Lesavre et al., 1979). Production of C3bBb is used for generation 
of large amounts of C3b by the alternative pathway, but it also acts as an 
amplification loop for the classical and lectin pathways of complement activation 
(Gros et al., 2008).  
Generation of C3 convertases attached to the pathogen surface by all three 
pathways of complement activation results in cleavage of many molecules of C3, 
generating large amounts of C3a, a peptide mediator of inflammation, and C3b, the 
principal effector molecule of the system (Janeway et al., 2001) (Figure 1.10). C3b 
contains a reactive thioester bond that rapidly forms a covalent linkage with adjacent 
molecules on the pathogen surface (Law and Dodds, 1997). C3b covalently attached 
to the pathogen surface acts as an opsonin and is recognised specifically by a family 
of complement receptors on phagocytes (Carroll, 1998). In addition, C3b molecules 
bind to both C3 convertases, generating a binding site for the molecule C5 and 
making it susceptible to cleavage into the products C5a, a highly potent peptide 
mediator of inflammation and C5b, which initiates the terminal pathway of 
complement activation (Muller-Eberhard, 1988). 
 
1.5.2 The terminal pathway 
The terminal pathway consists of a cascade of protein-binding events, each 
generated through the exposure of a binding site due to conformational changes that 
occur through the previous binding event in the pathway (Muller-Eberhard, 1986). 
The pathway is initiated when one molecule of C5b associates with one molecule of 
C6 and one molecule of C7. This association exposes a hydrophobic patch on the C7 
surface that inserts into the pathogen membrane. The binding of the β subunit of C8 
to C5b in the complex exposes a hydrophobic patch on the surface of the α subunit 
of C8 that also inserts into the lipid bilayer (Muller-Eberhard, 1986). The C5b678 
complexes can bind to each other generating small pores in the membrane or C8 can 
induce the polymerisation of many molecules of C9 that insert into the bilayer and 
produce a 100-Å pore referred to as the membrane attack complex (Muller-Eberhard, 
1986) (Figure 1.10). This pore permits the free movement of solutes across the 
membrane of the pathogen. The disruption of the proton gradient and the resulting 
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build up of osmotic pressure exhausts the energy supply of the cell and enables the 
movement of proteins and nucleic acids out of the cell (Janeway et al., 2001). 
 
1.5.3 Complement receptors 
In addition to generating the membrane-attack complex, the attachment of 
complement proteins to pathogens triggers their clearance through interactions with a 
family of complement receptors found on the surface of phagocytes (Aderem and 
Underhill, 1999). Binding of complement receptors to complement proteins attached 
to pathogens can be sufficient for phagocytosis or may require further forms of 
phagocyte stimulation. Binding of the complement receptor CR1 present on 
macrophages and leukocytes to opsonins C3b and C4b on pathogen surfaces 
enhances phagocytosis of the pathogen (Khera and Das, 2009). CR1-mediated 
phagocytosis requires further stimulation of the phagocytic cell by binding of C5a to 
the C5a receptor also found on macrophages or through IgG binding to the Fcγ 
receptor (Khera and Das, 2009). The complement receptors CR3 and CR4, also 
present on macrophages and leukocytes, bind to pathogens opsonised with iC3b, a 
product of C3b cleavage by complement factor I, and is sufficient to stimulate 
phagocytosis (Aderem and Underhill, 1999; Janeway et al., 2001).  
Binding of iC3b or C3dg, another degradation product of C3b, to complement 
receptor 2 (CR2) on the surface of B lymphocytes lowers the activation threshold for 
B cell activation, contributing to the adaptive immune response toward a pathogen 
(Carroll, 1998). CR2 forms part of the B cell co-receptor complex.  
 
1.5.4 Regulation of complement  
In order to minimise the potential harm that low level activation of C3 from the 
alternative pathway could cause to host cells, or the impact of active components of 
the lectin or classical pathways to host cells in their immediate vicinity, several 
regulatory mechanisms exist to deal with complement deposition on host cells 
(Janeway et al., 2001) (Figure 1.11). The cell-surface proteins decay-accelerating 
factor (DAF), CD59 and membrane cofactor of proteolysis (MCP) are all commonly 
expressed on host cells, whilst complement receptor 1 (CR1) is found primarily on 
macrophages and leukocytes. MCP and CR1 bind to C3b and C4b and facilitate their 
degradation by acting as cofactors for the protease factor I (Kim and Song, 2006). 
DAF binds to C3b, preventing the formation of the C3bBb C3 convertase (Kim and 
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Figure 1.11 Regulation of complement. The C3 convertases C2bC4b and C3bBb are 
regulated by proteins that bind to C3b and C4b molecules and induce dissociation of the 
complexes. Once bound to C3b or C4b, many regulators act as cofactors for the serine protease 
factor I, which proteolytically degrades C3b and C4b molecules. The formation of the 
membrane attack complex by C8-induced polymerisation of C9 molecules is directly inhibited 
by the membrane protein CD59.  The abbreviations used are: MCP - membrane cofactor of 
proteolysis. DAF - decay-accelerating factor. CR1 - complement receptor 1. C4BP - C4-binding 
protein.
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Song, 2006). CR1 and DAF are also able to displace both Bb and C2b from the C3 
convertases generated by either pathway. CD59 prevents the formation of the 
membrane attack complex on host cells by binding to C8 and C9 proteins (Janeway 
et al., 2001; Kim and Song, 2006).  
Several complement regulatory proteins circulate in plasma, including C4-
binding protein (C4bp), factor H and factor I. C4bp and factor H both act as cofactors 
for the protease factor I. C4bp aids factor I-mediated degradation of C4b whereas 
factor H aids the degradation of C3b, in addition to competing with factor B to binding 
to C3b, hindering the formation of the C3bBb convertase. Factor H binds to 
glycoproteins bearing sialic acid residues, commonly found on mammalian cell 
surfaces, which serves to localise the inhibitor to host cell surfaces (Rodríguez de 
Córdoba et al., 2004).  
 
1.5.5 MBP mediated complement-independent phagocytosis  
MBP can act directly as an opsonin for phagocytes without the deposition of 
complement on pathogen cell-surfaces (Kuhlman et al., 1989). This activity is 
achieved either through direct interaction of MBP with receptors on the surface of 
phagocytes or indirectly by enhancing the immune response generated through other 
pathogen-phagocyte interactions (Jack et al., 2005). Relatively little is known about 
these receptors, with only one firmly established to date. A glycoprotein termed C1qR 
(C1q receptor) was originally identified as a receptor that binds to the collagen region 
of MBP and other collectins (Malhotra et al., 1990). C1qR was subsequently 
identified as calreticulin, a protein located in the endoplasmic reticulum where it acts 
as a quality-control chaperone monitoring the folding of nascent proteins. The lack of 
a transmembrane domain or cell surface expression of calreticulin led to a 
questioning of its role as a collectin receptor, which was explained by the interaction 
of calreticulin with the endocytic receptor CD91. CD91 acts as an adaptor bringing 
calreticulin to the cell surface and linking the recognition of collectins by calreticulin to 
phagocytosis (Ogden et al., 2001). Inhibition of calreticulin binding to MBP by MASPs 
and the reciprocal inhibition of MASP binding to MBP by calreticulin suggests that the 
two proteins may bind to the same region of MBP (Pagh et al., 2008). 
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1.6 Physiological roles of MBP 
1.6.1 Defense against pathogens 
MBP binds carbohydrate structures on the surface of microorganisms and 
initiates clearance either through the activation of associated serine proteases that 
deposit complement on the pathogen surface or directly through interactions with 
collectin receptors on the cell surface of phagocytes. Human MBP has been shown 
to bind to a variety of pathogenic organisms including Gram-positive and Gram-
negative bacteria, viruses, parasites, and yeasts (Turner, 2003). The role of MBP in 
defense against individual organisms that it binds varies greatly. Binding to the 
Gram-negative bacteria genus Neisseria leads to clearance of the pathogen through 
activation of the terminal pathway of complement. Activation of the terminal pathway 
is necessary for full protection against Neisseria, the only known bacterial genus for 
which the deposition of C3 on the surface is not sufficient for immune resistance 
(Jack and Turner, 2003).  
MBP binds to and deposits complement protein on the surface of Gram-
negative Straphylococcus aureus, stimulating clearance by phagocytes (Jack et al., 
2000). Mice deficient in both MBPs have an increased susceptibility to 
Straphylococcus aureus infection (Shi et al., 2004) highlighting the importance of 
MBP in the protection against this pathogen. 
MBP can inhibit infection with Influenza A by binding to high-mannose 
oligosaccharides on haemagglutinin located near the binding pocket of the protein. 
This binding enhances uptake of the virus by neutrophils (Hartshorn et al., 1993). 
MBP also binds to the high-mannose structures present on the surface molecule 
gp120 of human immunodeficiency virus (HIV) (Ezekowitz et al., 1989). This binding 
inhibits the interaction of HIV with the C-type lectin DC-SIGN on dendritic cells, 
thereby preventing transmission of the virus from dendritic cells to T cells (Spear et 
al., 2003). Binding to gp120 by MBP opsonises HIV for detection by phagocytes, but 
does not appear to lead to neutralisation of the virus (Ying et al., 2004). 
 Mice lacking MBP-A exhibit impaired clearance of the nematode Brugia malayi 
(Carter et al., 2007). MBP-A binds to and deposits complement on the surface of the 
nematode, but also appears to generate protection by directing the humoral immune 
response toward the production of IgM antibodies against the pathogen. 
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1.6.2 Clearance of apoptotic cells 
In addition to detection and clearance of non-self components, MBP is also 
implicated in the clearance of apoptotic cells. Apoptotic cells exhibit several cell-
surface molecules that serve as signals for clearance by immune system mediators. 
One such signal is thought to be exposure of cell-surface carbohydrate structures 
including mannose residues (Dini, 2000). This hypothesis is supported by the 
observation that human MBP binds to apoptotic cells in vitro. MBP binding initiated 
the engulfment of the apoptotic cell by macrophages, in a process involving the 
collectin receptor calreticulin/CD91 complex (Ogden et al., 2001). Results from these 
in vitro studies are supported by in vivo studies on mice deficient in MBP-A, which 
exhibit impaired clearance of apoptotic cells (Stuart et al., 2005).  
 
1.6.3 Recognition of cancer cells 
The carbohydrate structures present on cell surface molecules of cancerous 
cells differ from those of normal cells (Kim and Varki, 1997). Cancer cells often 
express higher levels of certain glycosyltransferase enzymes which leads to the 
expression of unusual glycan structures on the cancer cell surface (see Section 
1.7.4). Human MBP has been reported to bind to human colorectal carcinoma cell 
line SW1116 and is able to reduce the growth of SW1116 tumours in vivo using a 
complement-independent mechanism (Ma et al., 1999). MBP appears to bind to 
highly fucosylated poly-N-acetyllactosamine structures on the surface of the 
colorectal cells. The long chains of repeating fucose residues are presumed to 
provide the spatial requirement for MBP binding (Kawasaki et al., 2009; Terada et al., 
2005). 
 
1.6.4 Physiological consequences of MBP-deficiency 
The involvement of human MBP in defence against common pathogens is 
highlighted by studies of individuals who are MBP deficient. MBP deficiency is a 
relatively common condition and has been linked to an increase in susceptibility to 
recurrent infections in children and adults (Summerfield et al., 1995; Summerfield et 
al., 1997). This susceptibility is not generally evident in healthy individuals but is seen 
in those who have been immunocompromised or are suffering from a serious 
underlying condition. MBP-deficient adults (Peterslund et al., 2001) and children 
(Neth et al., 2001) who have been immunosuppressed through cytotoxic 
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chemotherapy appear to be more susceptible to severe infections. Similarly, MBP-
deficient patients are more likely to develop sepsis as a result of post-operative 
infections (Garred et al., 2003a; Siassi et al., 2003). MBP-deficient individuals 
suffering from cystic fibrosis show a higher rate of lung infection from Burkholderia 
cepacia (Garred et al., 1999). These examples highlight the likely redundancy of the 
innate immune system of MBP-deficient individuals in a healthy state as well as the 
importance of MBP in providing an innate defense during severe 
immunocompromisation or periods of prolonged pathogen exposure. However, 
clinical studies correlating MBP deficiency to the increased risks of infection can be 
controversial, with studies indicating positive correlation invariably contrasted with 
those finding no correlation (Thiel et al., 2006). 
MBP deficiency has also been linked to the development of two autoimmune 
diseases, systemic lupus erythematosus (SLE) and rheumatoid arthritis (Garred et 
al., 2001). Here low levels of MBP are not thought to be the underlying cause but 
rather to aggravate the diseases and further their development.  
 
 
1.7 Glycosylation of mammalian proteins 
1.7.1 Introduction to glycosylation 
The goal of this project was to demonstrate and analyse the ability of modified 
forms of rat MBP-A to bind to glycoprotein ligands present on the surface of cancer 
cells. The following sections provide a brief outline of the pathways of protein 
glycosylation that lead to sugar structures presented on the surface of mammalian 
cells, and detail common changes that occur in these pathways during oncogenic 
transformation. The covalent attachment of carbohydrates is a common post-
translational modification to proteins destined for secretion or expression on the cell 
surface. Glycans attached to proteins fall into two groups: those attached to the 
amide nitrogen atom of asparagine side chains are referred to as N-linked glycans 
and those attached to the oxygen atoms of serine and threonine side chains 
designated O-linked glycans.  
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1.7.2 N-linked glycosylation 
N-linked protein glycosylation involves the transfer of an oligosaccharide 
precursor to the amide nitrogen atom of asparagine residues in the recognition 
sequence Asn-X-Ser/Thr, where X can be any amino acid except proline (Taylor and 
Drickamer, 2003). The precursor oligosaccharide is assembled on the lipid dolichol 
inserted into the membrane of the endoplasmic reticulum. The process is initiated in 
the cytoplasm with the addition of a GlcNAc residue from a UDP-GlcNAc sugar-
nucleotide donor to dolichol via a pyrophosphate linkage. This reaction is followed by 
sequential attachment of another GlcNAc residue followed by five mannose residues 
to the structure (Hubbard and Ivatt, 1981) (Figure 1.12). At this point the structure 
flips across the membrane where four mannose residues and three glucose residues 
are attached to the structure by transfer from mannose and glucose 
monosaccharides linked to dolichol. The precursor unit is transferred to the protein by 
the enzyme oliosaccharyltransferase, which acts on asparagine residues that are 
within the recognition sequences and are exposed at the protein surface in the lumen 
of the endoplasmic reticulum (Hubbard and Ivatt, 1981; Kornfeld and Kornfeld, 1985).  
Once attached to the protein, N-linked glycans are initially processed by 
removal of the three terminal glucose residues by ER-resident glucosidases. The 
resulting high-mannose structures are trimmed by mannosidases found in the 
endoplasmic reticulum and the cis Golgi, which remove some or all of the four 
mannose residues found in α1-2 linkage. N-linked glycans that do not undergo any 
further processing than the initial trimming are referred to as high-mannose 
structures (Kornfeld and Kornfeld, 1985) (Figure 1.12).  
The formation of hybrid- and complex-type glycan structures is initiated by the 
addition of a GlcNAc residue to the α1-3-linked mannose branch. This addition is 
catalysed by the enzyme GlcNAcTransferase-I (GlcNAcT-I) located in the medial 
Golgi. Glycans that do not undergo further processing on the α6-mannose arm are 
referred to as hybrid-type structures (Kornfeld and Kornfeld, 1985) (Figure 1.12). 
Complex-type N-linked glycans are generated through the action of α-mannosidase II 
on hybrid-type glycans containing the GlcNAc attached to the α3-mannose branch. 
This enzyme trims a further two mannose residues from the α6-mannose branch, 
creating a substrate for GlcNAcT-II to add a GlcNAc to the α6-mannose and resulting 
in two GlcNAc-terminated branches. Tri- and tetra-antennary glycans are generated 
through the addition of further GlcNAc residues to one or both of the mannose 
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Figure 1.12 Pathways of N-linked glycosylation. N-linked glycans are assembled as 
precursors attached to the lipid dolichol. Synthesis is initiated on the cytoplasmic side of the 
endoplasmic reticulum (ER) by the sequential addition of two GlcNAc residues followed by five 
mannose residues (i). Precursors then flip across the membrane to the lumen of the ER (iii), 
where a further four mannose residues and three glucose residues are added (iv). Completed 
precursors are attached to asparagine residues of proteins during translocation into the ER 
lumen (v). Correctly folded proteins are directed for transport out of the ER by the removal of 
three glucose residues, generating high-mannose type structures (vi). Further trimming of 
glycans by mannosidases in the Golgi apparatus produce hybrid-type structures (vii) that can 
either be capped with terminal structures (viii) or can be further processed to generate complex-
type structures (ix). Complex glycans can be modified by a family of glycosyltranferases that 
results in the production of many potential glycan structures (x).
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branches. GlcNAcT-IV adds a GlcNAc in β1-4 linkage to the α3-mannose branch and 
GlcNAcT-V adds a GlcNAc in β1-6 linkage to the α6-mannose arm (Varki et al., 
1999).  
The majority of complex and hybrid-type N-glycans have elongated branches 
formed by addition of a galactose residue to the GlcNAc in β1-4 linkage by 
galactosyltransferases resident in the trans Golgi. Sialic acid residues are typically 
attached to the terminal galactose residue of each branch, which is commonly 
referred to as ‘capping’ of the branch (Figure 1.12). 
Although branches typically consist of only one galactoseβ1-4GlcNAc unit, they 
can be further lengthened by GlcNActransferases and galactosyltransferases which 
add repeating GlcNAc and galactose residues referred to as N-acetyllactosamine 
(LacNAc) sequences. Branches extended with repeating LacNAc sequences are 
referred to as poly-N-acetyllactosamine chains and consist predominantly of Galβ1-
4GlcNAc repeats, referred to as type II chains. Other less common branch 
elongations include the addition of galactose in β1-3 linkage, generating a 
galactoseβ1-3GlcNAc N-acetyllactosamine unit. Chains composed of repeating 
galactoseβ1-3GlcNAc units are referred to as type I poly-N-acetyllactosamine chains. 
Typically poly-N-acetyllactosamine extensions occur on only one branch of a glycan, 
and this is commonly the outer branch of tetra-antennary glycans, where the GlcNAc 
is attached in β6 linkage to the α6-mannose arm (Varki et al., 1999). 
The level of branching, extension of branches and the terminal structures 
attached to branches all vary depending on the relative expression levels of 
glycosyltransferases to which the glycan is exposed during its movement through the 
trans-Golgi. Sialic acid is the most common terminal structure attached to N-linked 
glycan branches. A family of sialyltransferases catalyse the addition of sialic acid 
residues to galactose in linkages involving the 3- or 6- hydroxyl group of the 
galactose, with α2-3 being the most common linkage in humans (Harduin-Lepers et 
al., 1995). 
Another terminal modification involves the attachment of fucose residues to the 
3- or 4-hydroxyl groups of GlcNAc and the 2-hydroxyl group of galactose by a family 
of fucosyltransferases. Glycan structures generated by the attachment of fucose to 
GlcNAc or galactose are referred to as Lewis structures and are expressed on 
restricted subsets of cells in the body (Weston et al., 1992). 
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 The enzymatic activities of fucosyl- and sialyltransferases can be affected by 
previous modifications to a glycan branch. Sialyltransferases have substrate 
specificity for galactose residues from terminal N-acetyllactosamine branches that 
have not been fucosylated (Le Pendu et al., 2001; Varki et al., 1999). Many 
fucosyltransferases can act on internal residues within glycan branches and on 
terminal sialylated structures. Consequently, glycan branches can contain both 
terminal sialic acid and fucose (Nishihara et al., 1999).  
 
1.7.3 O-linked mucin-type glycosylation 
A wide variety of monosaccharides can be covalently attached to the oxygen of 
serine and threonine residues, including mannose, fucose, glucose, galactose, 
GlcNAc and xylose. O-linked glycans occur on cytoplasmic, nuclear and extracellular 
proteins and have important roles in cellular signalling, extracellular adhesion, and 
modulation of extracellular matrix components (Varki et al., 1999). For the purposes 
of this introduction, mucin-type O-glycosylation is discussed as a major source of 
cell-surface O-linked glycans, with known alterations during oncogenic transformation 
(Hollingsworth and Swanson, 2004).  
Mucin proteins project large arrays of O-linked glycans, and are commonly 
secreted by and expressed on epithelial cell surfaces (Hattrup and Gendler, 2008). 
Other cell-surface adhesion molecules also contain mucin-type glycosylation at 
varying levels. Mucin-type O-glycosylation involves the α-linkage of a GalNAc residue 
to serine or threonine residues by a family of polypeptide-N-
acetylgalactosylminyltransferases (ppGalNAcTs) resident in the cis Golgi (Clausen 
and Bennett, 1996). The recognition sequences of ppGalNAcTs on mucins are not as 
well conserved as those of N-linked glycosylation but commonly involve repeating 
peptide sequences rich in serine, threonine and proline residues. Different 
ppGalNAcTs have different substrate requirements, with some enzymes preferring 
threonine to serine residues and some preferentially acting on peptides that have 
previously been glycosylated by another ppGalNAcT (Ten Hagen et al., 2003). The 
level of O-glycosylation of a mucin sequence is therefore affected by the relative 
expression of ppGalNAcTs within the cell.  
Following initial attachment of GalNAc to a protein, a variety of enzymes 
catalyse the sequential addition of monosaccharides to the structure (Hanisch, 2001). 
Four common core structures form the basis of mucin-type O-linked glycan structures 
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(Figure 1.13). The core 1 β1-3 galactosyltransferase (C1GalT-1) is an essential 
enzyme in elongation of O-linked glycans and adds a galactose residue in β1-3 
linkage to the GalNAc, forming the core 1 structure. A core 2 structure is formed by 
one of three core 2 β1-6 N-acetylglucosaminyltransferases (C2GnT-1, 2 and 3) that 
add a GlcNAc in β1-6 linkage to the GalNAc of core 1. Core 3 structures are similar 
to core 1 but contain a GlcNAc in a β1-3 linkage to GalNAc, through the action of 
core 3 β1-3 N-acetylglucosaminyltransferase (C3GnT). Core 4 is generated from 
core 3 structures by C2GnT-2 adding a GlcNAc in β1-6 linkage to GalNAc (Figure 
1.13). Core 3 and core 4 structures are less abundant than core 1 and core 2 
structures but are often found on mucins from epithelial cells of the colon (Varki et al., 
1999). 
The basic mucin core structures can be modified and extended by 
glycosyltransferases principally resident in the trans Golgi. Core 1 and core 2 glycans 
can be extended by the addition of a GlcNAc to the galactose residue by the enzyme 
elongation β1-3 GlcNActransferase. The terminal GlcNAc residues of each core 
structure can then be extended by the sequential addition of galactose and GlcNAc, 
generating one or more N-acetyllactosamine extensions as seen in N-linked glycans 
(see Section 1.7.2). Elongated O-linked glycans have terminal structures containing 
sialic acid and fucose added through the action of sialyltransferases and 
fucosyltransferases that also act on N-linked glycans (Figure 1.13). 
Core structures can be sialylated, which serves to restrict further elongation of 
the glycan. α2-3 and α2-6 Siayltransferases catalyse the addition of sialic acid to the 
galactose and GalNAc of core 1 and core 2 structures. The sialylation of galactose 
from core 1 and core 2 structures prevents further extension of the branch. 
Additionally, the stringent requirement of C2GnTs for unmodified core 1 structures as 
a substrate means the action of either 2,3 or 2,6 sialyltranferases on core 1 prevents 
the formation of core 2 and any further extension. Some 2,6 sialyltransferases can 
act on GalNAc before the formation of core 1, producing a structure that is not a 
substrate for C1GalT-1 and consequently cannot be elongated. The structures of O-
glycans present on mucins are therefore dependent on both the level of 
glycosyltransferases in the Golgi and also the position of these enzymes within the 
Golgi (Hanisch, 2001).  
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Figure 1.13 Synthesis of mucin-type O-linked glycans. O-glycan synthesis is initiated 
through the addition of GalNAc to serine or threonine residues by a family of polypeptide-N-
acetylgalactosylminyltransferases (ppGalNAcTs). Subsequent addition of sugar units requires 
the action of either core 1 b1-3 galactosyltransferase (C1GalT-1) or core 3 b1-3 N-
acetylglucosaminyltransferase (C3GnT) generating core 1 and core 3 structures. Core 2 and 
core 4 structures are generated by the addition of a GlcNAc to GalNAc by core 2 b1-6 N-
acetylglucosaminyltransferases (C2GnTs). All four core structures can be extended and 
modified by the addition of terminal structures.
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1.7.4 Changes in protein glycosylation associated with cancer 
The oncogenic transformation of mammalian cells requires an accumulation of 
genetic changes necessary to induce unregulated cell growth and the invasion of 
surrounding tissues. Among the many alterations in cellular activity displayed by 
cancer cells, changes in the glycan structures presented at the cell surface appear to 
be a universal feature (Kim and Varki, 1997). As the synthesis of glycans is not 
directly encoded within the genome, these changes are caused by altered expression 
levels or altered localisation of glycosyltransferases within the cell (Hakomori, 1996). 
The inherent heterogeneity of both glycan formation and oncogenic transformation 
means that no single change in glycan structure is common to all cancerous cells 
(Kobata and Amano, 2005). Often a particular glycan structure may be lost in cancer 
cells derived from one tissue type yet increased in another. This heterogeneity is 
likely to reflect the requirement of a cancer cell for altered glycosylation compared to 
surrounding cells in order to migrate and invade surrounding tissues. Glycans found 
in cancer cells do not represent novel structures and are often found to be present in 
activated cells or cells during embryonic development (Feizi, 1985b). Several 
common changes in protein glycosylation have been found to occur, some of which 
correlate with a poorer prognosis for patient survival.  
Early studies of glycosylation in cancer cells showed an increase in the size of 
N-glycoproteins compared to normal cells (Meezan et al., 1969). This increase in size 
was found to be primarily due to an increase in the level of tetra-antennary glycans, 
primarily mediated by an increase in the expression of the enzyme GlcNAcT-V 
responsible for generating the β6 GlcNAc branch (Figure 1.14) (Yamashita et al., 
1985). The increase in the level of β1-6 branching has subsequently been found to 
be one of the most common examples of aberrant glycosylation in tumours and 
cancer cell models and correlates with an increase in the malignancy of the tumour 
cell (Kobata and Amano, 2005). Transcription of GlcNAcT-V has been shown to be 
stimulated by a variety of oncogenes including src and H-ras (Buckhaults et al., 1997; 
Guo et al., 2000), providing an important example of a link between known oncogenic 
pathways and changes in glycosylation.  
An increase in the level of terminal fucosylation is a common feature of N- and 
O-linked glycans on cancer cells. This change results in the expression of Lewis-type 
terminal structures on the cancer cell surface (Figure 1.14) (Pour et al., 1988; 
Sakamoto et al., 1986). Sialylated versions of Lewis structures are expressed in 
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many cancers and often correlate with a poor prognosis (Magnani, 2004). The 
increase in Lewis antigen expression can be due to the up regulation of one or more 
fucosyltransferases, with the enzyme fucosyltransferase-7 (FucT-VII) being 
particularly important in the synthesis of sialylated Lewis antigens.  
Mucin-type O-linked glycosylation in cancer cells, particularly those of epithelial 
origin, is characterised by an increase in the number of O-linked glycans, due to both 
an increase in the expression level of mucins and an increase in the occupancy of O-
glycosylation sites. Cancer cell mucins contain truncated O-linked glycan structures 
that are not common in normal cells but can be present in cells during embryonic 
development (Burchell et al., 2001; Muller et al., 1999). These glycans include the 
core 1 (Galβ1-3GalNAc-α1-O-Ser/Thr) and sialylated core 1 structures, which when 
expressed in an unextended form are referred to as the T and sialyl-T antigens. O-
linked glycans can be further truncated and consist of only the protein-linked GalNAc 
residue (GalNAc-α1-O-Ser/Thr) and its sialylated version (NeuAc2,6-GalNAc-α1-O-
Ser/Thr) which are referred to as the Tn and STn antigens (Figure 1.14). In addition 
to truncation, the level of sialylation on O-linked glycans is also increased, due to an 
increase in the level of α2-6-linked sialylation of GalNAc in T or Tn structures in 
addition to the α2-3-linked sialylation more common in normal cells. 
 A variety of changes in the distribution and expression levels of 
glycosyltransferases have been shown to contribute to the truncation of O-linked 
glycans in cancer cells (Brockhausen, 2006). The expression of Tn and STn 
structures can be caused by a reduction in the expression of the core 1 enzyme 
C1GalT-1. The mechanism of this reduction is due to mutations in the gene encoding 
the molecular chaperone Cosmc, whose activity is essential to the correct folding of 
C1GalT-1 (Ju and Cummings, 2002).  
The activity of the sialyltransferase ST6GalNAc-I is thought to be primarily 
responsible for generating the STn structure (Marcos et al., 2004), which is not a 
substrate for C1GalT-1 and therefore prevents further elongation of the glycan 
(Figure 1.15). ST6GalNAc-I has been shown to have a broad distribution within the 
Golgi of a breast cancer cell line enabling it to compete for substrate directly with 
C1GalT-1 (Sewell et al., 2006).  
The ppGalNAcT family of enzymes responsible for initiating O-glycosylation are 
localised to the cis Golgi in normal cells (Roth et al., 1994). However, several 
members have been shown to have a broader distribution throughout the Golgi in a 
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cancer cell line (Rottger et al., 1998). The alteration in Golgi localisation may explain 
the increase in the number of occupied glycosylation sites found in cancer mucins 
and the increase in the level of truncated glycans, as O-linked glycans formed in the 
trans Golgi will not be exposed to the core-synthesising enzymes present in the cis 
Golgi.  
The increase in the expression of T and sialyl-T structures in breast cancer cells 
can be partly explained by a decrease in the activity of core 2 enzyme C2GnT-1, 
coupled with an elevation in the level of the sialyltransferase ST3Gal-I relative to 
normal breast tissue. ST3Gal-I sialylates the galactose of core 1 structures and 
prevents elongation (Figure 1.15) (Brockhausen et al., 1995; Burchell et al., 1999).  
Although the truncation of O-linked glycans is a common feature in carcinomas, 
elongated structures are still formed and, like N-glycans, the N-acetyllactosamine 
branches produced are often carry Lewis antigens. The projection of sialylated Lewis 
antigens on mucin proteins is thought to be particularly important in the metastasis of 
colon cancer cells (Kim et al., 1998; Mannori et al., 1995). 
 
1.7.5 Pathological consequences of aberrant glycosylation in cancer cells 
Despite a large body of evidence identifying aberrant glycosylation pathways 
and the resulting glycan structures that are found in cancers, relatively little is known 
about the mechanisms of how these structures confer a selective advantage to the 
cancer cell. Perhaps the best characterised mechanism to date involves the 
interaction of sialylated Lewis structures with members of the selectin family of C-
type lectins. The selectin group of C-type lectins are membrane receptors that bind to 
sialylated Lewisx structures (Steeber et al., 1995; Vestweber and Blanks, 1999). 
There are three members of the selectin family: P-selectin is found on activated 
platelets and Weibel-Palade bodies in vascular endothelial cells, E-selectin is found 
on activated endothelial cells and L-selectin is found on the surface of leukocytes 
(Nelson and Bevilacqua, 1993). Interactions between selectins and their specific 
glycoprotein ligands, which contain sialylated Lewis structures, are important 
temporary adhesion events between leukocytes or platelets and endothelial cells 
(Smith and Cummings, 1992). The selectin-dependent tethering and rolling of 
leukocytes to endothelial cell surfaces is important in their migration into sites of 
inflammation (McEver, 1994). 
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The mechanisms of leukocyte rolling are thought to be exploited by cancerous 
cells that have successfully migrated from a primary tumour into the vasculature 
(Gorelik, 2001; Kannagi, 1997; Kim and Varki, 1997). Cancer cells projecting of a 
large array of sialylated Lewis structures on their surface can interact with selectins 
on endothelial cells, platelets and leukocytes. The adhesion to selectins on 
endothelial cells can aid the successful migration of the cancer cell into a secondary 
tissue. Alternatively, interactions of cancer cells with platelets and leukocytes can 
produce cell aggregates which protect the cancer cell from immune defence 
molecules and can form clots, slowing the flow rate of the bloodstream and thereby 
assisting the adhesion of cancer cells to the endothelial cell wall (Kannagi et al., 
2004; Kim and Varki, 1997).  
The role of sialylated Lewis antigens in cancer cell metastasis is supported 
experimentally by the direct contribution of sialyl Lewisa and sialyl Lewisx in the 
adhesion of cancer cells to the vascular endothelium (Takada et al., 1993) and 
clinically by the frequently observed correlation between the expression of sialyl 
Lewisx and the metastatic potential of a variety of cancers (Kannagi et al., 2004). The 
role of selectins in this process is supported by the reduction of cancer cell 
metastases in mice deficient in P-selectin or L-selectin (Borsig et al., 2002). 
Interactions between platelets and colon cancer cells are also reduced in P-selectin-
deficient mice (Kim et al., 1998). Overexpression of E-selectin in the liver of 
transgenic mice was found to redirect the metastasis of a cancer cell line that 
normally colonises the lung to the liver (Biancone et al., 1996).  
Expression of both Tn and STn antigens on mucins correlate with increase in 
metastasis and a poor prognosis in cancer patients (Itzkowitz et al., 1990). Mucins 
are thought to aid metastatic potential of the cell through anti-adhesive functions, 
disrupting normal cell-cell interactions due to their large size and negative charge 
(Wesseling et al., 1996). The increase in truncated, sialylated O-glycans is thought to 
aid the anti-adhesive functions and increase cell mobility (Julien et al., 2005). 
Interactions between the mucin protein MUC1, the expression of which is frequently 
increased in cancer cells of breast epithelial origin, and the macrophage receptor 
sialoadhesion, a member of the siglec family of sialic-acid binding lectins, has been 
demonstrated (Nath et al., 1999). Interactions between cancer mucins and sialic-acid 
binding proteins on immune cell molecules may serve to provide protection to the 
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cancer cell whilst in the bloodstream or may modulate innate immune responses 
toward the cancer cell.   
The T antigen carried on MUC1 serves as a ligand for galectin-3, a member of 
the galectin family of galactose-binding proteins (Glinsky et al., 2000). Galectins are 
expressed intracellularly and extracellularly and are frequently found in increased 
concentrations in the sera of patients with cancer (Liu and Rabinovich, 2005). 
Galectin-3 is a monomeric protein containing a lectin domain and an N-terminal 
chimeric region. Binding of galectin-3 monomers to dense arrays of glycans such as 
those found on MUC1 can lead to oligomerisation through interactions in the chimeric 
domains, forming large aggregates (Takenaka et al., 2004). Binding of galectin-3 to 
MUC1 has been proposed to mediate homotypic aggregation of a breast cancer cell 
line and also to promote the adhesion of the breast cancer cells to the endothelium, 
by reversing the anti-adhesive properties of MUC1 (Yu et al., 2007).  
The increase in β1-6 branching is thought to aid cancer cell migration through 
several mechanisms (Dennis et al., 1999). The increase in N-glycan size caused by 
β1-6 branches, the effects of which may be exasperated by the differing conformation 
of the β1-6 branch, has been proposed to modulate interactions of cell-surface 
molecules involved in adhesion. The increased expression of the enzyme GlcNAcT-V 
was shown to inhibit the clustering of integrin subunits increasing the motility of cells 
(Guo et al., 2002). Poly-N-acetyllactosamine extensions are preferentially formed on 
the β1-6 branches of N-glycans (see Section 1.7.2) and an increase in the level of 
extended branches may represent better scaffolds for the projection of Lewis-type 
structures. Poly-N-acetyllactosamine branches projected by both N- and O-linked 
glycans are high affinity ligands for galectins, in particular galectin-3 (Song et al., 
2009). The binding of galectin-3 to poly-N-acetyllactosamine chains on N-linked 
glycans has been implicated in the successful metastasis of a melanoma cell line 
(Srinivasan et al., 2009). Interaction between galectins and poly-N-acetyllactosamine 
chains may therefore mediate homotypic and heterotypic adhesion of cancer cells in 
a manner similar to those reported for MUC1 and the T antigen.  
 
 
1.8 Analysing the role of glycans in cancer pathology using glycoproteomics 
The completed sequence of the human genome, coupled with advances in 
techniques that allow high throughput analysis of cellular proteins and mRNAs, has 
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led to the development of concepts such as the proteome, a total collection of 
proteins expressed by a cell, tissue or organism under specified conditions of time, 
space, and environment (Sanchez et al., 1996).  
The dynamic nature of the repertoire of proteins expressed in a cell at a given 
time is further complicated by the range of post-translational modifications that 
individual proteins can be subjected to, a major modification for many proteins being 
glycosylation. This has given rise to the concept of the glycome, the total collection of 
glycans synthesised by a cell, tissue, or organism under specified conditions of time, 
space, and environment (Kasai and Hirabayashi, 2000). The subject of glycomics 
seeks to address the glycomes of a particular system, and how they relate to a 
particular biological process or event in that system.  
A variety of tools have been developed for glycomic analysis. Several enzymatic 
and chemical strategies are available for the cleavage of glycans from proteins or 
lipids. The structural composition of these glycans can then be explored, principally 
by mass spectrometry. The sensitivity of mass spectrometric techniques allows the 
identification of small populations of specific glycan structures within a large group of 
structures (North et al., 2009). These approaches can be complemented by 
antibodies and plant lectin-binding studies. Many antibodies and plant lectins have 
specificity for distinct glycan structures (Gabius and Rudiger, 2001) and so are useful 
for clarifying the presence of a particular structure in a cell or tissue (Hirabayashi, 
2008; Mislovicova et al., 2009).  
Advances in molecular biology have allowed cloning and purification of many 
glycosyltransferase enzymes, which have been used for the in vitro synthesis of 
many glycan structures. Arrays of glycans with defined structures are used to 
analyse the glycan specificities of glycan-binding proteins (Liu et al., 2009; Paulson 
et al., 2006). This approach has helped to show that receptors such as SRCL and 
LSECtin bind to distinct structures with high specificity (Coombs et al., 2005; 
Powlesland et al., 2008) and galectin-3 binding to internal residues within poly-N-
acetyllactosamine structures (Stowell et al., 2008). Knowledge of the glycan-binding 
specificity of a glycan-binding protein is important in defining the biological 
consequences of a change in the expression of a particular glycan structure.  
Despite a rapid increase in the analysis of glycan structures and the 
identification of many families of glycan-binding proteins with novel glycan 
specificities, relatively little is known about the protein carriers of specific glycan 
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structures, and how glycans modulate their activity. Glycoproteomics seeks to 
provide a link between glycomics and proteomics by analysing the specific glycan 
structures in a cell or tissue and the principal protein carriers of these glycans 
(Hirabayashi, 2004). With the aid of selective purification of glycoproteins using 
approaches such as lectin affinity chromatography, pools of glycoproteins can be 
analysed using antibody and lectin binding. Proteins can be identified by digestion 
with proteases followed by analysis of peptides by mass spectrometry. Glycan 
structures can also be cleaved from the proteins and analysed by mass spectrometry 
and neoglycolipid technologies (Dell and Morris, 2001; Feizi and Childs, 1994). Use 
of this methodology should provide a more systematic approach in the analysis of the 
role of glycans in processes such as cancer cell metastasis (Figure 1.16).  
 
 
1.9 Generating MBP mutants with altered glycan-binding specificity 
The open nature of the sugar-binding site of MBP, the small number of residues 
involved in sugar-binding and the conservation of key residues involved in the CRD 
fold make MBP an ideal candidate to investigate the requirements for altering ligand 
specificity in C-type lectins. The mutations Glu185Gln and Asn187Asp in MBP-A 
were found to be sufficient to create a preferential affinity for galactose over mannose 
(Drickamer, 1992). In order to generate both affinity and selectivity for galactose 
comparable to that of galactose-binding C-type lectins such as ASGPR-1, a further 
mutation of His189Trp and the introduction of a glycine-rich loop between residues 
189 and 190 is required (Iobst and Drickamer, 1994). Crystal structures of the 
galactose-binding mutants show that the high affinity for galactose is generated 
through packing interactions between the introduced tryptophan residue and the 
apolar β-face of the galactose residue (Figure 1.6). The presence of the glycine-rich 
loop secures the tryptophan side chain into a position for high affinity galactose 
binding and does not permit its movement away from the binding site that is required 
for mannose to bind in its favoured orientation (Taylor and Drickamer, 2003).  
Further MBP mutants have been generated to investigate the ligand-binding 
specificity of the selectin family of C-type lectins. The incorporation of a series of 
amino acids, which are important in ligand binding by E-selectin, into the CRD of 
MBP led to the identification of a region of three lysine residues that generated 
selectin-like binding (Blanck et al., 1996). Comparisons of the ligand-bound 
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Figure 1.16 Overview of glycoproteomic strategies
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structures of the selectin-like MBP mutants and E-selectin show marked differences 
in the mechanism of ligand binding, despite similar binding characteristics (Ng and 
Weis, 1997; Somers et al., 2000). Nevertheless, the ability to produce selectin-like 
binding characteristics in MBP without directly mimicking the selectin binding 
mechanism highlights the diversity of interactions that can be mediated by C-type 
lectin domains and raises the possibility of creating CRDs with novel specificities for 
cancer glycans (Drickamer, 1999).  
 
 
1.10 Aims addressed in the thesis 
 
To create a galactose-binding MBP mutant and to analyse its glycan-binding 
specificity. The CRD of rat MBP-A had been modified to bind galactose-type ligands 
prior to this project. However, a complete MBP molecule containing a galactose-
binding CRD has not been generated. A primary goal of this project was to create a 
full length version of a galactose-binding mutant of MBP and to assess the ability of 
this protein to detect galactose-type ligands on cell surfaces. To this end, a full-length 
version of a galactose-binding mutant of MBP, termed GalMBP, has been created 
and characterised. The oligomeric structure of GalMBP has been compared to that of 
the wild type protein in order to assess its ability to function in an analogous manner. 
The glycan-binding specificity of GalMBP has been investigated by measuring the 
binding to a panel of glycan structures, demonstrating binding specificity for two 
subsets of cancer-associated glycans.   
 
To evaluate the potential of GalMBP to act as a novel reagent for targeted 
killing of cancer cells. GalMBP binding cancer-associated galactose ligands has 
been utilised to investigate the ability to bind to and initiate complement-dependent 
cell lysis on cancer cells and evaluate its use as a novel reagent for cancer 
treatment.  
 
To examine the ability of GalMBP to selectively target breast cancer cells 
through binding to cancer-associated glycan structures. The ability of GalMBP 
to target breast cancer cells through binding to cancer-associated glycan structures 
has been examined. Direct binding assays were used to show GalMBP binding to a 
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panel of breast cancer cell lines and columns of immobilised GalMBP have been 
used as affinity tools to purify protein carriers of cancer-related glycan structures from 
these cells. The glycoproteins purified in this way have been identified and the 
glycans have been characterised. The proteins identified vary widely between 
different breast cancer cell lines, although many are involved in cell-cell adhesion 
and cellular activation associated with adhesion events. The N- and O-linked glycans 
present on purified glycoproteins from breast cancer cells include N-linked glycans 
containing cancer-associated terminal structures and truncated O-linked glycans. 
 
To use GalMBP as an analytical tool to identify common glycoproteins 
containing Lewisx structures on cancer cells from Hodgkin’s lymphoma. The 
ability of GalMBP to bind to glycans containing Lewisx structures has been exploited 
to analyse glycoproteins from Hodgkin’s lymphoma cells, which are diagnosed in part 
by the presence of Lewisx glycans. A survey of a panel of Hodgkin’s lymphoma cell 
lines has identified a common set of purified glycoproteins found in multiple cell lines.  
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Chapter 2 
 
Generation of a galactose-binding mutant of MBP (GalMBP), 
characterisation of oligomeric state and glycan-binding specificity 
 
2.1 Introduction 
Structural analysis of members of the C-type lectin family has revealed a 
common architecture among carbohydrate-recognition domains (CRDs) (Drickamer, 
1999). The underlying mechanisms of carbohydrate binding have been investigated 
by creation of a series of mutants of rat mannose-binding protein (MBP-A) that 
contain regions from the carbohydrate-binding site of the galactose-binding 
asialoglycoprotein receptor subunit 1 (ASGPR-1), a hepatic receptor responsible for 
the clearance of glycoproteins from circulation (Ashwell and Harford, 1982; Steirer et 
al., 2009). Substitution of two amino acids in the carbohydrate-binding site of rat 
MBP-A proved to be sufficient to alter the sugar-binding specificity from mannose to 
galactose (Drickamer, 1992). Further investigations led to the production of a MBP-A 
mutant termed GalMBP that contains the amino acid changes Glu185Gln, 
Asn187Asp and His189Trp and the insertion of a five amino acid region Tyr-Gly-His-
Gly-Leu between residues 189 and 190, and which was found to bind with high 
affinity to galactose and N-acetylgalactosamine (GalNAc) (Figure 2.1) (Iobst and 
Drickamer, 1994). Structural analysis of this mutant showed the inserted region 
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          FKNWRPEQPDDWYGHGLGGGEDCAHFD-DGRWNDDVCQRPYRWVCET
          YSNWKKD GSGEDCVTIVDNGLWNDISCQASHTYVCEFQPDDWYGHGL
          YSNWKKDEPNDHGSG-----EDCVTIVDNGLWNDISCQASHTYVCEF
Galactose binding
Mannose binding
GalMBP
MBP-A
ASGPR-1
MBP-A GalMBP
Galactose
Trp189
Asp187
Glu198
Gln185Asn210
Asp211
Mannose
Asn205
Glu185
Asp206
Asn187
His189
Glu193
Figure 2.1 Engineering galactose binding into MBP-A. Three amino acid changes and a five 
amino acid insertion were introduced into the sugar-binding site of MBP-A to mimic the binding 
site of the asiayloglycoprotein receptor subunit 1. The structures of MBP-A with bound 
mannose and GalMBP with bound galactose are shown above.  Carbon, nitrogen and oxygen 
2+ 
atoms are outlined in green, blue and red respectively. Ca are shown as large light blue 
spheres. Solid lines represent coordination bonds with dashed lines representing hydrogen 
bonds. This figure is adapted from Taylor and Drickamer, 2003, which was prepared from 
entries 2MSB and 1AFA in the Protein Databank using Molscript.
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forms a loop that orientates the residue Trp189 in a fixed position within the 
carbohydrate-binding site (Kolatkar and Weis, 1996). This orientation permits 
favourable hydrophobic interactions between the aromatic ring of the tryptophan and 
the sugar ring of galactose-type carbohydrate ligands, whilst also sterically hindering 
the accommodation of mannose-type ligands. 
 In order to investigate the use of galactose-binding MBP mutants to mimic the 
biological activities of MBP, but with differing ligand specificities, an expression 
plasmid encoding a full length version of GalMBP containing both collagen and 
cysteine-rich domains has been generated and transfected into a Chinese hamster 
ovary cell line. GalMBP has been purified from serum-supplemented medium by 
affinity chromatography on columns containing immobilised galactose and the 
oligomeric state has been investigated. The glycan-binding specificity of GalMBP has 
been further defined by probing fluorescently-labelled GalMBP against a panel of 
glycan structures. These results provide evidence that GalMBP interacts with a 
restricted set of glycan structures, some of which are commonly found on cancer 
cells. 
 
 
2.2 Materials and methods 
2.2.1 Materials 
Tissue culture medium, sera and supplements were purchased from Invitrogen 
Ltd (Paisley, UK), as were agarose and caesium chloride. Ammonium persulphate, 
Fluorescene isothiocyanate (FITC), D-galactose, HEPES, D-mannose, methotrexate, 
Sepharose 6B and tetramethylethylenediamine (TEMED) were all from Sigma-
Aldrich Company Ltd (Poole, Dorset, UK). Restriction enzymes, T4 DNA ligase, 
Calve intestinal phosphatase and molecular weight markers were purchased from 
New England Biolabs Ltd (Hitchen, Hertfordshire, UK). Sodium dodecyl-sulphate 
(SDS) was purchased from Biorad Laboratories Ltd (Hemel Hempstead, 
Hertfordshire, UK). Polyacrylamide gels were made using Acrylagel and bisAcrylagel 
from National Diagnostics (Atlanta, Georgia, USA).  
 
2.2.2 Generation of GalMBP constructs 
When rat MBP-A was previously modified to bind to galactose-related sugars 
amino acid changes were introduced by ligating a series of synthetic oligonucleotides 
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into a fragment of rat MBP-A encoding the C-terminal 92 amino acids (Iobst and 
Drickamer, 1994). This modified fragment was then inserted into an expression 
plasmid encoding the trimeric C-terminal fragment of rat MBP-A, consisting of the 
CRD and adjacent α-helical neck region. An expression plasmid for a full length 
GalMBP was constructed by ligating the modified fragment encoding the C-terminal 
region of the CRD of GalMBP into a plasmid encoding full-length MBP-A (Figure 
2.2). Restriction digestions and ligations were conducted using standard molecular 
biology techniques (Maniatis et al., 1982) with all enzyme digestions conducted in an 
appropriate concentration of the manufacturers recommended buffer. For expression 
in mammalian cells, an EcoRI-ApoI fragment containing the full coding region of 
GalMBP was moved into the vector pED that had been digested with EcoR1 
following the same procedures (Figure 2.2). 
 
2.2.3 Cell culture 
All cell lines were grown in a humidified 37ºC tissue culture incubator 
maintained at 5% CO2. Chinese hamster ovary (CHO) cell line DXB11 was grown in 
MEM α medium supplemented with 10% foetal bovine serum, 100 U/ml penicillin and 
100 µg/ml streptomycin. Transfected CHO cells were grown in MEM α medium 
without ribonucleosides or deoxyribonucleosides that was supplemented with 10% 
dialysed foetal bovine serum, 0.5 µM methotrexate, 100 U/ml penicillin and 100 
µg/ml streptomycin. 
 
2.2.4 Transfection of a plasmid encoding GalMBP into CHO cells 
 The cDNA encoding full length GalMBP in the expression vector pED was 
ethanol precipitated and redissolved in 1 mM EDTA (pH 8.0) under sterile conditions. 
The plasmid was transfected into the dihydrofolate-reductase deficient Chinese 
hamster ovary (CHO) cell line DXB11 using the calcium phosphate method (Chen 
and Okayama, 1987). Cells containing the construct were selected by growth in 
MEM α lacking nucleosides and ribonucleosides and supplemented with 10 % 
dialysed foetal bovine serum. The level of production of GalMBP was increased by 
passaging cells into increasing concentrations of methotrexate (0.02 µM, 0.1 µM and 
0.5 µM) over a period of several weeks. The resulting CHO cell line stably 
expressing GalMBP was maintained in MEM α lacking nucleosides and 
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Figure 2.2 Overview of the cloning strategy for GalMBP. The strategy used 
for generating a plasmid encoding GalMBP for transfection into a mammalian
cell expression system is shown, accompanied with more detailed view of the 
vector used for transfection. The components listed are: SV40 - fragment of the
SV40 virus containing the SV40 origin of replication and enhancer element. 
MLP - adenovirus major late promoter. TPL - adenovirus major late mRNA leader 
sequence. EMC-L - the 5' untranslated leader sequence from encephalomyocarditis
virus. DHFR - dihydrofolate reductase. SV40-pA - the SV40 virus polyadenylation sequence.
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ribonucleosides and supplemented with 10 % dialysed foetal bovine serum and 0.5 
µM methotrexate. 
 
2.2.5 Production and purification of GalMBP   
For harvesting of GalMBP, cells were grown in 225 cm2 flasks containing 50 ml 
of medium. Cells were grown to confluence and medium was replaced and 
harvested each day over four days. Pooled medium was centrifuged at 10,000 x g for 
15 min at 4 ºC and CaCl2, Tris-Cl, pH 7.8 and NaCl were added to 25 mM, 25 mM 
and 150 mM, respectively. GalMBP was purified on 5-ml columns of galactose-
Sepharose. Columns were washed with 10 ml of low-salt loading buffer (150 mM 
NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2) and protein was eluted with 20 ml of 
low-salt elution buffer (150 mM NaCl; 25 mM Tris-Cl, pH 7.8; 2.5 mM EDTA). Column 
fractions were analysed on 17.5% SDS-polyacrylamide gels. Galactose-Sepharose 
was prepared by the divinyl sulphone method (Fornstedt and Porath, 1975) 
 
2.2.6 Protein analysis by polyacrylamide gel electrophoresis. 
Proteins were analysed by SDS-polyacrylamide gel electrophoresis following 
the method of Laemmli (Laemmli, 1970). Proteins samples were mixed with an equal 
volume of 2X sample buffer (80 mM Tris-Cl, pH 6.8, 15% glycerol, 2% SDS, 0.006% 
bromophenol blue and 2% β-mercaptoethanol) and boiled at 100 ºC for 5 min prior to 
gel loading. For analysis under non-reducing conditions, β-mercaptoethanol was 
omitted from the sample buffer and for precipitated protein samples the sample 
buffer was diluted two-fold with H2O prior to use. Samples were loaded onto SDS-
polyacrylamide gels mounted in either a Biorad mini-Protean II or a Gibco BRL V15-
17 vertical gel electrophoresis apparatus filled with running buffer (0.19 M Glycine 
and 25 mM Tris) and analysed by electrophoresis. In addition to samples, protein 
molecular weight markers were used. For protein visualisation, gels were incubated 
with 1.6 mM Coomassie blue stain dissolved in 4.5:4.5:1 (v/v) methanol:H2O:acetic 
acid for thirty min at room temperature then destained with 12:25:3 (v/v) 
methanol:H2O:acetic acid.  
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2.2.7 Bacterial expression and purification of a GalMBP CRD and neck 
fragment 
GalMBP CRD and neck fragment was previously expressed and purified using 
a periplasmic-folding strategy (Iobst and Drickamer, 1996). Expression plasmid 
pINIIIompA3 containing the coding region for the CRD and neck fragment of GalMBP 
was transfected into E. coli strain JA221. Colonies were picked and grown in 2.5 ml 
Luria-Bertani medium containing 50 µg/ml ampicillin (LB/Amp) at 25 ºC with shaking 
for six hours and approximately 1 ml was transferred into 200 ml LB/Amp and grown 
overnight at 25 ºC with shaking. The overnight culture was used to inoculate six 1-l 
flasks of LB/Amp and bacteria were grown at 25 ºC with shaking until the culture 
reached an optical density of 0.8 at 550 nm. Protein expression was induced by the 
addition of 10 µg/ml of IPTG and 100 mM CaCl2 and cells were grown overnight at 
25 ºC with shaking. Bacteria were harvested by centrifugation at 4000 x g for 15 min, 
resuspended in loading buffer (1.25 M NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2) 
and sonicated for a total of 10 min in 1-min bursts, with rests on ice for 10 min 
between each sonication. Lysed bacteria were centrifuged at 10,000 x g for 30 min at 
4ºC then at 100,000 x g for 30 min at 4ºC and the supernatant was passed over a 5-
ml column of galactose-Sepharose. Columns were washed with 10 ml of loading 
buffer and protein was eluted with 20 ml of elution buffer in 2-ml fractions (1.25 M 
NaCl; 25 mM Tris-Cl, pH 7.8; 2.5 mM EDTA). Aliquots from each fraction were 
analysed on 17.5% SDS-polyacrylamide gels.  
 
2.2.8 Fluorescent labelling of GalMBP 
Bacterially-expressed GalMBP (4 ml of approximately 0.1 mg/ml protein) was 
dialysed against 250 ml of 150 mM NaCl; 100 mM Bicine, pH 9.0; 5 mM CaCl2 for 24 
hours with one buffer change. Protein was labelled with five 20-µl aliquots of 1 mg/ml 
FITC dissolved in dimethyl sulphoxide. The sample was vortexed between additions 
and the reaction was allowed to proceed overnight at 4 ºC in the dark. Samples were 
passed over a 1-ml galactose-Sepharose column, washed with 5 ml of low salt 
loading buffer (150 mM NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2) and FITC-
GalMBP was eluted with five 0.5-ml fractions of low salt elution buffer (150 mM NaCl; 
25 mM Tris-Cl, pH 7.8; 2.5 mM EDTA). Fractions were analysed by 17.5% SDS-
polyacrylamide gel electrophoresis and two fractions with the highest levels of 
protein were pooled.  
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2.2.9 Glycan array analysis 
 FITC-GalMBP (1 ml of 0.2 mg/ml protein) in low-salt elution buffer with CaCl2 
added to 5 mM was shipped to core H of the Consortium for Functional Glycomics 
for glycan array screening (www.functionalglycomics.org). After incubation and 
washing steps, FITC-GalMBP binding to glycans on the array was detected by 
fluorescence intensity with the assay performed with six replicates. 
 
 
2.3 Results 
2.3.1 Generation of GalMBP, protein purification and characterisation. . 
Due to the posttranslational modifications required for collagen formation, 
including the hydroxylation of proline and hydroxylation and glycosylation of lysine 
residues, the successful production of MBP requires exposure of MBP polypeptides 
to modification enzymes present in the lumen of the endoplasmic reticulum (ER) of 
mammalian cells. Consequently for expression of full length protein a eukaryotic 
expression system was used. The cDNA encoding GalMBP was inserted into the 
mammalian expression vector pED (Figure 2.2), which contains an origin of 
replication and enhancer sequences from the polyoma virus SV40 and major late 
promoter sequences from Adenovirus upstream of the inserted GalMBP sequence 
(Kaufman et al., 1991). Immediately downstream of the inserted sequence is an 
untranslated region of encephalomyelocarditis virus (ECMV), required to direct 
translation at internal initiation codons, followed by a gene encoding dihydrofolate 
reductase (DHFR) and a polyadenylation sequence from SV40 virus (Figure 2.2). 
Transcription of the vector generates a dicistronic mRNA, containing open reading 
frames for GalMBP followed by the resistance gene DHFR. Due to the inefficient 
translation of the second open reading frame, a high level of transcription is required 
for the production of sufficient levels of selection marker DHFR, leading to high level 
expression of GalMBP. Levels of protein are further increased by selection of cells in 
medium containing the DHFR inhibitor methotrexate resulting in gene amplification. 
In order to direct translation of GalMBP to the secretory pathway, a sequence 
encoding the signal sequence for the hormone insulin was inserted upstream of the 
first codon for GalMBP.  
GalMBP was harvested from the medium in which the CHO cell transfectants 
were grown and purified by affinity chromatography on galactose-Sepharose. Elution 
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fractions from the galactose column were analysed by SDS-polyacrylamide gel 
electrophoresis under reducing conditions, which showed the presence of GalMBP at 
levels similar to wild type MBP-A purified using this system (Wallis and Drickamer, 
1999) (Figure 2.3). The presence of intrachain and interchain disulphide bonds within 
the cysteine-rich regions of mannose binding proteins allows the analysis of 
oligomeric structure by polyacrylamide gel electrophoresis under non-reducing 
conditions. Polyacrylamide gels of GalMBP in the absence of reducing agent show 
an oligomeric profile similar to wild type MBP-A, with four major bands corresponding 
to monomers, dimers, trimers and tetramers of the trimeric polypeptide (Figure 2.3). 
Other minor bands are present that represent populations of GalMBP containing 
polypeptide chains that are not disulphide-bonded, which have dissociated in the 
presence of SDS.  
 
2.3.2 Analysis of GalMBP carbohydrate-specificity 
The affinities of GalMBP for monosaccharides including galactose and GalNAc 
have previously been determined using sugar competition assays, where the 
monosaccharides compete with a 125I-Gal30-BSA reporter ligand for binding to the 
immobilised protein. These assays showed GalMBP to have similar affinities for 
galactose and GalNAc (Iobst and Drickamer, 1994). To further investigate the 
carbohydrate-binding characteristics of GalMBP, fluorescently-labelled protein was 
used to screen version 2.1 of the glycan array provided by the Consortium for 
Functional Glycomics. This version of the array consists of a panel of 285 natural 
and synthetic glycans that are covalently linked to a chemically-modified glass slide 
(Figure 2.4). Following incubation with labelled GalMBP, the slide was washed with 
buffer and the level of GalMBP bound to each glycan was measured by detecting the 
level of fluorescence. The results of the array screening showed that GalMBP 
selectively binds to glycans bearing terminal galactose residues, with little binding to 
glycans containing terminal GalNAc (Table 2.1). Significant binding was only 
observed for one glycan that did not contain a terminal galactose residue (glycan 
157). In this glycan, a subterminal galactose is modified with an α1-6 linked N-
acetylglucosamine (GlcNAc) residue, suggesting that GalMBP can tolerate 
substitution on the 6-position. 
GalMBP shows preference for two distinct glycan subsets of the 78 glycans 
bearing terminal galactose residues. One subset of glycans contain a terminal fucose 
58
E3 E4 E5 E3 E4 E5
83 kDa
48 kDa
33 kDa
25 kDa
175 kDa
62 kDa
Reducing Non-reducing
EDTA elution fractions
Figure 2.3 Analysis of GalMBP by SDS-polyacrylamide gel electrophoresis under 
reducing and non-reducing conditions, visualised by staining with Coomassie blue. 
Polyacrylamide gels (15%) represent the peak elution fractions of GalMBP purified on 
galactose-Sepharose with the oligomeric species present indicated. Unlabelled species 
represent minor populations of GalMBP with polypeptide chains that are not disulphide 
bonded and some serum-derived contaminants.
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Figure 2.4 Screening of a glycan array with GalMBP. Glycans immobilised onto chemically-
modified glass microscope slides were probed with fluorescein-labelled GalMBP. A, Binding 
results are presented in order based on the position of glycans on the array. B, Data are re-
presented in rank order of the observed signals on the array. Glycans bearing terminal N-
acetylgalactosamine are indicated in blue, glycans bearing terminal galactose are highlighted 
in red with those that also contain fucose coloured in green. The level of fluorescence was 
normalised to glycan 138.  A full list of glycans present on the array is included in the Table 2.1.
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Table 2.1 List of glycans on the glycan array. 
Values for GalMBP binding to each glycan are given in relative fluorescence units. 
 
Glycan No. Glycan Name Average Standard Deviation 
7 α-D-Gal–Sp8 2635 1443 
8 α-D-Glc–Sp8 738 378 
9 α-D-Man–Sp8 509 1151 
10 α-GalNAc–Sp8 4595 1896 
11 α-L-Fuc–Sp8 1291 582 
12 α-L-Fuc–Sp9 1333 596 
13 α-L-Rhα–Sp8 438 160 
14 α-Neu5Ac–Sp8 678 335 
15 α-Neu5Ac–Sp11 804 448 
16 β-Neu5Ac-Sp8 576 322 
17 β-D-Gal–Sp8 2260 1475 
18 β-D-Glc–Sp8 976 311 
19 β-D-Man–Sp8 425 697 
20 β-GalNAc–Sp8 1043 624 
21 β-GlcNAc–Sp0 514 175 
22 β-GlcNAc–Sp8 383 214 
23 β-GlcN(Gc)-Sp8 613 317 
24 (Galβ1-4GlcNAcβ)2-3,6-GalNAcα–Sp8 1222 543 
25 GlcNAcβ1-3(GlcNAcβ1-4)(GlcNAcβ1-6)GlcNAc-Sp8 375 247 
26 [3OSO3][6OSO3]Galβ1-4[6OSO3]GlcNAcβ-Sp0 3905 524 
27 [3OSO3][6OSO3]Galβ1-4GlcNAcβ-Sp0 1861 1132 
28 [3OSO3]Galβ1-4Glcβ-Sp8 1822 643 
29 [3OSO3]Galβ1-4(6OSO3)Glcβ–Sp0 2250 957 
30 [3OSO3]Galβ1-4(6OSO3)Glcβ–Sp8 3185 568 
31 [3OSO3]Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 1361 404 
32 [3OSO3]Galβ1-3GalNAcα–Sp8 815 450 
33 [3OSO3]Galβ1-3GlcNAcβ–Sp8 1511 552 
34 [3OSO3]Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 737 159 
35 [3OSO3]Galβ1-4[6OSO3]GlcNAcβ-Sp8 2561 938 
36 [3OSO3]Galβ1-4GlcNAcβ–Sp0 1180 476 
37 [3OSO3]Galβ1-4GlcNAcβ-Sp8 974 349 
38 [3OSO3]Galβ–Sp8 1705 1440 
39 [4OSO3][6OSO3]Galβ1-4GlcNAcβ-Sp0 1633 518 
40 [4OSO3]Galβ1-4GlcNAcβ-Sp8 1351 453 
41 6-H2PO3Manα–Sp8 511 252 
42 [6OSO3]Galβ1-4Glcβ–Sp0 2256 1217 
43 [6OSO3]Galβ1-4Glcβ–Sp8 2742 1060 
44 [6OSO3]Galβ1-4GlcNAcβ–Sp8 2604 1243 
45 [6OSO3]Galβ1-4[6OSO3]Glcβ-Sp8 7262 2333 
46 NeuAcα2-3[6OSO3]Galβ1-4GlcNAcβ–Sp8 694 427 
47 [6OSO3]GlcNAcβ–Sp8 2103 690 
48 9-O-AcNeu5NAcα-Sp8 489 183 
49 9-O-AcNeu5NAcα2-6Galβ1-4GlcNAcβ-Sp8 597 198 
50 Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 738 543 
51 GlcNAcβ1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 564 147 
52 Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-
4GlcNAcβ1-4GlcNAcβ-Gly 
2076 459 
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53 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-
2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 
1263 780 
54 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-
2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp8 
1355 591 
55 Fucα1-2Galβ1-3GalNAcβ1-3Galα-Sp9 636 164 
56 Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp9 704 246 
57 Fucα1-2Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 307 178 
58 Fucα1-2Galβ1-3GalNAcα–Sp8 867 661 
59 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 847 273 
60 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp9 1289 370 
61 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp10 370 267 
62 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp8 404 300 
63 Fucα1-2Galβ1-3GlcNAcβ–Sp0 424 248 
64 Fucα1-2Galβ1-3GlcNAcβ–Sp8 211 106 
65 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 444 61 
66 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-
4(Fucα1-3)GlcNAcβ-Sp0 
607 371 
67 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 389 243 
68 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 383 152 
69 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc–Sp0 450 283 
70 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 546 187 
71 Fucα1-2Galβ1-4GlcNAcβ–Sp0 449 332 
72 Fucα1-2Galβ1-4GlcNAcβ–Sp8 339 150 
73 Fucα1-2Galβ1-4Glcβ–Sp0 282 97 
74 Fucα1-2Galβ–Sp8 1707 575 
75 Fucα1-3GlcNAcβ-Sp8 642 633 
76 Fucα1-3GlcNAcβ-Sp8 416 271 
77 Fucα1-4GlcNAcβ–Sp8 397 238 
78 Fucβ1-3GlcNAcβ-Sp8 814 1172 
79 GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ-Sp0 542 346 
80 GalNAcα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 443 150 
81 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp0 426 164 
82 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ–Sp8 398 128 
83 GalNAcα1-3(Fucα1-2)Galβ1-4Glcβ-Sp0 715 463 
84 GalNAcα1-3(Fucα1-2)Galβ–Sp8 6005 14001 
85 GalNAcα1-3GalNAcβ–Sp8 331 161 
86 GalNAcα1-3Galβ–Sp8 695 380 
87 GalNAcα1-4(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 459 142 
88 GalNAcβ1-3GalNAca–Sp8 228 123 
89 GalNAcβ1-3(Fucα1-2)Galβ-Sp8 4340 1928 
90 GalNAcβ1-3Galα1-4Galβ1-4GlcNAcβ-Sp0 1745 475 
91 GalNAcβ1-4(Fucα1-3)GlcNAcβ-Sp0 339 250 
92 GalNAcβ1-4GlcNAcβ–Sp0 669 265 
93 GalNAcβ1-4GlcNAcβ–Sp8 470 148 
94 Galα1-2Galβ–Sp8 459 217 
95 Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ-Sp0 357 244 
96 Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 340 197 
97 Galα1-3(Fucα1-2)Galβ1-4GlcNAc-Sp0 300 89 
98 Galα1-3(Fucα1-2)Galβ1-4Glcβ-Sp0 331 166 
99 Galα1-3(Fucα1-2)Galβ–Sp8 400 167 
100 Galα1-3(Galα1-4)Galβ1-4GlcNAcβ-Sp8 4983 2540 
101 Galα1-3GalNAcα-Sp8 510 66 
102 Galα1-3GalNAcβ–Sp8 258 191 
103 Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 413 194 
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104 Galα1-3Galβ1-3GlcNAcβ-Sp0 525 398 
105 Galα1-3Galβ1-4GlcNAcβ–Sp8 879 175 
106 Galα1-3Galβ1-4Glcβ–Sp0 363 229 
107 Galα1-3Galβ–Sp8 608 342 
108 Galα1-4(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 573 141 
109 Galα1-4Galβ1-4GlcNAcβ–Sp0 1173 353 
110 Galα1-4Galβ1-4GlcNAcβ–Sp8 1760 1164 
111 Galα1-4Galβ1-4Glcβ–Sp0 1004 494 
112 Galα1-4GlcNAcβ–Sp8 2245 462 
113 Galα1-6Glcβ-Sp8 1012 442 
114 Galβ1-2Galβ–Sp8 624 493 
115 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 27645 3827 
116 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 2362 413 
117 Galβ1-3(Fucα1-4)GlcNAc–Sp0 11544 3156 
118 Galβ1-3(Fucα1-4)GlcNAc–Sp8 25937 4145 
119 Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 13755 11332 
120 Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcα-Sp8 16480 6923 
121 Galβ1-3(GlcNAcβ1-6)GalNAcα-Sp8 3983 818 
122 Galβ1-3(Neu5Acα2-6)GalNAcα-Sp8 4411 2011 
123 Galβ1-3(Neu5Acβ2-6)GalNAcα-Sp8 5998 3514 
124 Galβ1-3(Neu5Acα2-6)GlcNAcβ1-4Galβ1-4Glcβ-Sp10 1480 342 
125 Galβ1-3GalNAcα-Sp8 6720 3221 
126 Galβ1-3GalNAcβ–Sp8 14254 3225 
127 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp0 27047 8778 
128 Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 22770 3463 
129 Galβ1-3GalNAcβ1-4Galβ1-4Glcβ–Sp8 20665 12510 
130 Galβ1-3Galβ–Sp8 3457 1537 
131 Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 723 310 
132 Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp10 1439 252 
133 Galβ1-3GlcNAcβ–Sp0 1270 830 
134 Galβ1-3GlcNAcβ–Sp8 1900 277 
135 Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 11018 3525 
136 Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 17675 2294 
137 Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 10200 1390 
138 Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-
3)GlcNAcβ–Sp0 
47546 5464 
139 Galβ1-4[6OSO3]Glcβ–Sp0 3820 1199 
140 Galβ1-4[6OSO3]Glcβ–Sp8 8256 2780 
141 Galβ1-4GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 35253 5429 
142 Galβ1-4GalNAcβ1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 38753 5948 
143 Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcα-Sp8 1883 225 
144 Galβ1-4GlcNAcβ1-3GalNAcα–Sp8 603 530 
145 Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-
Sp0 
2284 384 
146 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 430 178 
147 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 2497 970 
148 Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ–Sp0 933 468 
149 Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ–Sp8 1820 787 
150 Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα–Sp8 7136 5663 
151 Galβ1-4GlcNAcβ1-6GalNAcα–Sp8 22993 5394 
152 Galβ1-4GlcNAcβ–Sp0 757 482 
153 Galβ1-4GlcNAcβ–Sp8 644 396 
154 Galβ1-4Glcβ–Sp0 938 557 
155 Galβ1-4Glcβ–Sp8 2556 4729 
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156 GlcNAcα1-3Galβ1-4GlcNAcβ-Sp8 311 286 
157 GlcNAcα1-6Galβ1-4GlcNAcβ-Sp8 16641 2363 
158 GlcNAcβ1-2Galβ1-3GalNAcα–Sp8 230 305 
159 GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα–Sp8 285 237 
160 GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4GlcNAcβ–Sp8 738 481 
161 GlcNAcβ1-3GalNAcα–Sp8 189 143 
162 GlcNAcβ1-3Galβ-Sp8 336 181 
163 GlcNAcβ1-3Galβ1-3GalNAcα-Sp8 298 118 
164 GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 327 157 
165 GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 302 134 
166 GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 551 259 
167 GlcNAcβ1-3Galβ1-4Glcβ–Sp0 305 181 
168 GlcNAcβ1-4MDPLys 304 175 
169 GlcNAcβ1-4(GlcNAcβ1-6)GalNAcα-Sp8 203 117 
170 GlcNAcβ1-4Galβ1-4GlcNAcβ-Sp8 573 510 
171 (GlcNAcβ1-4)6β-Sp8 640 390 
172 (GlcNAcβ1-4)5β-Sp8 997 374 
173 GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ–Sp8 2040 552 
174 GlcNAcβ1-6(Galβ1-3)GalNAcα–Sp8 2459 2410 
175 GlcNAcβ1-6GalNAcα–Sp8 2300 761 
176 GlcNAcβ1-6Galβ1-4GlcNAcβ-Sp8 941 272 
177 Glcα1-4Glcβ–Sp8 175 92 
178 Glcα1-4Glcα–Sp8 519 387 
179 Glcα1-6Glcα1-6Glcβ-Sp8 549 699 
180 Glcβ1-4Glcβ-Sp8 300 172 
181 Glcβ1-6Glcβ-Sp8 348 286 
182 Sorbitol-Sp8 564 355 
183 GlcAα-Sp8 626 386 
184 GlcAβ-Sp8 384 263 
185 GlcAβ1-3Galβ-Sp8 614 462 
186 GlcAβ1-6Galβ-Sp8 3500 2173 
187 KDNα2-3Galβ1-3GlcNAcβ–Sp0 340 296 
188 KDNα2-3Galβ1-4GlcNAcβ–Sp0 451 215 
189 Manα1-2Manα1-2Manα1-3Manα-Sp9 524 94 
190 Manα1-2Manα1-3(Manα1-2Manα1-6)Manα-Sp9 295 56 
191 Manα1-2Manα1-3Manα-Sp9 456 288 
192 Manα1-6(Manα1-2Manα1-3)Manα1-6(Manα2Manα1-3)Manβ1-4GlcNAcβ1-
4GlcNAcβ-N 
298 188 
193 Manα1-2Manα1-6(Manα1-3)Manα1-6(Manα2Manα2Manα1-3)Manβ1-
4GlcNAcβ1-4GlcNAcβ-N 
432 269 
194 Manα1-2Manα1-2Manα1-3(Manα1-2Manα1-3(Manα1-2Manα1-6)Manα1-
6)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 
381 400 
195 Manα1-3(Manα1-6)Manα–Sp9 503 311 
196 Manα1-3(Manα1-2Manα1-2Manα1-6)Manα-Sp9 481 192 
197 Manα1-6(Manα1-3)Manα1-6(Manα2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 466 133 
198 Manα1-6(Manα1-3)Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4 GlcNAcβ-N 894 742 
199 Man5_9mix N 634 414 
200 Manβ1-4GlcNAcβ-Sp0 288 222 
201 Neu5Acα2-3(Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ-Sp0 29741 6517 
202 Neu5Acα2-3Galβ1-3GalNAcα-Sp8 457 277 
203 NeuAcα2-8NeuAcα2-8NeuAcα2-8NeuAcα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 846 402 
204 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 1292 512 
205 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ–Sp0 454 262 
206 Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ–Sp0 3261 4473 
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207 Neu5Acα2-8Neu5Acα2-8Neu5Acα-Sp8 222 126 
208 Neu5Acα2-3(6-O-Su)Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 479 384 
209 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp0 612 270 
210 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp8 404 156 
211 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ–Sp0 757 272 
212 NeuAcα2-3(NeuAcα2-3Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ-Sp0 412 141 
213 Neu5Acα2-3(Neu5Acα2-6)GalNAcα–Sp8 419 222 
214 Neu5Acα2-3GalNAcα–Sp8 481 281 
215 Neu5Acα2-3GalNAcβ1-4GlcNAcβ-Sp0 510 469 
216 Neu5Acα2-3Galβ1-3(6OSO3)GlcNAc-Sp8 464 601 
217 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 450 428 
218 NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ Sp0 725 305 
219 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ-Sp8 507 221 
220 Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα-Sp8 1075 736 
221 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα–Sp8 444 215 
222 Neu5Acα2-3Galβ-Sp8 797 501 
223 NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp0 411 371 
224 NeuAcα2-3Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 529 220 
225 Neu5Acα2-3Galβ1-3GlcNAcβ–Sp0 406 239 
226 Neu5Acα2-3Galβ1-3GlcNAcβ–Sp8 344 147 
227 Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ-Sp8 828 630 
228 Neu5Acα2-3Galβ1-4(Fucα1-3)(6OSO3) GlcNAcβ –Sp8 1394 329 
229 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-
3Galβ1-4(Fucα1-3) GlcNAcβ–Sp0 
790 425 
230 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 713 520 
231 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 456 280 
232 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ-Sp8 380 271 
233 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 1446 269 
234 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc-Sp0 519 291 
235 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 966 329 
236 Neu5Acα2-3Galβ1-4GlcNAcβ–Sp0 428 430 
237 Neu5Acα2-3Galβ1-4GlcNAcβ–Sp8 606 458 
238 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 620 734 
239 Neu5Acα2-3Galβ1-4Glcβ–Sp0 715 553 
240 Neu5Acα2-3Galβ1-4Glcβ–Sp8 270 167 
241 Neu5Acα2-6(Galβ1-3)GalNAcα–Sp8 4542 2836 
242 Neu5Acα2-6GalNAcα–Sp8 545 601 
243 Neu5Acα2-6GalNAcβ1-4GlcNAcβ-Sp0 388 90 
244 Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ-Sp8 2798 1633 
245 Neu5Acα2-6Galβ1-4GlcNAcβ–Sp0 385 289 
246 Neu5Acα2-6Galβ1-4GlcNAcβ–Sp8 353 157 
247 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-
3)GlcNAcβ-Sp0 
951 349 
248 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 785 442 
249 Neu5Acα2-6Galβ1-4Glcβ–Sp0 601 192 
250 Neu5Acα2-6Galβ1-4Glcβ–Sp8 450 352 
251 Neu5Acα2-6Galβ–Sp8 1147 365 
252 Neu5Acα2-8Neu5Acα-Sp8 615 610 
253 Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ–Sp0 945 529 
254 Neu5Acβ2-6GalNAcα–Sp8 203 212 
255 Neu5Acβ2-6Galβ1-4GlcNAcβ-Sp8 483 236 
256 Neu5Acβ2-6(Galβ1-3)GalNAcα–Sp8 2480 2916 
257 Neu5Gcα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 437 335 
258 Neu5Gcα2-3Galβ1-3GlcNAcβ-Sp0 714 206 
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259 Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 880 582 
260 Neu5Gcα2-3Galβ1-4GlcNAcβ–Sp0 647 212 
261 Neu5Gcα2-3Galβ1-4Glcβ–Sp0 712 253 
262 Neu5Gcα2-6GalNAcα–Sp0 365 116 
263 Neu5Gcα2-6Galβ1-4GlcNAcβ–Sp0 748 200 
264 Neu5Gcα–Sp8 243 237 
265 [3OSO3]Galβ1-4(Fucα1-3)(6OSO3)Glc-Sp0 1598 452 
266 [3OSO3]Galβ1-4(Fucα1-3)Glc-Sp0 514 260 
267 [3OSO3]Galβ1-4[Fucα1-3][6OSO3]GlcNAc-Sp8  1995 366 
268 [3OSO3]Galβ1-4[Fucα1-3]GlcNAc-Sp0  394 303 
269 Fucα1-2[6OSO3]Galβ1-4GlcNAc-Sp0 1381 985 
270 Fucα1-2Galβ1-4[6OSO3]GlcNAc-Sp8 1305 1220 
271 Fucα1-2[6OSO3]Galβ1-4[6OSO3]Glc-Sp0 2156 1083 
272 Fucα1-2-(6OSO3)-Galβ1-4Glc-Sp0 1701 2480 
273 Fucα1-2-Galβ1-4[6OSO3]Glc-Sp0 1359 559 
274 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 4469 2914 
275 Galβ1-3-(Galβ1-4GlcNacβ1-6)GalNAc-T 12027 8153 
276 Galβ1-3(GlcNacβ1-6)GalNAc-T 8636 2146 
277 Galβ1-3-(Neu5Aα2-3Galβ1-4GlcNacβ1-6)GalNAc-T 3835 1833 
278 Galβ1-3GalNAc-T 10274 5772 
279 Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 160 91 
280 Galβ1-4[Fucα1-3][6OSO3]GlcNAc-Sp0  3319 3394 
281 Galβ1-4[Fucα1-3][6OSO3]Glc-Sp0 2356 1641 
282 Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 2981 1602 
283 Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 373 213 
284 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0  472 201 
285 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0           437 293 
    
Spacer arm codes: 
Sp0 -CH2CH2NH2  
Sp8 -CH2CH2CH2NH2  
Sp9 -CH2CH2CH2CH2CH2NH2  
Sp10 -NHCOCH2NH  
Sp11 -OCH2C6H4-p-NHCOCH2NH  
mMDPLys -Mur-L-Ala-D-iGlnь-(CH2)4NH2  
T -Threonine  
N -Asparagine 
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residue adjacent to the terminal galactose residue that is linked by an α1-3 or α1-4 
linkage. Little binding is observed to glycans containing terminal fucose in a α1-2 
linkage (glycans 95-99 and 108). This preference is evident as eight of the twenty 
highest binding ligands for GalMBP contain either the Lewisa (Galβ1-3(Fucα1-
4)GlcNAc) or the Lewisx (Galβ1-4(Fucα1-3)GlcNAc) trisaccharides (Figure 2.4B). Of 
the remaining highest binding ligands that do not contain terminal fucose, the 
majority contain the disaccharide Galβ1-3GalNAc. Specificity for GalNAc in the 
subterminal position is highlighted by the lack of binding to glycans containing Galβ1-
3GlcNAc (glycans 131-134) or Galβ1-3Gal (glycan 130). The disaccharide Galβ1-
3GalNAc is the core I structure of mucin-type O-linked glycans, which in an 
unmodified form is commonly referred to as the cancer-associated Thomsen-
Friedenriech antigen (T antigen). The ability of GalMBP to bind to the T antigen is 
supported by its binding to glycan 278, where Galβ1-3GalNAc is presented on a 
threonine linker. 
 
 
2.4 Discussion 
Although the CRD of MBP-A was originally mutated to mimic the galactose-
binding CRD of the asialoglycoprotein receptor subunit 1 (ASGPR-1) the resulting 
protein, GalMBP, shows a novel binding specificity. ASGPR-1 shows specificity for 
GalNAc- and galactose-terminating glycans, but preferentially binds to GalNAc due 
to secondary interactions with the 2-acetamido group of the sugar (Kolatkar et al., 
1998). Receptors such as rat macrophage galactose lectin (MGL) lack the secondary 
interactions with acetamido groups and consequently bind Gal and GalNAc with 
roughly equal affinity (Coombs et al., 2006). Although monosaccharide-binding 
assays suggested that GalMBP resembles rat MGL in recognising galactose and 
GalNAc with equal affinity (Iobst and Drickamer, 1994), GalMBP has shown a strong 
preference for glycans containing terminal galactose when tested on an array of 
glycans. This discrepancy may be due to the presentation of terminal GalNAc on an 
oligosaccharide affecting the way it can be accommodated in the primary binding site 
of GalMBP.  
The glycan array profile of GalMBP reveals a preference for subsets of 
galactose-terminated glycans that contain fucose or have a β1-3 linkage to GalNAc. 
The preference for terminal fucose shows some similarity to that of the macrophage 
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galactose receptor (Coombs et al., 2006). The array profile suggests that GalMBP 
makes primary interactions with a terminal galactose residue and this binding is 
enhanced through secondary interactions with an adjacent terminal fucose residue. 
Modelling the Lewisx trisaccharide into the primary binding site of GalMBP reveals a 
potential mechanism for the preference of ligands containing terminal fucose (Figure 
2.5A). Two potential interactions between GalMBP and the fucose from the Lewisx 
structure are evident. Distances between the 4-hydroxyl group of fucose and the 
amide side group of Gln185 and the backbone carbonyl group of Lys183 are both 
consistent with potential hydrogen bonding (Figure 2.5B). In addition, the alkyl chain 
from the side chain of Lys182 is in close proximity to the C6 methyl group of fucose, 
which may provide additional van der Waals interactions between protein and 
carbohydrate (Figure 2.5C). Interactions between protein and the C6 methyl group of 
fucose would explain the preference for fucose and not other sugar units. The 
selectivity of GalMBP for Galβ1-3GalNAc has not been observed in other galactose-
binding receptors, but preference of the β1-3 linkage to GalNAc over galactose 
suggests that additional interactions with the 2-acetamido group may occur. 
However, the distinction between GalNAc and GlcNAc suggests that the positioning 
of the 4-hydroxyl group in an axial position is also important. 
The successful creation of a galactose-binding mutant of MBP-A that has 
altered ligand specificity validates the development of mutant versions of MBP as 
tools for cancer cell detection and killing. If the CRD of MBP-A could be altered to 
bind glycan structures commonly found on cancer cells, then the full length protein 
could be used as a means of identifying such cells to the immune system. Analysis 
of the carbohydrate specificity of GalMBP suggests that it might be able to function in 
this capacity. GalMBP shows preferential binding to ligands containing the Lewisx or 
Lewisa trisaccharides, which have been shown to be expressed at increased levels in 
a variety of cancers including breast carcinomas (Brockhausen, 2006; Brooks and 
Leathem, 1995; Capurro et al., 1998; Kadota et al., 1999). Another GalMBP ligand, 
the disaccharide Galβ1-3GalNAc, is a common O-linked glycan structure found on 
the surface of breast and colon carcinomas (Brockhausen, 2006).  
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Figure 2.5 Modelling the binding of Lewis  by GalMBP. A, The structure of a glycan 
x
containing the Lewis  trisaccharide was modelled into the carbohydrate-binding site of 
x 
GalMBP. B, Detailed analysis of the region surrounding the fucose residue in the Lewis
structure shows two possible hydrogen bonding interactions between protein and glycan. C, 
An energetically favourable packing interaction is also evident. This figure was prepared using 
x 
entries 1AFA and 1SL5 from the Protein Databank. The structure of a Lewis oligosaccharide 
was extracted from entry 1SL5 and was modelled into the binding site by overlapping the 
galactose residue with the galactose bound in the protein structure. Figures were prepared 
using PyMOL version 0.99. 
B
B = 2.58 Å 
A = 2.85 Å
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Chapter 3 
 
GalMBP as a tool for the detection and characterisation of breast 
cancer cells  
 
3.1  Introduction 
The specificity for glycan structures commonly found on cancer cells suggested 
that GalMBP may have the capacity to selectively recognise cancer cell surfaces and 
thus act as a novel reagent for cancer cell detection. As GalMBP can interact with 
molecules of the innate system, GalMBP binding to cancer cells could lead to their 
identification and clearance. In order to test this hypothesis, the binding of GalMBP to 
breast cancer cell lines has been investigated.  
Breast cancer is the second most common type of cancer and accounts for a 
large number of cancer-related deaths (Anderson and Jakesz, 2008). Due to the high 
prevalence of this disease, breast cancer is one of the most active areas of cancer 
research. Immortalised cell lines are commonly used as models for the in vitro 
analysis of breast cancers. The availability of cell lines is invaluable for in vitro 
biochemical analyses such as proteomic and glycomic profiling. Tumours are only 
available in limited and finite quantities, and the inherent heterogeneity of tumour 
tissue makes any interpretation of studies such as glycomic profiling difficult. A large 
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number of cell line models for breast cancer are available, but the vast majority of 
published literature has used only a restricted subset. The most commonly used cell 
lines, including MCF7, T47D and SKBR3, have all been extensively characterised 
and investigated as models of breast cancers (Lacroix and Leclercq, 2004). 
The identification of proteins expressed at high levels on breast cancer cell-
surfaces has led to the development of therapeutic antibodies including Herceptin 
(Dillman, 1999). Herceptin binds to the Her2 protein, an epidermal growth factor 
receptor, whose expression is upregulated in a significant percentage of breast 
cancers. The anti-tumour activities of Herceptin are mediated primarily through 
antibody-dependent cell cytotoxicity, using antibody receptors on the surface of 
macrophages and natural killer cells. Therapeutic antibodies have been developed 
for the treatment of other cancers that do not generate significant innate immune 
responses against their cancer cell targets. These can mediate anti-tumour activities 
in a neutralising capacity, by inhibiting the action of the protein which they bind, or as 
delivery systems for cytotoxic reagents to the cancer cell (Carter and Senter, 2008; 
Satoh et al., 2006).  
The use of glycan structures as cell-surface markers for cancer cells is well 
established (Dube and Bertozzi, 2005). Aberrant glycosylation is a universal feature 
of cancer cells and many antibodies that have cancer-cell specific reactivity have 
been found to react with carbohydrate epitopes (Feizi, 1985a). Antibodies that bind to 
carbohydrates have been used as diagnostic reagents for certain cancers including 
anti-Lewisx antibodies in the diagnosis of Hodgkin's lymphoma and anti-Lewisa 
antibodies for some colon cancers (Dorfman et al., 1986; Macdonald, 1999).  
The demonstration of distinct carbohydrate specificity toward cancer-associated 
glycan structures by GalMBP suggested that it could act to target cancer cells. In the 
work described in this chapter, binding by GalMBP to breast cancer cell lines has 
been investigated and the glycoprotein ligands of GalMBP identified. GalMBP has 
been shown to act as an effective tool for the identification and purification of 
glycoproteins from breast cancer cells. This glycoproteomic approach has allowed 
identification of the heavy chain of the cell-surface receptor CD98 as the predominant 
carrier of GalMBP ligands on the MCF7 breast cancer cell line. The ability of GalMBP 
to bind to a panel of breast cancer cell lines varies widely and reflects heterogeneity 
in the expression of GalMBP ligands. Analysis of proteins bound by GalMBP from a 
panel of cell lines shows large variations in the protein carriers of cancer-associated 
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glycosylation in breast cancer cells. Despite the lack of a common protein carrier, the 
purification of proteins involved in cell-cell adhesion in multiple cell lines highlights a 
potential role of glycans in disease progression.  
 
 
3.2 Materials and methods 
3.2.1 Materials 
Ammonium bicarbonate, bovine serum albumin (BSA) , 2,5-dihydroxybenzoic 
acid, α-cyano-4-hyroxycinnamic acid, dithiothreitol, epidermal growth factor, 
haemoglobin, hydrocortisone, insulin, iodoacetic acid, Dulbecco’s phosphate-
buffered saline (PBS) and non-enzymatic cell dissociation solution were all from 
Sigma-Aldrich Company Ltd (Poole, Dorset, UK). Bolton Hunter reagent was 
supplied by Amersham Biosciences (Little Chalfont, Buckinghamshire, UK). MP 
Biomedicals (Illkirch, France) supplied goat anti-rabbit-HRP conjugated antibody. 
Horseradish peroxidase substrate was purchased from Pharmingen (Oxford, UK). 
Protease inhibitors and 5-Bromo-4-chloro-3-indolylphosphate/Nitroblue Tetrazolium 
(BCIP/NBT) alkaline phosphatase substrate were purchased from Calbiochem 
(Nottingham, UK). Perbio Science Ltd. (Cramlington, Northumberland, UK) were 
suppliers of sulpho-N-hydroxysuccinimide biotin (sulpho-NHS biotin) and avidin-
conjugated agarose beads. N-hydroxysuccinimide conjugated agarose (agarose-
NHS) was purchased from Biorad Laboratories Ltd (Hemel Hempstead, 
Hertfordshire, UK). Sequencing grade modified trypsin was purchased from Promega 
Corp. (Southampton, UK). High quality solvents and reagents acetic acid, acetonitrile 
and trifluoroacetic acid were purchased from Romil Ltd (Cambridge, UK). Protran 
nitrocellulose was supplied by Whatman Plc, (Maidstone, Kent, UK). Sequazyme 
peptide mass standards were purchased from Applied Biosystems (Foster city, CA 
USA) 
 
3.2.2 Cell culture 
Cell line MCF7 was grown in Dulbecco’s modified-Eagle’s medium/ Ham’s 
nutrient mixture F-12 (1:1) supplemented with 10% foetal calf serum, 2 mM 
glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. Cell lines MDA-MB-231, 
T47D and ZR75-1 were purchased from the European collection of cell cultures. 
MDA-MB-231 cells were grown in Leibovitz’s L-15 medium supplemented with 15% 
72
  
foetal bovine serum, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml 
streptomycin. T47D cells were grown in Dulbecco’s modified Eagle medium (DMEM) 
supplemented with 10% foetal bovine serum, 2 mM glutamine, 100 U/ml penicillin 
and 100 µg/ml streptomycin. ZR75-1 cells were grown in RPMI 1640 medium 
supplemented with 10% foetal bovine serum, 1 mM sodium pyruvate, 100 U/ml 
penicillin and 100 µg/ml streptomycin. Cell line SKBR3 was purchased from the 
American Type Culture Collection and was grown in McCoy’s 5a modified medium 
supplemented with 10% foetal bovine serum, 100 U/ml penicillin and 100 µg/ml 
streptomycin. 
 
3.2.3 Production and purification of MBP-A   
CHO cell lines stably expressing MBP-A were previously generated (Wallis and 
Drickamer, 1999) and protein was produced using an identical procedure to GalMBP 
(Section 2.2.5), with the exception that mannose-Sepharose was used in place of 
galactose-Sepharose. Mannose-Sepharose was prepared by the divinyl sulphone 
method (Fornstedt and Porath, 1975) 
 
3.2.4 Cell-binding assays 
Cells were grown to confluence in 96-well plates. Assays for each cell line used 
the recommended medium for cell growth but without phenol red indicator present 
and without supplements. Wells were washed twice with 250 µl of medium and were 
incubated with 100 µl of MBP-A or GalMBP in medium for 30 min at room 
temperature. Solutions were removed and wells were washed four times with 250 µl 
of medium and incubated for 60 min at room temperature with rabbit serum 
containing anti-MBP-A antibodies diluted 1:800 in medium containing 5% BSA. Wells 
were washed with 250 µl of medium four times and incubated for 60 min at room 
temperature with a 1:800 dilution of goat anti-rabbit antibody conjugated to 
horseradish peroxidase (HRP) (27 µg/ml). Wells were washed four times with 250 µl 
of medium and incubated with 100 µl of HRP substrate for 10 min at room 
temperature in the dark. Reactions were terminated with 50 µl of 2 M HCl and 
samples were centrifuged at 250 x g for 5 min. Supernatant (100 µl) was transferred 
to a 96-well ELISA plate and the absorbance was read at 450 nm.  
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3.2.5 GalMBP radiolabelling 
GalMBP (1 ml at 0.5 mg/ml) was dialysed against 1 l of labelling buffer (150 mM 
NaCl; 100 mM Bicine, pH 8.5; 5 mM CaCl2) overnight at 4 °C. Dialysed protein was 
labelled with 125I by incubation at room temperature for 30 min with 20 µl of Bolton-
Hunter reagent that was dried under nitrogen immediately prior to use. Labelled 
protein was passed over a 1-ml galactose-Sepharose column which was washed 
with 5 ml of low salt loading buffer and protein was eluted in five 0.5-ml fractions of 
low salt elution buffer. Radioactivity for each fraction was measured using a Wallac 
1470 Wizard γ counter and fractions containing the highest levels of radioactivity 
were pooled and added to 25 ml of low salt loading buffer containing 2 % 
haemoglobin.  
 
3.2.6 Cell membrane solubilisation. 
Cells were grown to confluence in a 75 cm2 flask, washed with 10 ml of PBS 
and harvested by scraping. Cells were washed off the flask with 5 ml of PBS and 
centrifuged at 450 x g for 2 min, resuspended in 1 ml of cell lysis buffer (150 mM 
NaCl; 25 mM Tris-Cl, pH 7.8) containing 1% Triton X-100 and protease inhibitors (0.5 
mM AEBSF; 150 nM Aprotinin; 1 µM E-64 protease inhibitor; 0.5 mM EDTA; 1 µM 
Leupeptin), sonicated for 5 s and incubated on ice for 30 min. Samples were 
centrifuged at 16,000 x g for 5 min at 4 °C and the supernatant was transferred to a 
new tube and stored at -20 ºC prior to analysis. 
 
3.2.7 MCF7 cell-surface biotinylation. 
MCF7 cells were grown in 100 mm plates to 80% and 40% confluence. Cells 
were washed twice with PBS containing 0.1 mM CaCl2 and 1 mM MgCl2 (PBS-
Ca/Mg) and incubated with gentle shaking for 20 min at 4°C with 4 ml of 1 mg/ml 
sulpho-NHS-biotin, dissolved in PBS-Ca/Mg. Cells were washed twice and incubated 
at 4 °C with gentle shaking for 40 min with PBS-Ca/Mg containing 100 mM glycine, 
washed twice with PBS-Ca/Mg and harvested by scraping into 5 ml of PBS-Ca/Mg 
and centrifugation at 450 x g for 2 min. Pellets were dissolved in 1 ml of biotinylation 
lysis buffer (150 mM NaCl; 100 mM Tris-Cl, pH 7.4; 1 mM EDTA; 1 % Triton X-100) 
containing protease inhibitors, sonicated for 5 s and incubated at 4 °C for 10 min with 
end-over-end mixing. Solubilised pellets were centrifuged at 14,000 x g for 5 min and 
the supernatant was transferred to a new tube. Aliquots of supernatant were 
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removed for analysis and the remaining supernatants were incubated with 100 µl of a 
50 % suspension of avidin-conjugated agarose beads for 60 min at 4 °C with end-
over end mixing. Beads were pelleted by centrifugation at 14,000 x g for 5 min. The 
supernatants were removed and the pellets were resuspended in 1 ml of biotinylation 
lysis buffer. After four washes proteins were eluted from the beads by boiling at 100 
°C for 5 min in 50 µl 1x sample buffer containing 1% β-mercaptoethanol.  
 
3.2.8 Preparation of GalMBP affinity columns 
Bacterially expressed GalMBP was dialysed overnight in coupling buffer (150 
mM NaCl; 100 mM HEPES, pH 8.0; 50 mM CaCl2). A 2 ml aliquot of Affigel 10 
agarose-NHS conjugate was rinsed with 10 ml of cold H2O before the dialysed 
protein (2 ml at 5 mg/ml) was added. The suspension was mixed vigorously and 
incubated at 4 °C for 240 min on an end-over-end mixer. The column was drained, 
rinsed with 10 ml of low salt loading buffer and stored in low salt loading buffer 
overnight before use. 
 
3.2.9 Purification of membrane proteins   
Flasks (2 x 225 cm2) of cells were grown to confluence, washed twice with 10 
ml of PBS and harvested by scraping into 10 ml of PBS followed by centrifugation at 
450 x g for 2 min. Pellets were resuspended in 10 ml of cell lysis buffer containing 2 
mM CaCl2, 1% Triton X-100 and protease inhibitors, sonicated for 10 s and incubated 
on ice for 30 min. Lysate was precleared by centrifugation at 100,000 x g for 15 min 
at 4ºC and passed over a column containing immobilised GalMBP. The column was 
washed with 5 ml of cell lysis buffer containing 2 mM CaCl2 and 0.1% Triton X-100 
and protein was eluted with five 1-ml fractions of low salt elution buffer containing 
0.1% Triton X-100.  
The purity of elution fractions was increased by repurification over a GalMBP 
column. Elution fractions were pooled, CaCl2 was added to 25 mM, and the protein 
was again passed over the GalMBP affinity column. The column was washed with 5 
ml of loading buffer and 5 ml of low salt loading buffer (both containing 0.1% Triton X-
100) and ligands were eluted in five 1-ml fractions of low salt elution buffer containing 
0.1% Triton X-100. Fractions were analysed on 15% SDS-polyacrylamide gels.  
 
 
75
  
3.2.10 Western blot analysis of GalMBP ligands. 
For analysis with radiolabelled GalMBP, samples were analysed on 15% SDS-
polyacrylamide gels and electroblotted onto nitrocellulose membranes (Burnette, 
1981). Membranes were blocked using 2% haemoglobin in low salt loading buffer 
overnight at 4 °C and incubated with radiolabelled GalMBP for 120 min at room 
temperature with gentle shaking. Following four washes with 100 ml of Tris-buffered 
saline (TBS), radioactivity on membranes was detected using a Phosphorimager SI 
from Molecular Dynamics (Sunnyvale, USA). 
For detection of Mucin1 (MUC1) using anti-MUC1 antibodies, samples were 
analysed on 5% SDS-polyacrylamide gels and electroblotted onto nitrocellulose. 
Membranes were blocked at room temperature for 2 hours in 3% BSA dissolved in 
PBS and incubated with HMFG2 anti-MUC1 antibody (as undiluted serum from 
HMFG2- expressing hybridoma cultures) overnight at 4 °C with gentle shaking. 
Membranes were washed three times with PBS containing 0.05% Tween-20 and 
incubated with goat anti-mouse IgG/IgM antibody conjugated to alkaline phosphatase 
(1:5000 in PBS) for two hours at room temperature with gentle shaking. Following a 
further three washes with PBS containing 0.05% Tween-20, membranes were rinsed 
briefly in H2O and incubated in BCIP/NBT for 30 min in the dark. 
 
3.2.11 Analysis of purified ligands by in-gel trypsin digestion followed by mass 
spectrometry  
 Aliquots of 200 µl of each elution fraction were precipitated by the addition of 
trichloroacetic acid (TCA) to 10% of total volume and incubated on ice for 10 min. 
Samples were centrifuged at 16,000 x g for 5 min and pellets were washed twice with 
1 ml of ethanol:ether (1:1) and lyophilised for 2 min. Precipitated fractions were 
analysed on 15% SDS-polyacrylamide gels and protein bands approximately 1 mm 
wide were excised and cut into 1 mm pieces. Coomassie stain was removed from the 
gel pieces by incubation in 200 µl of 50 mM ammonium bicarbonate, pH 8.4 and 200 
µl of acetonitrile for 5 min at room temperature. Gel pieces were dried in a vacuum 
centrifuge before incubation at 56°C for 30 min in 200 µl of 10 mM dithiothreitol, 
dissolved in 50 mM ammonium bicarbonate, pH 8.4. Gel pieces were washed in 200 
µl of acetonitrile then dried in a vacuum centrifuge. Dried pieces were incubated in 
the dark at room temperature for 30 min with 200 µl of 55 mM iodoacetic acid 
dissolved in 50 mM ammonium bicarbonate, pH 8.4. The iodoacetic acid was 
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removed and the gel pieces were washed in 500 µl of 50 mM ammonium 
bicarbonate, pH 8.4, for 15 min at room temperature. The volume of the gel pieces 
was reduced by incubation in 200 µl of acetonitrile for 5 min before drying on a 
vacuum centrifuge. Dried gel pieces were rehydrated by the addition of 20 µl of 25 
ng/µl sequencing grade modified trypsin, dissolved in 50 mM ammonium 
bicarbonate, pH 8.4 for 15 min at room temperature. An additional 20 µl of 50 mM 
ammonium bicarbonate, pH 8.4, was added to the gel pieces and protein in-gel 
digested by incubation overnight at 37 ºC.  
The supernatant was removed from the gel pieces and placed in a new tube. 
Gel pieces were incubated in 50 µl of 0.1% triflouroacetic acid (TFA), diluted in H2O, 
for 10 min at 37 °C followed by the addition of 100 µl of acetonitrile and incubation for 
a further 15 min at 37 °C. The supernatant was removed, combined with the previous 
supernatant and the elutions process was repeated once. The pooled supernatants 
were reduced to 30 µl using a vacuum centrifuge. Samples (0.5 µl) were spotted onto 
a MALDI stainless steel plate and 0.5 µl of 10 mg/ml α-cyano-4 hydroxycinnamic 
acid, dissolved in acetonitrile:0.1% TFA (1:1) was spotted on top of each sample. 
Samples were air dried before analysis. Samples were subjected to MALDI MS 
profiling complemented with tandem mass spectrometry (MS/MS) sequencing of the 
ten most abundant ions in each sample, on an Applied Biosystems 4800 MALDI 
TOF/TOF mass spectrometer. For peptide mass fingerprint data, peak picking was 
conducted using GPS Explorer software version 3.6 (Applied Biosystems, Foster 
City, USA). A signal-to-noise threshold of 10 was used, sequazyme peptide mass 
standards were used as external standards for calibration and no ions were 
contaminant excluded. For MS/MS experiments, peak list generation and database 
searching was conducted using GPS Explorer software version 3.6 (Applied 
Biosystems, Foster City, USA) with the default parameters.   
Both MS and MS/MS data were used to search the SwissProt protein database 
using the Mascot database search algorithm with the following parameters; peptide 
masses were stated to be monoisotopic; methionine residues were assumed to be 
partially oxidised; the carboxymethylation of cysteine residues was considered; the 
mass tolerance was kept at 75 ppm; fragment ion tolerance was kept at 0.1 Da; 
tryptic digests were assumed to have no missed cleavages and the taxonomy group 
searched was Homo sapiens. Peptides positively identified from MS and MSMS data 
were combined to give a probability-based Mowse protein score (Perkins et al., 
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1999), equal to –10 x Log(P), where P is the probability that the observed match is a 
random event. Protein identifications with a probability score of greater than 95% 
were considered significant. For all samples additional searches were conducted with 
varied parameters including increasing the number of missed tryptic cleavages to 
one or two and altering the mass tolerance to 50 ppm or 100 ppm.  
 
3.2.12 Analysis of purified ligands by in-solution trypsin digestion followed by 
liquid chromatography and tandem mass spectrometry. 
Aliquots of 400 µl from peak elution fractions were precipitated with 
trichloroacetic acid (TCA) as described above. Precipitated fractions were dissolved 
in 25 µl of 8 M Urea; 10mM HEPEs (8.0), diluted with 25 µl of 50mM ammonium 
bicarbonate and reduced with 2 µl of 0.5 mg/ml DTT at room temperature for 30 min. 
Free cysteine thiols were alkylated with 10 µl of 0.5 mg/ml iodoacetic acid at room 
temperature for 20 min, diluted with 325 µl of 50 mM ammonium bicarbonate and 
digested with 2 µg of sequencing grade modified trypsin overnight at 37°C. Samples 
were dried on a vacuum centrifuge and resuspended in 80 µl of 0.1% TFA. Tryptic 
peptides were desalted and purified by nano-liquid chromatography using an 
Ultimate 3000 (LC Packings, Dionex, Sunnyvale, USA). Peptides were loaded in 
buffer A (2% acetonitrile:0.1% trifluoroacetic acid) and eluted using a 8-45% gradient 
over 60 min of buffer B (90% acetonitrile:0.1% trifluoroacetic acid) with a flow rate of 
0.3 µl/min. Eluting peptides were collected with retention times of between 12 and 60 
min in 30 second intervals with a total of 96 spots for each sample. Samples were 
spotted directly onto a MALDI steel target plate using a Probot (LC Packings, Dionex, 
Sunnyvale, USA) with α-cyano-4 hydroxycinnamic acid used as matrix. Samples 
were subjected to MALDI-MS profiling with major peaks selected for collisionally-
induced dissociation and sequencing by tandem mass spectrometry. A maximum of 
ten peaks were considered per spot; peaks with identical masses present in multiple 
spots were only sequenced once.   
 Fragment ions detected in the MS/MS spectra were used to search the 
SwissProt database with the Mascot database search algorithm for peptide 
sequences consistent with the ion fragments observed. The parameters used for 
database searching where identical to those described above, except that the 
fragment ion tolerance was increased to 0.5. Probability-based Mowse scores were 
generated for each peptide sequence identified and only values of greater than 95% 
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significance were considered (Perkins et al., 1999). Positive identification of a protein 
required identification of three or more unique peptide sequences identified with 
scores of greater than 95% significance.  
 
 
3.3 Results 
3.3.1 Detection of glycans on cancer cell surfaces with GalMBP 
The ability of GalMBP to bind to the cell surface of cancer cells was tested in a 
colourimetric assay using the human breast cancer cell line MCF7. MCF7 cells grown 
in 96-well plates were incubated with GalMBP, washed, and incubated with a rabbit 
polyclonal anti-MBP antibody. Following a further series of washes, cells were 
incubated with a goat anti-rabbit antibody conjugated to horseradish peroxidase, 
washed again, and a horseradish peroxidase substrate added. As a control, the 
binding of rat MBP-A to MCF7 cells was examined in parallel. The binding assay 
demonstrated that GalMBP binds to MCF7 cells with high affinity compared to MBP-
A (Figure 3.1). After normalisation of binding, the concentration of GalMBP required 
for 50% of maximal binding was approximately 10 ng whereas the concentration of 
MBP-A required for the same level of binding was 2 µg. GalMBP therefore binds to 
MCF7 cells with several hundred-fold greater affinity than MBP-A.  
 
3.3.2 Analysis of GalMBP ligands on MCF7 cells 
A more detailed analysis of GalMBP ligands present on MCF7 cells was 
performed by probing cell membranes with GalMBP that had been radioactively 
labelled with 125I. MCF7 cells were sonicated and cell membranes were separated by 
ultracentrifugation. The soluble components of the membrane pellet were dissolved 
in sample buffer. Cell lysates were prepared by sonication of cells in detergent buffer. 
Purified membranes and cell lysates were analysed by SDS-polyacrylamide gel 
electrophoresis followed by blotting onto nitrocellulose. When probed with 
radiolabelled GalMBP two distinct bands at approximately 75 kDa and 100 kDa were 
identified in both MCF7 membranes and lysates (Figure 3.2). To ensure that the 
bands identified represent proteins expressed on the cell surface, MCF7 cell surface 
proteins were biotinylated and purified on avidin-conjugated agarose beads. Both 
bands were present in blots of the purified biotinylated proteins (Figure 3.3).  
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Figure 3.1 GalMBP binding to MCF7 breast cancer cells. Experimental data (symbols) are 
shown together with the theoretical curves fitted to the data using a direct binding equation.
80
Figure 3.2 GalMBP ligands on MCF7 cells. A, Solubilised MCF7 membranes and B, MCF7 
cell lysates were analysed on 15% polyacrylamide gels. Gels were stained with Coomassie 
125
blue (left panels) or electroblotted onto nitrocellulose and probed with I-GalMBP (right 
panels). Samples were loaded in high (H), medium (M) or low (L) levels.  
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Figure 3.3 Cell-surface biotinylation of MCF7 cells. Total cell lysate and biotinylated 
proteins purified on avidin-conjugated beads were analysed by 15% SDS-polyacryamide gel 
electrophoresis followed by Coomassie blue staining (left panel) and blotting onto 
125
nitrocellulose then probing with I-GalMBP (right panel). The experiment was performed with 
a high (H) and low (L) number of MCF7 cells.
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3.3.3 Purification of cancer cell-surface glycoproteins using GalMBP 
In order to further characterise GalMBP ligands on MCF7 cells, glycoprotein 
ligands were enriched using columns of immobilised GalMBP (Figure 3.4). MCF7 
cells were solubilised in detergent buffer by sonication, precleared by centrifugation, 
and passed over columns of agarose containing a high level of immobilised GalMBP. 
The columns were washed with a buffer containing Ca2+ and ligands were eluted with 
EDTA.  
Analysis of the wash and elution fractions from the GalMBP column by SDS-
polyacrylamide gel electrophoresis showed protein binding and eluting from the 
column at the molecular weight of the two previously identified bands (Figure 3.5). 
Blotting fractions onto nitrocellulose and probing with radiolabelled GalMBP 
confirmed that the dominant bands in the elution fractions were GalMBP ligands, with 
the low level of GalMBP binding in the wash fractions and flow through from the 
column suggesting that the majority of ligand was retarded (Figure 3.5). The elution 
profile of the column indicated that many proteins were interacting non-specifically 
with the GalMBP column. To increase the purity of GalMBP ligands, elution fractions 
were pooled and again passed through the GalMBP column in the presence of Ca2+. 
A more stringent washing step was used for repurification using high and low salt 
buffers, in an effort to reduce the level of non-specific binding to the column. 
Repurification removed the majority of contaminating proteins with only 35 kDa and 
25 kDa low molecular weight bands eluting that were not recognised by radiolabelled 
GalMBP (Figure 3.6). 
 
3.3.4 Identification of GalMBP ligands on MCF7 cells by mass spectrometry 
The major bands present in the elution fractions of repurified MCF7 cells were 
excised, digested with trypsin and analysed by mass spectrometry. Proteins present 
were identified by searching the SwissProt protein database (Table 3.1). Based on 
the proteomic analysis, both GalMBP ligands were identified as the heavy chain of 
the cell-surface glycoprotein CD98 (CD98hc) with no other proteins identifiable 
across a range of search conditions. The 35-kDa band not recognised by GalMBP 
was identified as the large neutral amino-acid transporter LAT1, one of a six light 
chains (CD98lc) that form disulphide-linked dimers with CD98hc (Nakamura et al., 
1999). The 25-kDa band is GalMBP, presumably present due to minor proteolytic 
degradation of the column. CD98hc is a 58 kDa polypeptide with four potential N-
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Figure 3.4 Overview of the procedure used for the purification of glycoproteins from 
breast cancer cell lines.
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Figure 3.5 Purification of GalMBP ligands from MCF7 cell lysates using a GalMBP affinity 
column. Fractions were analysed  by 15% SDS-polyacrylamide gel electrophoresis followed 
by staining with Coomassie blue (left panel) and electroblotting onto nitrocellulose followed by 
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probing with I-GalMBP (right panel). 
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Figure 3.6  Proteomic analysis of GalMBP ligands from MCF7 cells. GalMBP ligands
were repurified on the GalMBP column, washed, eluted and analysed by 15% SDS-
polyacrylamide gel electrophoresis. Bands 1-8 from the elution fractions were excised, and 
digested with trypsin, and the proteins present were identified by mass spectrometry. Proteins 
identified in each band are listed in Table 3.1.
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Table 3.1 Proteins identified in GalMBP elution fractions from MCF7 cells. 
Peak list generation and database searching were conducted using GPS Explorer software 
version 3.6 (Applied Biosystems). A peak density filter of 50 peaks per 200 Da was used and 
a maximum of 65 peaks considered. Protein scores greater than 55 are considered significant 
(p < 0.05). 
 
 
 
 
 
Band 
No. 
 
SwissProt 
Accession 
number 
 
 
Protein name 
 
Precursor
mass 
 
Protein
score 
 
Peptides 
matched 
 
Sequence
Coverage 
(%) 
 
1 
 
P19999 
 
Mannose-binding 
protein A (precursor) 
 
25292 
 
63 
 
9 
 
34 
2 Q01650 Large neutral amino 
acids transporter 
small subunit 1 
(CD98lc) 
54974 111 7 17 
3 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
57909 375 23 47 
4 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
57909 349 22 43 
5 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
57909 204 19 37 
6 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
57909 190 18 38 
7 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
57909 89 14 25 
8 P08195 4F2 cell-surface 
antigen heavy chain 
(CD98hc) 
 
57909 58 9 17 
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glycosylation sites. The heterogeneity of CD98hc purified from MCF7 cells is likely to 
be caused by variations in the number and the size of N-linked glycans, with two 
dominant populations being evident. LAT1 has a molecular weight of 55 kDa but is 
known to migrate anomalously on SDS-polyacrylamide gels due to its hydrophobic 
composition (Deves and Boyd, 2000).  
CD98 was originally identified as a surface antigen in lymphocytes and 
subsequently was found to be expressed in most tissues and virtually all tumour cells 
(Deves and Boyd, 2000). CD98hc is required for cell-surface expression of the 
CD98lc amino acid transporter (Nakamura et al., 1999). High level expression of 
CD98hc therefore may be required for MCF7 cells to produce large amounts of 
amino acid transporter necessary for sustained growth. At the same time, CD98hc 
projects an extensive array of glycans that could mediate adhesion to the vascular 
endothelium and facilitate invasion of tissues. A direct role of CD98hc in tumour-cell 
activation and adhesion is suggested by the finding that crosslinking of CD98hc with 
monoclonal antibodies specific to CD98hc protein or carbohydrate blocks the 
proliferation of tumour cells (Yagita et al., 1986) and the demonstration that 
overexpression of CD98hc induces malignant transformation of fibroblasts (Hara et 
al., 1999). 
 
3.3.5 Detection of GalMBP ligands on a panel of breast cancer cell lines 
The ability of GalMBP to bind glycans present on a restricted subset of MCF7 
cell-surface proteins prompted the probing of additional breast cancer cell lines. 
Breast cancer cell lines are typically classified and compared on the basis of the 
expression of receptors for the steroids estrogen and progesterone (ER and PgR). 
The cell lines MCF7, T47D, ZR75-1 are all classified as ER+/PgR+, as are the 
majority of breast tumours (Lacroix and Leclercq, 2004). SKBR3 and MDA-MB-231 
cell lines are classified as ER-/PgR-; in the case of SKBR3 cells this is due to the 
amplicification of the ERBB2 gene locus, leading to over-expression of the growth 
factor receptor Her-2 (Borrello et al., 1988). This amplification is seen in 
approximately 30% of breast tumours and leads to downregulation of the steroid 
receptors ER and PgR (Freedman et al., 2008). MDA-MB-231 cells are a highly 
metastatic cell line that does not express epithelial protein markers and has a 
fibroblastoid phenotype, so its epithelial origin is in some doubt (Lacroix and 
Leclercq, 2004). The cell lines MCF7, T47D, ZR75-1, SKBR3 and MDA-MB-231 are 
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used in the vast majority of published literature and encompass a range of steroid 
and growth factor receptor statuses that reflect the common changes seen in breast 
tumours. The investigation of GalMBP binding to this panel of breast cancer cell lines 
would therefore give a representative view of GalMBP ligands on breast cancer cells. 
Direct binding assays revealed that the breast cancer cell lines differ in their 
capacity for binding GalMBP, with higher affinity binding observed for MCF7 and 
SKBR3 cells compared to ZR75-1 and T47D cells (Figure 3.7). A much lower level of 
binding was observed for MDA-MB-231 cells. 
GalMBP ligands were successfully purified from SKBR3, ZR75-1, T47D and 
MDA-MB-231 cells using columns of immobilised GalMBP (Figure 3.8). In contrast to 
elution fraction from MCF7 cells, very few well defined bands are present in the 
elution fractions of SKBR3, ZR75-1 and T47D cell lines. The broad staining patterns 
seen are likely to reflect low levels of individual protein carriers that do not contain 
uniform glycan species, and therefore do not run identically on the gel. The low level 
of individual glycoproteins, which do not form distinct bands, makes protein 
identification by in-gel trypsin digestion difficult.  
In order to identify the glycoproteins present in elution fractions from SKBR3, 
ZR75-1, T47D and MDA-MB-231 cells, a sample of the elution fractions from each 
breast cancer cell line was precipitated, dissolved in urea and digested with trypsin in 
solution. The resulting peptides were separated by high pressure liquid 
chromatography and sequenced by tandem mass spectrometry. Initially, the analysis 
of elution fractions from MCF7 cells was used to assess the validity of the method. 
CD98hc was again identified as the dominant species present, but CD166 (activated 
leukocyte cell adhesion molecule, ALCAM) was also identified in the elution pool at 
lower levels. Levels of CD166 are either too low for identification by in-gel digestion 
or the large amount of CD98hc present hampers its detection. 
Proteomic analysis of a panel of breast cancer cell lines reveal differences in 
the protein carriers of GalMBP glycan ligands (Table 3.2). The major ligand on MCF7 
cells, CD98hc, is also present in the elution fractions from SKBR3 and T47D cells but 
not in ZR75-1 or MDA-MB-231 cells. ZR75-1 elution fractions contained CD166, the 
other protein identified in MCF7 cells. Common themes are evident amongst the 
variety of proteins identified in the panel of breast cancer cell lines. Proteins identified 
in multiple cell lines appear to mediate cell-cell adhesion or are involved in the 
modulation of signalling pathways. The glycoproteins CD98hc, galectin-3-binding 
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Figure 3.7. GalMBP binding to breast cancer cells. Experimental data (symbols) are shown 
together with the theoretical curves fitted to the data using a direct binding equation.
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Figure 3.8 Examples of elution fractions from solubilised breast cancer cells purified 
over a columns of immobilised GalMBP. Fractions were analysed on 15% SDS-
polyacrylamide gels and visualised with Coomassie blue stain. 
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Table 3.2 Analysis of GalMBP ligands on breast cancer cell lines by in-solution 
digestion followed by liquid chromatography and tandem mass spectrometry. 
Lists of proteins containing three or more peptides that have ion scores higher than 29, 
which indicates identity or extensive homology (p<0.05), are displayed. Total ion scores 
and the total number of peptides matched are shown.  
 
 
MCF7 Cells 
 
Protein 
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
P08195 CD98 heavy chain (CD98hc) 18 1077 
Q01650 CD98 light chain (LAT1) 4 253 
Q13740 CD166. Activated leukocyte adhesion molecule (ALCAM) 4 188 
 
SKBR3 Cells 
 
Protein 
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
Q9UGT4 Sushi domain-containing protein 2 (SUSD2) 6 335 
P51912 Neutral amino acid transporter B(0)  4 232 
Q08380 Galectin-3-binding protein precursor (MAC2BP) 4 171 
P11166 Solute carrier family 2, facilitated glucose transporter member 1  3 157 
Q9Y289 Sodium-dependent multivitamin transporter 3 155 
P08195 CD98 heavy chain (CD98hc) 3 154 
P05023 Na/K-transporting ATPase subunit alpha-1 3 130 
 
ZR75-1 Cells 
 
Protein 
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
P11279 Lysosome-associated membrane protein-1 (LAMP1) (CD107a) 6 293 
P05141 ADP/ATP translocase 2 5 238 
Q5XXA6 Anoctamin-1 5 180 
P13473 Lysosome-associated membrane protein-2 (LAMP2) (CD107b) 3 175 
P05023 Na/K-transporting ATPase subunit alpha-1 3 142 
Q13740 Activated leukocyte adhesion molecule (ALCAM) (CD166) 3 118 
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T47D Cells 
 
Protein  
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
P15941 Mucin-1 (CD227) 6 438 
P11279 Lysosome-associated membrane protein-1 (LAMP1) (CD107a) 6 369 
Q9UIQ6 Leucyl-cystinyl aminopeptidase (LCAP) 4 269 
P08195 CD98 heavy chain (CD98hc) 5 261 
P13473 Lysosome-associated membrane protein-2 (LAMP2) (CD107b) 3 168 
O75976 Carboxypeptidase D (CPD) 3 149 
Q9P2B2 Prostaglandin F2 receptor Negative regulator precursor (CD315) 3 141 
 
 
MDA-MB-231 Cells 
 
Protein  
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
P26006                     Integrin alpha 3 (CD49c) 10 714 
P42892 Endothelin-converting enzyme 1  7 430 
P21589 5’-nucleotidase (CD73) 6 353 
Q9UIQ6 Leucyl-cystinyl aminopeptidase  6 282 
O15118 Niemann-Pick C1 protein  5 297 
P16070 CD44 4 240 
P05556 Integrin beta1 (CD29) 4 230 
O75976 Carboxypeptidase D (CPD) 4 162 
P13473 Lysosome-associated membrane protein-2 (LAMP2) (CD107b) 3 188 
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protein, α3 integrin and β2 integrin are all proteins involved in mediating or promoting 
integrin-type cell adhesion (Feral et al., 2005; Sasaki et al., 1998). The two 
peptidases identified in multiple cell lines can have positive roles in signalling 
pathways important for the growth of breast tumours (Hattori and Tsujimoto, 2005; 
Too and Abdelmagid, 2008). Leucyl-cystinyl aminopeptidase (LCAP) is responsible 
for degrading the hormone oxytocin, an inhibitor of breast cancer growth. The 
production of extracellular arginine by the action of carboxypeptidase d (CPD) leads 
to the generation of the signalling molecule nitric oxide (NO). NO signalling 
stimulates a variety of cellular responses including the dilation of smooth muscle with 
a concomitant increase in blood flow into the tumour tissue (Too and Abdelmagid, 
2008). The functions of other proteins identified, such as sushi-domain containing 
protein 2 (SUSD2), have yet to be clearly defined and may represent novel targets 
for the targeting of breast cancers.  
Two lysosome-associated membrane proteins, LAMP1 and LAMP2, were 
identified in T47D, ZR75-1 and MDA-MB-231 cells. The expression of Lewis-type 
structures has been previously reported for these proteins in human colon cancer 
cells (Saitoh et al., 1992). Although these proteins are predominantly located in 
lysosomes, cell-surface expression has also been reported (Dong and Hughes, 
1997). The expression of LAMP1 and LAMP2 on lymphocyte cell surfaces increases 
upon activation and cell-surface LAMPs have been shown to mediate binding of 
activated lymphocytes to endothelial cells (Kannan et al., 1996). Both LAMP proteins 
may therefore also be involved in mediating cell-cell adhesion. However, the dense 
array of glycans projected by these proteins means that their presence could be an 
artifact of the purification procedure.  
The ability of GalMBP to interact with the T antigen suggested that O-linked 
glycans displayed on cell surface mucins might be additional targets (Brockhausen et 
al., 1995). The O-glycosylated protein mucin1 (MUC1) is expressed on the cell 
surface of breast epithelia and is frequently aberrantly glycosylated in breast 
carcinoma. Although MUC1 has been positively identified in the elution fractions from 
T47D cells, it cannot be easily detected by mass spectrometry because few tryptic 
peptides are released from the core polypeptide of the mucin. Consequently, the 
presence of MUC1 was demonstrated by using a monoclonal antibody to probe gels 
of the GalMBP ligands (Figure 3.9). The blot reveals that the presence of GalMBP-
binding glycans on MUC1 in MCF7, SKBR3, T47D and ZR75-1 cells, suggesting that 
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Figure 3.9 Analysis of GalMBP ligands from breast cancer cell lines using anti-MUC1 
antibodies. Ligands purified on GalMBP from breast cancer cell lines (0.5 and 2.5% of total 
2
ligand pool purified from 2 x 225 cm  flasks of confluent cells) were analysed on 5% SDS-
polyacrylamide gels, electroblotted onto nitrocellulose and probed with anti-MUC1 antibody 
HMFG2.
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the presence of O-linked glycans containing the T antigen are contributing to 
GalMBP binding of these cells. The presence of MUC1 could not be detected in the 
fractions from MDA-MB-231 cells. 
 
3.4 Discussion  
GalMBP has been shown to bind to a heterogeneous population of breast 
cancer cell-surface proteins containing both N-linked and O-linked glycans. GalMBP 
affinity columns to purify GalMBP ligands from breast cancer cells represent a novel 
proteomic tool for purifying and concentrating cell-surface glycoproteins with N-linked 
and O-linked glycans containing terminal galactose, including terminal elaborations 
such as the Lewisx trisaccharide.  
Proteins purified from breast cancer cells on GalMBP provide potential clues 
about the role of specific glycan structures in the pathology of breast cancers. A 
direct role in tumour-cell activation is highlighted by the finding that overexpression of 
CD98hc induces malignant transformation of a fibroblast cell line (Hara et al., 1999). 
A role for CD98hc in tumour-cell adhesion is supported by the interaction of CD98hc 
with adhesion molecules including β1 integrins (Fenczik et al., 1997; Feral et al., 
2005; Henderson et al., 2004) and Carcinoembryonic antigen-related cell adhesion 
molecule 1 (CEACAM1) (Kakugawa et al., 2003). CD98hc mediates integrin 
signalling via a mechanism thought to involve clustering of molecules, because 
antibody-mediated crosslinking of CD98hc stimulates β1 integrin-dependent 
adhesion of a small cell lung cancer cell line (Rintoul et al., 2002). The endogenous 
ligands responsible for CD98hc activation have yet to be identified, but the potential 
involvement of interactions between CD98hc glycans and lectins in CD98hc 
activation is supported by the finding that CD98hc is a ligand for galectin-3 (Dong 
and Hughes, 1997). Recently, carbohydrate-dependent interaction between CD98hc 
and galectin-3 has been implicated in cell adhesion events (Dalton et al., 2007).  
Many complex physiological changes are required for tumour cell metastasis. 
Tumour cells contacts with surrounding cells need to be disrupted so the cells can 
migrate through tumour tissue into circulation. The cells then need to survive in 
circulation and eventually colonise a secondary site. Expression of large amounts of 
mucins such as MUC1 is thought to contribute to this process through the disruption 
of cell adhesion, with an associated increase in cell motility, and by providing 
protection to the cancer cell whilst in circulation (Hollingsworth and Swanson, 2004). 
96
  
Adhesion molecules identified by GalMBP could also be important in many of these 
processes. The expression of Lewisx on cell adhesion molecules such as CD98hc, 
galectin-3-binding protein and integrins may promote interactions with endogenous 
lectins expressed on endothelium, including the scavenger receptor C-type lectin. 
Interactions between cancer cell adhesion molecules and endothelial lectins would 
potentially serve several functions in aiding tumour cell migration through circulation. 
Short term interactions could provide activation signals sufficient for tumour cell 
survival. Longer-term interactions may play a pivotal role in both providing initial 
tumour cell adhesion prior to integrin binding and cell migration through the 
vasculature.  
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Chapter 4 
Glycomic analysis of GalMBP ligands on  
breast cancer cells 
 
4.1 Introduction 
The purification of glycoproteins from breast cancer cell lines using GalMBP has 
revealed that glycans bound by GalMBP are carried on different protein scaffolds in 
each cell line, with no common set of proteins bound to the columns. The variety of 
proteins purified on GalMBP from breast cancer cells highlights the importance of 
studying multiple breast cancer cell models before attempting to interpret any 
findings at a general level. Many of the glycoproteins purified from breast cancer cell 
lines may express Lewisx structures as part of their function in cancer pathology. For 
example, for proteins that have roles in cell-cell adhesion and cellular activation 
following adhesion events, unusual terminal glycan structures such as Lewisx could 
be used as a means of mediating initial cell-cell contact prior to the adhesion 
molecule binding to its counter receptor.  
An array of biochemical and biophysical tools can be used to analyse glycan 
structures. Antibodies and lectins specific to particular glycan epitopes are used to 
detect the presence of glycan structures on cell surfaces or on purified proteins, 
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providing a useful link between proteomic and glycomic investigations (Dube and 
Bertozzi, 2005; Kim et al., 2009). The presentation of released glycans on a lipid 
scaffold provides a useful means of separating a heterogeneous population of 
glycans and analysing the relative distribution of bi, tri- and tetra-antennary species, 
as well as differentiating which population is responsible for high affinity binding by 
lectins (Feizi and Childs, 1994). The study of glycans and glycoproteins using mass 
spectrometry is a rapidly expanding field (Dell and Morris, 2001). Mass spectrometric 
analysis of released N-linked and O-linked glycans provides a glycan profile of a 
particular system, be it a purified protein, a cell type or a whole organ. Specific 
glycans within this profile can be further examined and structural information 
obtained through collisionally-induced dissociation (CID) followed by the 
interpretation of fragmentation data by tandem mass spectrometry (MS/MS) (North et 
al., 2009).  
The analysis of glycan structures requires a high degree of sensitivity. Often 
only small amounts of glycan can be purified and glycan structures responsible for 
mediating distinct binding events can often represent only very small populations 
within a total glycan pool. This issue is highlighted by the studies of P-selectin 
binding to its high affinity counter receptor P-selectin glycoprotein ligand-1 (PSGL-1) 
(Li et al., 1996). P-selectin binds with high affinity to sialylated Lewisx structures on 
PSGL-1 but only a very small proportion of PSGL-1 has been found to contain this 
particular glycan structure (Kawar et al., 2008).   
Glycan structures presented on cell-surface proteins can play an important role 
in the ability of a cell to interact with other cells within its environment. The 
involvement of lectins in cell-cell adhesion events is particularly important for cells 
such as leukocytes, which are required to migrate through tissues to sites of 
infection. The migration of leukocytes through the endothelium is initiated through 
initial interactions of cell-surface lectins found on both leukocyte and endothelium 
with specific glycan structures, in a process is commonly referred to as leukocyte 
rolling (McEver, 1994).  
The use of glycans as a means of disrupting cell contacts, increasing cell 
motility, and enabling successful metastasis to secondary sites are all well 
established processes in cancer cell biology. Whether through the expression of 
specific structures that mimic the processes of leukocyte rolling or more global 
changes that act in a general manner to disrupt cell-cell contacts and increase cell 
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motility, glycosylation is frequently altered in cancer and many alterations are known 
to correlate with a poor patient prognosis (Dennis et al., 1999; Ono, 2003). The 
identification of common glycosylation changes in individual cancers is therefore 
useful to aid understanding of the role of glycosylation in disease progression and 
may help to predict likely sites of metastasis.  
In the work described in this chapter, glycan structures present on breast cancer 
glycoproteins purified by GalMBP affinity chromatography have been investigated 
using a variety of biochemical and biophysical techniques. The presence of Lewisx on 
glycoproteins purified from MCF7 cells has been demonstrated using antibody and 
lectin-binding studies. The N-linked and O-linked glycans purified from MCF7 cells 
have been released and analysed by mass spectrometry, revealing a large 
population of novel, heavily fucosylated, multi-antennary cancer-associated N-linked 
glycans and cancer-associated truncated O-linked glycans. Glycomic analysis of a 
further four breast cancer cell lines demonstrates the presence of cancer-associated 
N-linked and O-linked glycan structures at varying levels, with heterogeneity in the 
levels of terminally fucosylated N-linked glycans and truncated O-linked glycans with 
exposed terminal galactose residues accounting for variations in GalMBP binding to 
each cell line. 
 
 
4.2 Materials and methods 
4.2.1 Materials 
Asialo-orosomucoid, 2,5-dihydroxybenzoic acid, haemoglobin, poly-
isobutylmethacrylate, potassium borohydride and sodium cyanoborohydride were all 
from Sigma-Aldrich Company Ltd (Poole, Dorset, UK). Peptide:N-glycosidase F was 
purchased from New England Biolabs Ltd (Hitchen, Hertfordshire, UK). Monoclonal 
antibody MCS-1 was purchased from Quest Biomedicals Ltd (Solihull, West 
Midlands, UK)) and goat anti-mouse IgG/IgM alkaline phosphatase conjugate was 
supplied by Stratech Scientific Ltd (Newmarket, Suffolk, UK). L-1-tosylamido-2-
phenylethyl chloromethyl ketone-treated trypsin (TPCK-trypsin) was supplied by 
Worthington Biochemical Corp. (Lakewood, New Jersey, USA). C18 Sep-Pak 
columns were from Waters Ltd (Elstree, Hertfordshire, UK). Iodomethane was 
supplied by Alfa Aesar (Lancashire, UK). Asialo, galactosylated, bi-antennary and tri-
antennary glycans were supplied by Dextra (Reading, UK). 1,2-
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dipalmitoylphosphoethanolamine (DPPE) was purchased from Avanti Polar Lipids Inc 
(Alabaster, AL, USA ). Silica gel 60 aluminium-backed TLC plates were supplied by 
Merck Chemicals Ltd (Nottingham, UK). All other materials used are detailed in 
Sections 2.2.1 and 3.2.1. 
 
4.2.2 Galactose inhibition assays  
Galactose inhibition assays followed the same procedures as the cell-binding 
assays detailed in Section 3.2.2, but the GalMBP solution contained varying 
concentrations of galactose that had been dissolved in cell medium. 
 
4.2.3 GalMBP and SRCL radiolabelling 
Radiolabelled GalMBP was prepared as described in Section 3.2.3. SRCL was 
dialysed against 1 l of labelling buffer (500 mM NaCl; 100 mM Bicine, pH 8.5; 5 mM 
CaCl2) overnight at 4 °C. Dialysed protein was labelled with 125I by incubation at room 
temperature for 30 min with 20 µl of Bolton-Hunter reagent that was dried under 
nitrogen immediately prior to use. Labelled protein was passed over a 1-ml 
galactose-Sepharose column which was washed with 5 ml of low salt loading buffer 
and protein was eluted in five 0.5-ml fractions of low salt elution buffer. Radioactivity 
for each fraction was measured using a Wallac 1470 Wizard γ counter and fractions 
containing the highest levels of radioactivity were pooled and added to 25 ml of buffer 
(0.5 M NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2) containing 2 % haemoglobin.  
 
4.2.4 Analysis of GalMBP ligands with anti-Lewisx antibodies 
Samples were analysed on 15% SDS-polyacrylamide gels and electroblotted 
onto nitrocellulose membranes (Burnette, 1981). Membranes were blocked using 3% 
bovine serum albumin (BSA) in phosphate-buffered saline (PBS) overnight at 4 °C, 
incubated with monoclonal antibodies MCS-1 (1:50 dilution in PBS) or FC-2.15 (20 
µg/ml in PBS) overnight at 4 °C with gentle shaking and washed three times with 
PBS containing 0.05% Tween-20. Membranes were incubated with a goat anti-
mouse IgG/IgM antibody conjugated to alkaline phosphatase (1:5000 dilution in PBS) 
for two hours at room temperature with gentle shaking. Following a further three 
washes with PBS containing 0.05% Tween-20, membranes were rinsed briefly in 
H2O and incubated in BCIP/NBT for 30 min in the dark. 
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4.2.5 Purification of N-linked glycans 
Total protein from peak elution fractions purified from two 225 cm2 flasks of cells 
were precipitated by the addition of trichloroacetic acid (TCA) to 10% of total volume 
and incubated on ice for 10 min. Samples were centrifuged at 16,000 x g for 5 min 
and pellets were washed twice with 1 ml of ethanol:ether (1:1) and lyophilised for 2 
min. Protein pellets were dissolved in 25 µl of 8 M Urea; 10 mM HEPES (pH 8.0), 
diluted with 215 µl of 50 mM ammonium bicarbonate and digested overnight at 37°C 
with 10 µg of TPCK-treated trypsin. Samples were loaded onto a Sep-Pak C18 
cartridge that had been pre-equilibrated by eluting successively with 5 ml of 
methanol, 5 ml of 5% acetic acid, 5 ml of propan-1-ol and 15 ml of 5% acetic acid. 
The cartridge was washed with 5 ml of 5% acetic acid and glycopeptides eluted with 
4 ml aliquots of 20%, 40%, and 100% propan-1-ol. The 20% and 40% fractions were 
reduced in volume using a vacuum centrifuge, pooled, and lyophilised overnight.  
Glycopeptides were dissolved in 200 µl of 50 mM ammonium bicarbonate and 
incubated at 37°C for 24 hours with 500 New England Biolabs (NEB) units of 
peptide:N-glycosidase F. Samples were loaded onto a Sep-Pak C18 cartridge that 
had been pre-equilibrated by eluting successively with 5 ml of methanol, 5 ml of 5% 
acetic acid, 5 ml of propan-1-ol and 15 ml of 5% acetic acid. N-glycans were eluted in 
5 ml 5% acetic acid and O-glycopeptides eluted with 4 ml aliquots of 20%, 40% and 
100% propan-1-ol. The 5% acetic acid fraction containing released N-linked glycans 
was reduced in volume using a vacuum centrifuge and lyophilised overnight. 
 
4.2.6 Purification of O-linked glycans. 
Elution fractions containing 20% and 40% propan-1-ol from the Sep-Pak C18 
purification of peptide:N-glycosidase F digested glycopeptides were reduced in 
volume using a vacuum centrifuge and lyophilised overnight. O-glycans were 
chemically cleaved from peptide backbones by incubation at 45°C for 24 hours with 
400 µl of 54 mg/ml potassium borohydride dissolved in 0.1 M potassium hydroxide. 
The reaction was terminated by the dropwise addition of acetic acid until hydrogen 
effervescence ceased. Samples were desalted by passing over a column of Dowex 
beads preequilibrated with 5% acetic acid. O-glycans were eluted in 5 ml of 5% 
acetic acid and dried by vacuum centrifugation followed by lyophilisation. Excess 
borate present in the samples was removed by coevaporating with four 0.5 ml 
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aliquots of methanol:acetic acid (9:1 v/v) at room temperature and dried under a 
stream of nitrogen.  
 
4.2.7 Generation of neoglycolipids 
N-linked glycans were prepared from MCF7 cells following the procedures 
described in Section 4.2.4, as were N-glycans from asialo-orosomucoid (0.1 mg). N-
linked glycans purified from MCF7 cells and asialo-orosomucoid were each dissolved 
in 5 µl of H2O. Asialo, galactosylated, bi-antennary (NA2) and tri-antennary (NA3) 
glycans (5 µg) were each dissolved in 2.5 µl of H2O and combined. N-linked glycans 
were incubated with 0.5 mg of 1,2-dipalmitoylphosphoethanolamine (DPPE) and 
dissolved in 100 µl of chloroform:methanol (1:1), for two hours at 60 °C. Aliquots (10 
µl) of 10 mg/ml sodium cyanoborohydride, dissolved in methanol, were added to 
each tube and the reaction was incubated for a further sixteen hours at 60 °C and 
dried using a vacuum centrifuge. The reaction mixture was dissolved in 200 µl of 
chloroform:methanol:H2O (15:70:30) and loaded onto a Sep-Pak C18 cartridge that 
had been pre-equilibrated by eluting successively with 2 ml of chloroform:methanol: 
H2O (60:35:8) and 6 ml of chloroform:methanol:H2O (15:70:30). Columns were 
washed with 2 ml of chloroform:methanol:H2O (60:35:8) and neoglycolipids eluted in 
4 ml of chloroform:methanol:H2O (20:70:30) and dried using a vacuum centrifuge.  
 
4.2.8 Separation of neoglycolipids by thin layer chromatography (TLC) and 
analysis of GalMBP binding 
Neoglycolipids eluted from the Sep-Pak C18 cartridge were resuspended in 20 
µl of chloroform:methanol:H2O (20:70:30) and 3 µl of each sample was spotted onto 
a silica gel 60 aluminium-backed TLC plate. Samples were dried and separated by 
normal phase TLC using chloroform:methanol:H2O (98:96:28) as solvent. TLC plates 
were dried and plasticised by incubation for one minute at room temperature with 
0.1% polyisobutylmethacyrlate, in hexane. Plasticised TLC plates were blocked for 
thirty min at room temperature with 2% haemoglobin in low-salt loading buffer (150 
mM NaCl; 25 mM Tris-Cl, pH 7.8; 25 mM CaCl2). Plates were incubated with 
radiolabelled GalMBP for 120 min at room temperature with gentle shaking and 
washed four times with 100 ml of Tris-buffered saline (TBS). Radioactivity was 
detected using a Phosphorimager SI from Molecular Dynamics (Piscataway, NJ 
USA). 
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4.2.9 Permethylation of N-linked and O-linked glycans 
N-linked and O-linked glycans were permethylated using the anhydrous sodium 
hydroxide method (Sutton-Smith and Dell, 2005). Pellets (4-5) of sodium hydroxide 
were placed in a dry mortar with 3 ml of anhydrous dimethylsulphoxide and ground 
into a slurry. A portion (0.5-1 ml) of the slurry was added to the sample using a 
Pasteur pipette followed by 0.2-0.5 ml of iodomethane. Samples were vortexed 
thoroughly and the reaction was agitated on an automatic shaker for 10 min at room 
temperature. The reaction was quenched by the dropwise addition of 5 ml of H2O. 
Chloroform (1 ml) was added, mixed thoroughly and the upper aqueous layer 
removed. The chloroform layer was washed a further four times by mixing with 5 ml 
of H2O and then dried down at room temperature under a gentle stream of nitrogen. 
 
4.2.10 Purification and analysis of permethylated glycans by mass 
spectrometry 
Permethylated glycans were dissolved in 200 µl of methanol:H2O (1:1) and 
loaded onto a Sep-Pak C18 cartridge that had been pre-equilibrated by eluting 
successively with 5 ml of methanol, 5 ml of H2O, 5 ml of acetonitrile and 15 ml of 
H2O. The cartridge was eluted successively with 5 ml of H2O, and 3 ml each of 15, 
35, 50 and 75% aqueous acetonitrile. Fractions were reduced in volume using a 
vacuum centrifuge and lyophilised.  
Fractions (35, 50 and 75%) were redissolved in 10 µl of methanol:H2O (4:1) and 
1 µl aliquots of each fraction mixed with 1 µl of 10 mg/ml 2,5-dihydroxybenzoic acid in 
methanol:H2O (4:1). Samples were spotted onto a stainless steel plate and air dried 
before analysis. Samples from 35, 50 and 75% acetonitrile fractions were subjected 
to matrix-assisted laser desorption/ionisation mass spectrometry (MALDI MS) 
profiling, with selected ions from the fractions containing identified glycans further 
analysed by tandem mass spectrometry (MS/MS) (Domon and Costello, 1988). Both 
MALDI MS and MS/MS data were acquired using an Applied Biosystems 4800 
MALDI tandem time-of-flight (TOF/TOF) mass spectrometer with sequazyme peptide 
mass standards used as external calibrants. 
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4.3 Results 
4.3.1 Identification of Lewisx structures on MCF7 glycoproteins using anti-
Lewisx antibodies 
Proteomic identification of the heavy chain of CD98 as the predominant ligand 
for GalMBP in MCF7 cells suggested that this glycoprotein may be the carrier for 
cancer-associated glycans recognised by GalMBP. The binding preference of 
GalMBP for Lewis type structures, coupled with previous reports of Lewisx expression 
on MCF7 cells (Elola et al., 2007), suggested that the N-linked glycans on CD98hc 
that are recognised by GalMBP may contain Lewisx. The presence of Lewisx was 
tested by probing purified MCF7 fractions with two monoclonal antibodies, MCS-1 and 
FC.2.15, each of which specifically recognises Lewisx. Blots revealed strong binding 
of both antibodies to CD98hc, suggesting the presence of a significant level of Lewisx 
(Figure 4.1A). This finding was further supported by the recognition of CD98hc by 
radiolabelled SRCL (Figure 4.1B), known to bind highly selectively to Lewisx (Coombs 
et al., 2005).  
 
4.3.2 Generation of neoglycolipids using GalMBP purified N-linked glycans from 
MCF7 cells 
N-linked glycans on GalMBP-purified CD98hc were enzymatically released and 
presented as neoglycolipids separated by normal phase thin layer chromatography. 
The binding of GalMBP to bi-, tri and tetra-antennary glycans present on CD98hc was 
compared to binding to glycans from asialo-orosomucoid, a serum glycoprotein that is 
known to bear tri- and tetra-antennary N-linked glycans that contain terminal fucose 
structures (Treuheit et al., 1992). Binding was detected using radiolabelled GalMBP 
with bi- and tri-antennary glycans containing terminal galactose residues used as size 
markers (Figure 4.2). The chromatogram shows major populations of bi- and tri-
antennary glycans from asialo-orosomucoid and populations of bi-antennary glycans 
containing extended branches are also evident. Reactivity below the tri-antennary 
glycan standard represents extended tri-antennary, tetra-antennary and extended 
tetra-antennary structures that are present on asialo-orosomucoid at significant levels. 
The levels of neoglycolipid derived from CD98hc N-linked glycans are lower than 
those of asialo-orosomucoid. Bi- and tri-antennary glycans are present, but the bulk of 
GalMBP reactivity resides in the lower end of the chromatogram, suggesting that a 
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Figure 4.1 Detection of Lewis  on GalMBP ligands from MCF7 cells. A, Purified MCF7 
fractions were analysed on 15% SDS-polyacrylamide gels, electroblotted onto  nitrocellulose 
X 
membranes and probed with anti-Lewis monoclonal antibodies MCS-1 and FC.2.15. Blots 
were visualised using a goat anti-mouse IgG/IgM secondary antibody conjugated to alkaline 
125
phosphatase. In addition, fractions were stained with Coomassie blue and probed with I-
x 
GalMBP. B, The presence of Lewis was confirmed by probing nitrocellulose blots of purified 
x 
GalMBP ligand with radiolabelled scavenger receptor C-type lectin (SRCL) that binds to Lewis
with high selectivity.      
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Figure 4.2 Binding of GalMBP to neoglycolipids. N-linked glycans presented as 
125
neoglycolipids were resolved by normal phase thin layer chromatography and probed with -
GalMBP. Arrows indicate the position of bi-antennary and tri-antennary glycan standards.
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significant proportion of the N-linked glycans on CD98hc are large, tetra-antennary 
structures. 
 
4.3.3 Mass spectrometric analysis of N-linked glycans from MCF7 glycoproteins 
purified by GalMBP 
The presence of a large population of tetra-antennary N-linked glycans on 
CD98hc was confirmed by mass spectrometric analysis. The MALDI TOF profile 
shows that the majority of molecular ions correspond to large, complex-type N-
glycans composed of 5-11 hexose residues, 4-10 N-acetylhexosamine residues and 
1-6 fucose residues (Figure 4.3). CID MS/MS analysis of the major molecular ions 
was coupled with knowledge of the biosynthetic pathway of N-linked glycosylation to 
predict the structures of the main glycans present (Dell et al., 1994). This method of 
analysis allows identification of terminal structures and extended antenna, but does 
not differentiate between linkages, so Lewisx and Lewisa cannot be distinguished. 
Many of the glycans identified are tetra-antennary, with bi- and tri-antennary 
structures also present at lower levels. There is evidence of substantial terminal 
fucosylation but very limited terminal sialylation and some high-mannose 
oligosaccharides are also present. 
 MS/MS analysis provided evidence that Lewisa/x, Lewisy/b and core fucose are 
present in all molecular ion peaks containing two or more fucose residues (Figure 
4.4). All of the peaks analysed produced fragment ions at m/z 660, corresponding to 
Lewisa/x. Diagnostic fragments corresponding to elimination of fucose from the 3 
position of GlcNAc indicate that Lewisx is the predominant singly fucosylated terminal 
structure, although some Lewisa termini may also be present. For example, the 
dominant species at m/z 2591 consists of a bi-antennary glycan with both of the 
antennae terminating in Lewisx (Figure 4.4A). Similarly, a fragment at m/z 834 is 
present in multiply fucosylated peaks, indicating the presence of Lewisy/b (Figure 
4.4A-C). Analysis of larger molecular ions revealed the presence of two- and three-
repeat poly-N-acetyllactosamine extensions bearing one or two fucose residues, 
which have the potential to form repeated Lewisx/a structures (Figure 4.4C-D). The 
detection of heavily fucosylated tetra-antennary structures on CD98hc is consistent 
with the previous blotting studies and also accounts for the high molecular mass 
observed. 
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Figure 4.3  Mass spectrometric analysis of N-linked glycans from GalMBP ligands on 
MCF7 cells. Purified GalMBP ligands were digested with trypsin and N-linked glycans were 
released by peptide:N-glycosidase F. N-linked glycans were permethylated and subjected to 
Sep-Pak purification. The MALDI TOF mass spectrum of one of the elution fractions from the 
Sep-Pak is shown. All labelled ions were additionally subjected to MALDI TOF/TOF MS/MS 
analysis. The schemes for each ion represents the most likely structure based on the precise fit 
between the calculated composition and the m/z (z =1) ratio of the ion detected, taking into 
account the biosynthetic pathways of N-glycosylation in addition to the MS and MS/MS data 
collected. Satellite peaks surrounding major signals represent minor sialylated components or 
are artefacts of the permethylation process.     
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Figure 4.4 MALDI TOF/TOF spectra of permethylated N-linked glycans from GalMBP 
ligands on MCF7 cells. Ions at m/z 2591 (Fuc Hex HexNAc ), 3838 (Fuc Hex HexNAc ), 
5 7 63 5 4
5360 (Fuc Hex HexNAc ) and 5809 (Fuc Hex HexNAc ) were selected for collisionally-
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induced dissociation. Assignments of the fragment ions are shown either as loss of glycan 
moieties from the molecular ion (see annotations on horizontal arrows) or as antenna 
fragments which are B ions for cleavage at HexNAcs and C ions for cleavage at hexoses 
12
(Domon and Costello, 1988). Assigned masses correspond to the C isotope throughout. The 
annotated ions not assigned in the schematics correspond to double or triple cleavages.
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4.3.4 Mass spectrometric analysis of O-linked glycans from MCF7 glycoproteins 
purified by GalMBP 
The identification of MUC1 in the elution fractions of MCF7 cells showed that 
GalMBP is likely to recognise O-linked glycans on this protein. Consequently, the O-
linked glycans present in elution fractions from MCF7 cells were chemically cleaved 
from peptide backbones and analysed by MALDI TOF mass spectrometry followed by 
CID MS/MS analysis. The MALDI TOF profile shows that only four O-linked glycan 
species are present at detectable levels (Figure 4.5). The major molecular ion present 
at m/z 534 corresponds to the unmodified core 1 structure, also known as the T 
antigen. In addition, minor levels of the unmodified core 2 structures are present, as 
are fucosylated versions of both core 1 and core 2, with fucosylation of the latter 
producing Lewisa/x structures.  
 
4.3.5 Glycomic analysis of glycans on GalMBP-purified glycoproteins from a 
panel of breast cancer cell lines 
As reported in the previous chapter, analysis of a panel of breast cancer cell 
lines revealed differences in their capacity for binding GalMBP, with higher affinity 
binding observed for MCF7 and SKBR3 cells compared to ZR75-1 and T47D cells, 
and even lower binding for MDA-MB-231 cells, a highly metastatic cell line commonly 
used as a model for breast cancer, which has an expression profile and morphology 
that differ significantly from cell lines of epithelial origin (Lacroix and Leclercq, 2004). 
Analysis of anti-Lewisx antibody binding to GalMBP ligands purified from the panel of 
cell lines reveals that the differences in binding correlate partially with variations in the 
levels of Lewisx epitopes on glycoproteins from these cells. Significant levels of Lewisx 
are evident on MCF7 and SKBR3 cells with low levels present on ZR75-1 and no 
detectable reactivity on T47D and MDA-MB-231 cells (Figure 4.6).  
MALDI TOF mass spectrometry of the N-linked and O-linked glycans purified on 
GalMBP from SKBR3, ZR75-1, T47D and MDA-MB-231 cell lines was coupled with 
CID MS/MS analysis of major molecular ions present to identify the glycan structures 
responsible for GalMBP binding. As in the case of the N-linked glycan pool isolated 
from MCF7 cells, high-mannose structures were detected in N-glycan pools from all 
other cell lines. The affinity of GalMBP for mannose is approximately 50 times less 
than the affinity for galactose (Iobst and Drickamer, 1994), so these glycans are not 
likely to be GalMBP ligands. Theoretically a glycoprotein only need present one high 
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Figure 4.5 Mass spectrometric analysis of O-linked glycans on GalMBP Ligands from 
MCF7 cells. O-linked glycans were chemically cleaved from peptides, permethylated, and 
subjected to Sep-Pak purification. The MALDI TOF mass spectrum of the major elution 
fractions from the Sep-Pak purification is shown above with all labelled ions additionally 
subjected to MALDI TOF/TOF MS/MS analysis. 
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xFigure 4.6 Analysis of GalMBP ligands from breast cancer cells with anti-Lewis  
antibodies. Elution fractions of GalMBP ligands from breast cancer cell lines (7% of total 
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ligand pool from two 225 cm  flasks of confluent cells) were precipitated with trichloroacetic 
acid and analysed on 15% SDS-polyacrylamide gels. Samples were run in triplicate with one 
panel stained with Coomassie blue and two electroblotted onto nitrocellulose and probed with 
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affinity GalMBP ligand to be purified, and could contain other glycan structures that 
are not recognised by GalMBP. Many of the proteins purified on GalMBP are heavily 
glycosylated. In particular, the lysosomal proteins LAMP1 and LAMP2 have been 
detected in many of the cell lines and contain between 18 and 20 N-linked glycans on 
each polypeptide chain. These proteins are also expressed at high levels, 
representing 12% of the total protein content of lysosomes and have been shown to 
contain both complex and high-mannose type glycans (Carlsson et al., 1988; Saitoh 
et al., 1992). GalMBP could be interacting with a subset of complex N-linked glycans 
on these proteins, but high-mannose structures attached to the same polypeptides 
would also be purified and detected in the analysis. High-mannose N-linked glycans 
have also been reported on MUC1 (Parry et al., 2006). In this case, GalMBP would be 
binding to truncated O-linked glycan structures, with the N-linked glycans copurifying 
as passengers.  
The MALDI TOF profile of N-linked glycans from SKBR3 cells shows molecular 
ions corresponding to bi-, tri and tetra-antennary glycans which predominantly contain 
both outer arm fucosylation and sialylation (Figure 4.7). The level of terminal 
fucosylation is high, with glycan species containing up to three fucose residues 
evident. CID MS/MS analysis confirmed the presence of Lewisa/x terminal structures 
as well as terminal sialylated structures. No fragment ions containing both sialic acid 
and fucose were detected, suggesting that fucose and sialic residues are attached to 
different branches. The degree of fucosylation is reduced compared to that of the 
MCF7 cells and there are notably lower levels of tetra-antennary glycans, with no 
evidence of poly-N-acetyllactosamine extensions. 
A wider array of truncated O-linked glycans was detected in SKBR3 cells in 
comparison to MCF7 cells (Figure 4.7). The major molecular ions present still 
correspond to the T antigen, but in addition lower levels of T antigen containing 
fucose or up to three sialic acid residues are present, as are a minor population of 
sialylated core one structures that contain an additional terminal HexNAc residue 
which are likely to represent the blood group antigen Sd(a), a structure associated 
more with O-linked glycans found in the colon (SerafiniCessi, 1996). The low level of 
MUC1 detected in SKBR3 elution fractions suggests that some of the O-linked 
glycans identified are likely to have come from other mucin-type proteins present 
within the elution fraction.  
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Figure 4.7 Glycomic analysis of GalMBP Ligands from SKBR3 cells. N-linked and O-
linked glycans were permethylated and subjected to Sep-Pak purification. The MALDI TOF 
mass spectra of the major elution fractions from the N-glycan (top panel) and O-glycan (bottom 
panel) pool are shown, with all labelled ions additionally subjected to MALDI TOF/TOF MS/MS 
analysis. 
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Analysis of N-linked glycans from ZR75-1 cells reveals that the majority 
corresponds to tri- and tetra-antennary glycans, with lower levels of bi-antennary 
glycan also present (Figure 4.8). Outer arm fucosylation is present at considerably 
lower levels than SKBR3 cells, with the majority present on tetra-antennary glycans 
that also contain terminal sialic acid. Glycans carrying more than one terminal fucose 
were not evident. CID MS/MS analysis confirmed the presence of Lewisa/x structures 
and demonstrated that fucose and sialic residues are again located on separate 
antenna. O-linked glycans from ZR75-1 cells consist nearly exclusively of the T 
antigen, with only very low levels of core 2 structures also present (Figure 4.8). 
The N-linked glycans present in GalMBP elution fractions from T47D cells 
predominantly correspond to bi-antennary sialylated glycans, with lower levels of tri- 
and tetra-antennary glycans also present (Figure 4.9). Molecular ions identified 
correspond to glycans containing terminal sialic acid on at least one branch and many 
ions also containing some outer arm fucosylation. In a similar fashion to ZR75-1 and 
SKBR3 cell lines, the fragmentation analysis provided evidence of terminal Lewisx/a 
structures and no evidence of sialylated Lewis structures. The lack of reactivity of 
anti-Lewisx antibodies toward glycoproteins purified from T47D cells is likely to reflect 
the low levels of N-linked glycan compared to the other cell lines. 
The major molecular ion present in the MALDI TOF profile of O-linked glycans 
purified from T47D cells corresponds to sialylated T antigen, with significant levels of 
disialylated T and trisialylated T antigen also present (Figure 4.9). As in the profile of 
SKBR3 cells, there are minor populations of structures corresponding to sialylated 
Sd(a) blood group antigens. T47D cells appear to have a higher level of sialylation 
than other cell lines, with the molecular ion corresponding to the T antigen not present 
at detectable levels. CID MS/MS analysis shows that the majority of the sialylated T 
antigen species contain the sialic acid linked to the galactose with a minor population 
containing sialic acid linked to GalNAc, leaving the galactose free to be bound by 
GalMBP. The large amounts of MUC1 present on these cell lines and the high levels 
of O-linked glycosylation known to be present on MUC1 from T47D cells suggests 
that sufficient levels of this glycan were present for GalMBP binding. The presence of 
the Tn antigen could not be determined using MALDI approaches, as the mass is too 
low for detection above the background matrix signals. The presence of Tn antigen 
would also contribute to GalMBP binding. 
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Figure 4.8  Glycomic analysis of GalMBP Ligands from ZR75-1 cells. N-linked and O-linked 
glycans were permethylated and subjected to Sep-Pak purification. The MALDI TOF mass 
spectra of the major elution fractions from the N-glycan (top panel) and O-glycan (bottom panel) 
pool are shown, with all labelled ions additionally subjected to MALDI TOF/TOF MS/MS 
analysis. 
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Figure 4.9 Glycomic analysis of GalMBP Ligands from T47D cells. N-linked and O-linked 
glycans were permethylated and subjected to Sep-Pak purification. The MALDI TOF mass 
spectra of the major elution fractions from the N-glycan (top panel) and O-glycan (bottom 
panel) pools are shown, with all labelled ions additionally subjected to MALDI TOF/TOF MS/MS 
analysis. 
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The N-linked glycan profile of GalMBP ligands from MDA-MB-231 cells shows 
significant levels of bi-, tri- and tetra-antennary glycans (Figure 4.10). Major molecular 
ions correspond to bi-, tri- and tetra-antennary glycans without the presence of 
terminal fucosylation or sialylation. Minor molecular ions corresponding to glycans 
with terminal fucose are present and CID MS/MS analysis confirmed that these 
include terminal Lewisx/a structures. Larger ions containing one and two poly-N-
acetyllactosamine repeats were also identified. Although the presence of MUC1 could 
not be detected in cell lysates from MDA-MB-231 cells, glycan analysis of GalMBP 
elution fractions from MDA-MB-231 cells revealed the presence of some truncated O-
linked glycans (Figure 4.10). The major molecular ions present correspond to the T 
antigen and the core 2 structure. Minor levels of sialylated core 1 and core 2 
structures are also present, as is a fucosylated core 2 structure bearing Lewisa/x. The 
low level of N-linked glycans containing Lewisa/x structures and of O-linked glycans on 
MDA-MB-231 cells accounts for the considerably lower level of GalMBP binding to 
this cell line. 
4.3.6 Investigation of the relative affinities of GalMBP for cell-surface Lewisx 
structures and T antigen using inhibition of cell binding by galactose. 
GalMBP binding to an array of glycans highlighted two distinct glycan 
preferences: glycans bearing terminal Lewisa or Lewisx structures and glycans 
containing the disaccharide Galβ1-3GalNAc (see Section 2.3.3). Analysis of N-linked 
and O-linked glycans from a panel of breast cancer cell lines has shown both glycan 
subsets can be purified from breast cancer cell lines on GalMBP. Glycans purified 
from the cell lines MCF7 and SKBR3 contain significant levels of both Lewisa/x and of 
the disaccharide Galβ1-3GalNAc, in the form of the O-linked glycan the T antigen. 
ZR75-1 cells contained much lower levels of Lewisa/x structures, but high levels of the 
mucin MUC1 with O-glycans consisting almost exclusively of the T antigen, 
suggesting that the major structure contributing to GalMBP binding on ZR75-1 cells 
are glycans containing the disaccharide Galβ1-3GalNAc. In order to establish the 
relative affinity of GalMBP for the two glycan structures when presented at the cell 
surface, cell binding assays were conducted with GalMBP binding inhibited by the 
presence of varying concentrations of the monosaccharide galactose (Figure 4.11). 
As expected, inhibition of GalMBP binding to SKBR3 cells required a higher 
concentration of galactose than ZR75-1 cell lines, with MCF7 cells requiring a 
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Figure 4.10 Glycomic analysis of GalMBP Ligands from MDA-MB-231 cells.N-linked and 
O-linked glycans were permethylated and subjected to Sep-Pak purification. The MALDI TOF 
mass spectra of the major elution fractions from the N-glycan (top panel) and O-glycan (bottom 
panel) pools are shown, with all labelled ions additionally subjected to MALDI TOF/TOF MS/MS 
analysis. 
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Figure 4.11 Inhibition of GalMBP binding to breast cancer cells by galactose. 
Experimental data (symbols) are shown together with theoretical curves fitted to the data using 
(log IC50 - x) * Hill coefficient
the equation y = min + (max-min)/ 1 + 10  where IC50 represents the 
concentration of galactose required for 50% inhibition of GalMBP binding.
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significantly higher concentration again. Galactose was able to inhibit GalMBP 
binding to ZR75-1 cells to a much greater degree than SKBR3 and MCF7 cells. This 
result is consistent with the presence of higher affinity GalMBP ligands on these cell 
lines, suggesting that Lewisa/x structures are higher affinity ligands for GalMBP than 
the disaccharide Galβ1-3GalNAc. 
 
 
4.4 Discussion 
Several common changes in N-linked glycosylation are reported to occur during 
the oncogenic transformation of mammalian cells. These changes include an 
increase in the level of glycan branching, expression of fucosylated terminal 
structures and an increase in poly-N-acetyllactosamine branch extensions. Of these 
changes, the presence of tetra-antennary glycans and terminal fucose structures 
including Lewisa/x has been identified at varying levels in all breast cancer cell lines 
analysed. Poly-N-acetyllactosamine extensions have been identified in MCF7, ZR75-
1 and MDA-MB-231 cells.  
Glycomic analysis of GalMBP ligands from breast cancer cell lines 
demonstrates that breast cancer cells vary widely in the nature of their glycosylation, 
in spite of their similar origins and phenotypes. Analysis of N-linked glycans reveals a 
large degree of variation in the level of outer arm fucosylation, sialylation and in the 
levels of bi-, tri- and tetra-antennary glycans. Each cell line appears to have a distinct 
population of glycans that carry outer arm fucose, with MCF7 and ZR75-1 cell lines 
predominantly presenting outer arm fucosylation on tetra-antennary scaffolds and 
T47D and SKBR3 cell lines across a range of bi-, tri- and tetra-antennary glycans. 
GalMBP can be used to purify Lewisa/x-containing glycans that could not be detected 
by antibodies. The ability of GalMBP to purify such small amounts of Lewisx 
illustrates the high affinity of GalMBP for these ligands and shows that GalMBP can 
be a powerful tool for identifying and analysing glycoproteins bearing Lewis antigens. 
This result is particularly important when considering the relatively low levels of many 
glycan species that carry important terminal structures responsible for mediating 
binding events. 
 The most abundant protein carriers of the fucosylated N-linked glycans vary 
between different cell lines, with MCF7 cells being unusual in that a single 
glycoprotein, CD98hc, is the predominant carrier of the heavily fucosylated 
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structures. The detection of heavily fucosylated tetra-antennary structures on 
CD98hc from MCF7 cells explains the high affinity binding of GalMBP to this cell line. 
These results emphasise the importance of looking at more than one breast cancer 
cell line when examining glycosylation differences. They also provide a molecular 
explanation of variability in the response of breast cancers to treatments with 
antibodies directed against carbohydrate epitopes (Mordoh, 1995) and they suggest 
that screening may help to identify tumours more likely to respond to treatment with 
anti-CD15 antibodies.  
The presence of an array of Lewisx structures on CD98hc and other adhesion 
molecules suggests that they may provide a scaffold for interactions of breast cancer 
cells with endothelia (Elola et al., 2007). This suggestion was supported by the fact 
that CD98hc is bound by the scavenger receptor C-type lectin (Figure 4.1B). SRCL is 
an endothelial receptor that recognises Lewisx selectively and has been proposed to 
function in adhesion of tumour cells during metastasis (Elola et al., 2007).  
 The populations of O-linked glycans purified by GalMBP also reveal different 
patterns for each cell line. For the cell lines that were examined, the majority of O-
linked glycans were truncated structures. This finding is particularly evident in ZR75-
1 and MCF7 cells, in which the T antigen is the major species present and only very 
minor populations of other truncated structures are evident. T47D and SKBR3 cells 
also show a heavy level of truncated glycans, but with a significant population of 
sialylated glycans including the sialyl-T antigen. The striking differences in sialylation 
seen in MCF7 and ZR75-1 compared to T47D and SKBR3 cell lines illustrates 
strongly the importance of studying multiple cell lines to validate findings related to O-
glycosylation changes in breast cancer pathology. The highly metastatic cell line 
MDA-MB-231 did not express MUC1 and does not share the epithelial-like 
expression profile of the other cell lines. The fact that GalMBP can still be used to 
purify O-linked glycans from this cell line provides evidence for the utility of GalMBP 
in the purification of small populations of O-linked glycans from solubilised cells.  
The accumulated glycan analyses demonstrate that the relative contributions of 
fucosylated N-linked structures and O-linked T antigen to GalMBP binding vary 
widely between different breast cancer cell lines. In addition to differences in the 
relative contributions of these two classes of glycans, the different molecular weights 
of glycoproteins bearing CD15 antigens on the different cell lines supports the finding 
that these are carried on different protein scaffolds. These results suggest that the 
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extent of cancer-associated glycosylation in different cell lines may depend on the 
abundance of different target proteins as well changes in the expression of 
components of the glycosylation machinery of the cell. 
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Chapter 5 
In vitro analysis of complement-dependent cell lysis by GalMBP  
 
5.1 Introduction  
In the preceding chapters, GalMBP has been shown to bind to N-linked and O-
linked glycan structures such as Lewisx and T antigen present on the surface of 
breast cancer cells. These structures are not commonly found on normal cells but are 
often present at increased levels on cancer cell-surfaces, making them useful targets 
for the development of drugs in the treatment of cancer. The use of Lewisx as a 
cancer cell marker is highlighted by the monoclonal antibody FC-2.15, an antibody 
drug developed for the treatment of breast cancers that reacts specifically with 
glycans containing the Lewisx trisaccharide (Capurro et al., 1998).  
Mannose-binding protein (MBP) can target innate immune responses following 
the recognition of non-self carbohydrate structures (Gadjeva et al., 2004a). MBP 
interacts with and activates molecules of the immune system, the best characterised 
of which are the serine proteases of the complement system (Vorup-Jensen et al., 
1998). Activation of MASPs following MBP binding to microorganisms leads to 
deposition of complement. Complement deposited on pathogen surfaces serves as 
an opsonin that enhances clearance by phagocytes of the immune system (Muller-
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Eberhard, 1988). MBP can also act directly as an opsonin that enhances the uptake 
of pathogens by phagocytes of the immune system through interactions with collectin 
receptors on the surface of phagocytic immune cells (Ogden et al., 2001). In addition, 
MBP can act indirectly by enhancing the rate of pathogen uptake by phagocytes that 
have already recognised a pathogen (Jack et al., 2005). Complement deposited on 
pathogen surfaces by MBP can also exert direct killing of pathogens by forming large 
pores in the cell membrane (Muller-Eberhard, 1986). 
In this chapter, the ability of GalMBP to initiate protective responses following 
binding to cancer-associated glycan structures has been investigated in vitro. 
GalMBP has been shown to initiate complement-dependent cell lysis on erythrocytes 
that have been altered to present cancer-associated glycan structures. The ability of 
GalMBP to activate the complement system following binding on the surface of 
breast cancer cells has also been investigated in vitro to evaluate the potential of 
GalMBP as a novel therapeutic drug for cancer treatment.  
 
 
5.2 Materials and methods 
5.2.1 Materials 
Neuraminidase was provided by New England Biolabs Ltd (Hitchen, 
Hertfordshire, UK). Sheep erythrocytes and guinea pig complement were supplied by 
TCS biosciences Ltd (Buckingham, Buckinghamshire, UK). MP Biomedicals (Illkirch, 
France) supplied goat anti-rabbit-HRP conjugated antibody and anti-Guinea Pig C3-
HRP conjugated antibody. CytoTox 96 cytotoxicity assay kits were purchased from 
Promega Corp. (Southampton, UK).  
 
5.2.2 Haemolysis assays 
Sheep erythrocytes (5 ml of a 20% suspension) were centrifuged at 3,200 x g 
for 5 min to collect 1 ml of packed cells, which were washed three times with 10 ml of 
phosphate buffered saline (PBS), resuspended in 2 ml of PBS and incubated with 80 
µl of neuraminidase ( 4000 NEB units) for 30 min at 37 ºC. Cells were washed three 
times with gelatine veronal buffer (145 mM NaCl; 4.4 mM barbituric acid; 1.8 mM 
sodium barbitone; 2 mM CaCl2; 0.5 mM MgCl2; 0.1% gelatin) (GVB) and 
resuspended in 10 ml of GVB for storage. 
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Aliquots (0.1 ml) of neuraminidase-treated cells (corresponding to 
approximately 108 cells) were used for each assay. Cells were incubated with 400 µl 
of GVB containing GalMBP at room temperature for 15 min. Samples were 
centrifuged for 4 min at 4,000 x g, washed with 1 ml of GVB and resuspended in 0.1 
ml of GVB. After guinea pig complement (1.3 ml) dissolved in GVB was added to 
each sample, the suspensions were incubated at 37 ºC for 60 min, with end-over-end 
mixing. Cells were centrifuged at 1,000 x g for 5 min and the absorbance of the 
supernatant was read at 540 nm using a Victor3 plate reader from Perkin Elmer 
(Waltham, MA, USA) 
 
5.2.3 Cell cytotoxicity assays  
MCF7 cells were grown to confluence in 96-well tissue culture plates, rinsed 
twice with 250 µl of medium and incubated for 15 min at room temperature with 90 µl 
of medium containing GalMBP or 0.1% Triton X-100. Guinea pig serum dissolved in 
medium (10 µl) was added to each well as a source of complement and serine 
protease, and wells were incubated for a further 60 min at 37 ºC followed by 
centrifugation at 250 x g for 5 min. Aliquots (50 µl) of supernatant were removed and 
transferred to a 96-well ELISA plate. Lactate dehydrogenase (LDH) substrate was 
added to each well (50 µl) and incubated in the dark for 30 min at room temperature. 
The substrate is coupled to a colourimetric detection system that results in the 
conversion of a tetrazolium salt into a red formazan product (Korzeniewski and 
Callewaert, 1983). The reaction was terminated by the addition of 50 µl of 1 M acetic 
acid and the absorbance was read at 490 nm using a Victor3 plate reader from Perkin 
Elmer (Waltham, MA, USA). 
 
5.2.4 Complement deposition assays  
Cells were grown to confluence in 96-well tissue culture plates, washed, and 
incubated with GalMBP and Guinea Pig serum as described above for cell killing 
assays. Wells were washed four times with 250 µl of medium and incubated at 37 ºC 
for 60 min with a 1:800 dilution of anti-Guinea Pig C3 antibody (25 µg/ml) conjugated 
to horseradish peroxidase (HRP) in medium containing 5% BSA. Wells were washed 
four times with 250 µl of medium and incubated with 100 µl of HRP substrate for 10 
min at room temperature in the dark. Reactions were terminated with 50 µl of 2 M 
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HCl and samples were centrifuged at 250 x g for 5 min. Supernatant (100 µl) was 
transferred to a 96-well ELISA plate and the absorbance was read at 450 nm. 
 
 
5.3 Results 
5.3.1 Activation of the complement system by GalMBP 
Many of the biological functions of mannose-binding protein involve interactions 
between the collagen domain of the protein and molecules of the immune system. 
This region has not been altered in GalMBP and so it should still act in an analogous 
fashion. Therefore, the ability of GalMBP to activate serine proteases of the innate 
immune system and deposit complement on the surface of target cells was 
measured by haemolysis of erythrocytes in a modification of an assay previously 
used for MBP-A (Ikeda et al., 1987). Erythrocytes were pre-treated with 
neuraminidase to cleave terminal sialic acid residues, which exposes terminal 
galactose in the form of the T antigen on red blood cell glycans (Bray et al., 1981). 
Neuraminidase-treated erythrocytes were incubated with GalMBP, washed, and 
incubated in buffer containing guinea pig serum as a source of complement and 
serine protease. The level of complement-dependent cell lysis was measured by the 
amount of haemoglobin released into the cell medium and was compared to 
erythrocytes incubated in medium (0% lysis) or water (100% lysis). GalMBP 
efficiently fixes complement and initiates complement-dependent haemolysis on 
neuraminidase-treated erythrocytes at concentrations consistent with previous 
haemolysis assays conducted with MBP-A (Wallis and Drickamer, 1999) (Figure 
5.1). The complement-dependent haemolysis of neuraminidase-treated erythrocytes 
shows that GalMBP has an altered binding specificity, but retains the complement-
fixing ability of MBP-A. 
 
5.3.2 Investigation of GalMBP-mediated complement activation on MCF7 cells 
As GalMBP is able to activate the complement pathway following binding to 
cancer-associated glycan structures, the ability of GalMBP to initiate the 
complement-dependent cell lysis of MCF7 cells was investigated. Lysis of cancer 
cells was measured using an enzyme-linked assay that detects the activity of lactate 
dehydrogenase (LDH) in the medium of cells that have previously been incubated 
with GalMBP and guinea pig complement (Figure 5.2). LDH was chosen due to its 
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Figure 5.1  Complement-dependent haemolysis of neuraminidase-treated erythrocytes 
8
by GalMBP. Neuraminidase-treated sheep erythrocytes (1 x 10  cells) were sensitised with 1-
500 ng of GalMBP and lysed by incubation with guinea pig complement in a total volume of 1.5 
ml at 37°C for one hour. The level of lysis was compared to cells incubated in buffer (0% lysis) or 
in water (100% lysis) for the same period.  
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cytosolic location and stability. The level of cell killing is compared to cells that have 
been incubated in medium with complement or a detergent-containing cell lysis 
solution. GalMBP was not able to induce cell killing above background levels across 
a broad range of concentrations and levels of complement significantly higher than 
that required to lyse completely an equivalent number of red blood cells (Table 5.1).  
There are several mechanisms used by cells to inhibit complement-dependent 
cell lysis and these act at different points of the complement pathway. The proteins 
decay accelerating factor (DAF), membrane co-factor of proteolysis (MCP) and factor 
H all bind to C3b molecules and facilitate their degradation (Kim and Song, 2006), 
whereas CD59 acts further down the pathway, preventing formation of the membrane 
attack complex by inhibiting complement protein C9 binding to C5678 complexes 
(Kim and Song, 2006) (Figure 1.11). In order to examine whether GalMBP is able to 
deposit complement protein C3 on the surface of MCF7 cells, adherent cells were 
incubated with GalMBP and guinea pig complement, washed, and stained with an 
anti-guinea pig C3 antibody conjugated to horseradish peroxidase. Following further 
washes, horseradish peroxidase substrate was added and the level of horseradish 
peroxidase activity was measured. The mean absorbance values for cells incubated 
with GalMBP or with medium alone were identical (0.25 +/- 0.05), suggesting that any 
early stage complement components deposited in response to GalMBP binding are 
cleared efficiently by MCF7 cells. 
 
 
5.4 Discussion 
GalMBP has been shown to trigger complement-dependent cell lysis on 
erythrocytes that present cancer-associated glycan structures. This assay suggests 
that GalMBP could initiate a protective response against cancer cells through the 
activation of complement.  
The in vitro assays conducted on MCF7 cells indicates that GalMBP does not 
deposit complement on the cell surface. This inability to deposit complement on 
MCF7 cells could be due to the intrinsic protective mechanisms of this cell line, a 
conclusion that is supported by the finding that MCF7 cells were not lysed by the 
complement pathway when treated with anti-MCF7 antibodies (Caragine et al., 
2002). The in vitro assay system used may also have been limited by several factors. 
Guinea pig serine proteases are likely to have a reduced affinity for GalMBP in 
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Table 5.1 Complement-dependent cell lysis of MCF7 cells by GalMBP. 
MCF7 cells were grown to confluence in 96-well tissue culture plates and incubated with 
varying concentrations of GalMBP with no, low (10%), medium (20%) or high (40%) levels of 
guinea pig complement. Levels of cell lysis were detected by measuring of the activity of the 
cytosolic enzyme lactate dehydrogenase. Cell killing was calculated by comparing values for 
cells incubated in medium alone (0%) or a solution containing detergent (100%).  
 
 
 
 
 
 
 
 
 
 
 
Cell Killing (%) GalMBP 
Concentration 
(µg/ml) No 
Complement 
Low 
Complement
Medium 
Complement
High 
Complement 
0 6 2.4 1.5 5.9 
10 4.5 0 3 4.1 
50 5 2.9 2.3 3.6 
250 6.4 1.5 2.4 6.2 
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comparison to their rat equivalents. These serine proteases could be MASPs or the 
classical complement pathway proteases C1r and C1s, which have also been 
reported to be activated by MBP (Lu et al., 1990). Analysis of human serum suggests 
that MASPs exist at high levels in serum, with up to 95% not complexed with MBP 
(Thiel et al., 2000). Conversely, only relatively small amounts of C1r and C1s exist 
uncomplexed with C1q (Laurell et al., 1976; Thiel et al., 2000), suggesting that 
GalMBP:MASP complexes are likely to be the predominant species formed in this 
assay. High levels of MASP1 in serum have been reported (Terai et al., 1997), which 
could affect the complement fixing ability of GalMBP in this assay by reducing the 
number of GalMBP:MASP2 complexes that are required for complement deposition.  
In order to fully assess the complement-fixing activity of GalMBP in an in vitro 
system, complexes of rat MASP2 and GalMBP would need to be formed. This is 
likely to require the purification of rat MASP2 from rat serum using an anti-MASP2 
antibody as a capturing reagent. As noted, MASPs have been reported to be present 
at higher levels than MBPs in serum, so free MASP2 should be present (Thiel et al., 
2000). Purification using MASP2 antibodies would have the advantage of precisely 
defining the MASP associated with GalMBP and would also allow the MASPs to 
remain in an inactivated state.  
 It is likely that many of the potential clearance mechanisms used by GalMBP 
cannot be recreated in an in vitro system and will instead require the use of in vivo 
animal models. In an in vivo environment, GalMBP could interact with immune 
system mediators including MASPs, collectin receptors and other uncharacterised 
MBP-enhanced clearance mechanisms. These uncharacterised mechanisms are 
highlighted by studies on the therapeutic potential of human MBP to treat colon 
cancer (Ma et al., 1999). MBP was able to decrease tumour size and increase the 
survival time of mice subcutaneously injected with a colon cancer cell line. The anti-
tumour activity was mediated primarily by an undefined complement-independent 
mechanism that has been referred to as MBP-dependent cell cytotoxicity (Ma et al., 
1999). Assessment of the anti-tumour activity of GalMBP in an animal model would 
therefore more accurately reflect the effectiveness of retargeted mannose-binding 
proteins as cancer treatments. 
 
 
. 
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Chapter 6 
 Identification of glycoproteins bearing Lewisx structures on 
cancer cells from Hodgkin’s lymphoma. 
 
6.1 Introduction 
The use of columns of immobilised-GalMBP to identify and characterise 
glycoproteins in breast cancer cell lines suggested that GalMBP could be used as a 
tool for purifying glycoproteins from other cells known to express Lewisa or Lewisx. 
The presence of Lewisa and Lewisx has been reported on many different cancers and 
cancer cell lines. In particular, Hodgkin’s lymphomas are frequently associated with 
the expression of cell-surface glycans containing Lewisx structures (Gruss et al., 
1997).  
Hodgkin’s lymphoma is a common form of lymphocytic cancer characterised by 
the development of lymph node tumours that spread progressively from one lymph 
node system to another. A hallmark of Hodgkin’s lymphoma is the relatively small 
number of neoplastic tumours cells, referred to as Hodgkin’s Reed/Sternberg (HRS) 
cells. The major mass of tumour tissue typically consists of non-neoplastic reactive 
cells including T lymphocytes, granulocytes, macrophages and plasma cells 
(Brauninger et al., 2006). The variable regions (V-regions) of the immunoglobulin 
genes of HRS cells have been rearranged, indicating that the vast majority of HRS 
cells have a B cell lineage. In addition to rearrangement, the V-regions of the HRS 
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cells show evidence of somatic hypermutation, and are therefore believed to have 
originated from B cells undergoing clonal selection in germinal centres (Braeuninger 
et al., 1997; Kuppers and Rajewsky, 1998). The V-regions in many HRS cells contain 
mutations in the coding sequence which prevents the production of immunoglobulin. 
HRS cells are thought to have undergone a transforming event within the germinal 
centre, which has enabled them to escape the antigen-driven apoptotic cell death 
that normally occurs for B cells in which mutations have not led to an increase in 
affinity for antigen (Kanzler et al., 1996).  
HRS cells express a wide array of cell-surface markers specific for many 
different myeloid and lymphocytic cell lineages, including granulocytes, dendritic 
cells, B lymphocytes and T lymphocytes (Gruss et al., 1997). One of the many 
markers associated with HRS cells is the Lewisx trisaccharide, which in 
immunological studies is often referred to as the CD15 antigen (Boyd, 1987). Lewisx 
is a common marker expressed on normal mature myeloid cells such as 
granulocytes but is not found on lymphocytes. The presence of Lewisx has been 
used as a diagnostic marker to distinguish Hodgkin’s lymphoma from other 
lymphocytic cancers (Hall and D'Ardenne, 1987; Pellegrini et al., 2007).  
Although the presence of Lewisx on HRS cells is well characterised, the role of 
these structures has been less well defined, with protein carriers of Lewisx structures 
on HRS cells yet to be identified. However, crosslinking of HRS cell-surface 
molecules containing Lewisx, using anti-Lewisx antibodies, has been shown to 
stimulate cellular signalling through the tyrosine phosphorylation of proteins including 
c-Cbl (Ohana-Malka et al., 2003). Identification of the protein carriers of Lewisx on 
HRS cells may indicate how this cellular activation is achieved and thus contribute to 
further understanding of the disease.  
In the work reported in this chapter, the use of GalMBP to purify Lewisx-bearing 
glycoproteins from HRS cells has been examined. Purification of ligands from HRS 
cells by GalMBP has been demonstrated and the presence of glycans containing 
Lewisx has been confirmed using monoclonal antibodies and analysis of purified N-
linked glycans by mass spectrometry. Analysis of a panel of HRS cell lines has led to 
identification of a common set of proteins that carry Lewisx on many of the cell lines. 
Glycoproteins purified on GalMBP from multiple HRS cell lines have roles in 
mediating cell-cell adhesion and in the activation of T lymphocytes, suggesting a 
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potential role for Lewisx structures in the functioning of these molecules in Hodgkin’s 
lymphoma.  
 
 
6.2 Materials and methods 
6.2.1 Materials 
All materials used in the analysis of HRS cell lines are detailed in Sections 3.2.1 
and 4.2.1. 
 
6.2.2 Cell culture 
HRS cell lines L-428, KMH-2, L-1236, L-540, HDLM-2 and UHO-1 were 
purchased from the DSMZ, Braunschweig, Germany. Cell lines L-428, KMH-2 and L-
1236 were grown in RPMI-1640 medium supplemented with 10% foetal calf serum, 2 
mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. HRS cell lines L-540 
and HDLM-2 were grown in RPMI-1640 medium supplemented with 20% foetal calf 
serum, 2 mM glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin. The HRS 
cell line UHO-1 was grown in 1:4 Iscove’s modified Dulbecco’s medium:RPMI-1640 
medium supplemented with 20% foetal calf serum, 2 mM glutamine,100 U/ml 
penicillin and 100 µg/ml streptomycin. 
 
6.2.3 Purification of membrane proteins   
Cells were grown to saturation density (0.5-1 x 106 cells/ml) in 100 ml of 
medium. Cells were harvested by centrifugation at 450 x g for 2 min and washed 
twice by resuspension in 10 ml of PBS. Pellets were dissolved and GalMBP ligands 
purified as previously described (see Section 3.2.9). 
 
6.2.4 Proteomic and glycomic analysis 
GalMBP affinity columns (Section 3.2.8), analysis of GalMBP ligands using 
radiolabelled GalMBP and anti-Lewisx antibodies (Section 4.2.4), in-gel trypsin 
digestion followed by mass spectrometry (see Section 3.2.11), in-solution trypsin 
digestion followed by liquid chromatography and tandem mass spectrometry (Section 
3.2.12), and N-glycan analysis (see Sections 4.2.5, 4.2.9 and 4.2.10) were all 
performed as previously described. 
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6.3 Results 
6.3.1 Demonstration of GalMBP binding to glycoproteins bearing Lewisx 
structures on HRS cells 
The HRS cell line L-428 was initially chosen to demonstrate the purification of 
glycoproteins containing Lewisx by GalMBP because it is a commonly studied HRS 
cell line for which the presence of Lewisx has previously been demonstrated (Ohana-
Malka et al., 2003). L-428 cell lysates were passed over columns of immobilised 
GalMBP which were washed in the presence of Ca2+ and eluted with EDTA following 
the same procedure as that used for MCF7 cells. Cell lysates were found to contain 
GalMBP ligands when blotted onto nitrocellulose and probed with radiolabelled 
GalMBP (Figure 6.1). The blots indicated a broader distribution of GalMBP binding in 
comparison to the distinct bands observed for the MCF7 breast cancer cells. The 
elution fractions were also probed with anti-Lewisx antibodies demonstrating the 
presence of glycoproteins containing Lewisx within the elution fractions (Figure 6.1). 
Broad reactivity was observed from approximately 48 kDa up to sizes well over 175 
kDa. A defined band at 200 kDa shows reactivity toward both antibodies and toward 
radiolabelled GalMBP.  
 
6.3.2 Analysis of N-linked glycans by mass spectrometry 
MALDI TOF MS was used to confirm the presence of Lewisx structures on the 
glycoproteins purified from L-428 cells on GalMBP. The MALDI TOF profile of L-428 
N-linked glycans enzymatically released from glycoproteins shows the presence of 
molecular ions corresponding to large, complex N-glycans composed of 5-10 hexose 
residues and 4-9 N-acetylhexosamine residues (Figure 6.2). Fucosylated glycans 
containing up to 3 fucose residues are present, as are some minor components 
containing sialic acid. High-mannose oligosaccharides are also evident at similar 
levels to those seen in the glycomic analysis of breast cancer cell lines and are 
presumed to be present on heavily glycosylated glycoproteins that also contain 
complex-type glycans bound by GalMBP (see Section 4.3.5). MS/MS analysis of the 
major molecular ions, coupled with knowledge of the biosynthetic pathway of N-
linked glycosylation, was used to predict the structures of the main glycans present 
(Figure 6.2).  
The glycans identified include bi-, tri- and tetra-antennary complex glycans that 
are predominantly terminally fucosylated. MS/MS analysis provided evidence that 
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xFigure 6.1 Analysis of GalMBP ligands from L-428 cells with anti-Lewis  antibodies. 
Elution fractions from solubilised L-428 cells purified over a column of immobilised GalMBP 
were analysed on 15% SDS-polyacrylamide gels followed by Coomassie blue staining 
x
or electroblotting onto nitrocellulose and probing with anti-Lewis  antibodies and radiolabelled 
GalMBP.
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Figure 6.2.  Mass spectrometric analysis of N-linked glycans from GalMBP ligands 
on L-428 cells. Purified GalMBP ligands were digested with trypsin and N-linked 
glycans were released by peptide:N-glycosidase F. N-linked glycans were permethylated 
and subjected to Sep-Pak purification. The MALDI TOF mass spectrum of one of the 
elution fractions from the Sep-Pak is shown above. All labelled ions were subjected to MALDI 
TOF/TOF MS/MS analysis. The schemes for each ion represent the most likely structure based 
on the precise fit between the calculated composition and the m/z (z =1) ratio of the ions 
detected, taking into account the biosynthetic pathways of N-glycosylation in addition to the MS 
and MS/MS data collected. 
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Lewisa/x and core fucose are present in all molecular ion peaks containing two or 
more fucose residues. The presence of Lewisx is highlighted by the molecular ions at 
m/z 2416 and 2591, which correspond to bi-antennary glycans containing two and 
three fucose residues. Analysis of these glycans by collisionally-induced dissociation 
gave fragment ions at m/z 660, corresponding to terminal FucHexHexNAc, 
consistent with the presence of terminal Lewisa or Lewisx. The relative intensities of 
these two glycans is comparable to that of the molecular ion m/z 2243, 
corresponding to a bi-antennary glycan without terminal fucosylation, suggesting that 
a significant proportion of the bi-antennary glycans present contain terminal Lewisa or 
Lewisx. A large proportion of the N-glycans present are tetra-antennary structures 
containing zero, one or two fucosylated branches. Analysis of larger molecular ions 
revealed the presence of two- and three-repeat poly-N-acetyllactosamine extensions 
bearing zero or one terminal fucose residue.  
 
6.3.3 Identification of GalMBP ligands on L-428 cells by in-gel trypsin digestion 
followed by mass spectrometry 
 The identity of glycoproteins present in the elution fractions was investigated by 
in-gel trypsin digestion. Elution fractions were analysed on SDS-polyacrylamide gels 
and stained with Coomassie blue. A broad staining pattern was observed, probably 
due to the heterogeneity of glycans present on individual glycoproteins. Despite the 
lack of distinct bands, several glycoproteins were identified from L-428 cells that 
were bound by GalMBP (Figure 6.3), including the dendritic and epithelial cell 
receptor DEC-205 (CD205) and intercellular adhesion molecule 1 (ICAM-1). DEC-
205 and ICAM-1 are both heavily glycosylated proteins known to be expressed in 
HRS cells (Kato et al., 2003; Uchihara et al., 2006). The heavy chain of the cell 
surface molecule CD98 (CD98hc) was identified across a region of the gel between 
approximately 75 and 100 kDa, with the accompanying small chain LAT1 also 
detected, but below confidence levels for the analysis (Table 6.1).  
 
6.3.4 Identification of GalMBP ligands on L-428 cells by in-solution trypsin 
digestion followed by liquid chromatography and tandem mass spectrometry 
Analysis by in-gel trypsin digestion was hampered by the difficulty of visualising 
distinct bands on the SDS-polyacrylamide gel and by the presence of contaminating 
proteins such as tubulins and keratins, which proved difficult to remove completely 
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Figure 6.3 GalMBP ligands from L-428 cells. Cell extracts were fractionated on columns 
of immobilised GalMBP. Bound and eluted material was analysed by 15% SDS-polyacrylamide
gel electrophoresis. Proteins present in bands 1-16 were identified by mass spectrometry
following trypsin digestion. Proteins identified in each band are listed in the right hand 
column and in Table 6.1. 
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Table 6.1 MALDI TOF/TOF mass spectrometry of tryptic fragments from L-428 cell 
proteins. 
Proteins were enriched on columns of GalMBP and analysed by SDS-polyacrylamide gel 
electrophoresis as shown in Figure 6.3. Peak list generation and database searching 
were conducted using GPS Explorer software version 3.6 (Applied Biosystems). A peak 
density filter of 50 peaks per 200 Da was used and a maximum of 65 peaks considered. 
Protein scores greater than 55 are considered significant (p < 0.05). 
 
 
Band 
No. 
 
SwissProt 
Accession 
number 
 
 
Protein name 
 
Precursor 
mass 
 
Peptide 
score 
 
Peptides 
matched 
 
Sequence 
Coverage 
(%) 
 
1 
 
      Q8WWH5 
 
Probable tRNA pseudouridine 
synthase 1 
 
37253 
 
65 
 
9 
 
32 
2 Q01650 Large neutral amino acids 
transporter small subunit 1 
(CD98lc) 
54974 54 6 17 
3 P07437 
Q9UPN3 
Tubulin beta chain 
Microtubule-actin  
crosslinking factor 1 
49671 
620418 
83 
78 
10 
40 
29 
10 
4 P68363 Tubulin alpha chain 50152 99 12 41 
5 P68363 
P04264 
Tubulin alpha chain 
Keratin, type II cytoskeletal 1 
50152 
66018 
95 
90 
10 
18 
30 
29 
6 P04264 Keratin, type II cytoskeletal 1 66018 57 12 25 
7 P04264 Keratin, type II cytoskeletal 1 66018 82 15 29 
8 Q15758 Neutral amino acid transporter 
B(0) 
 
56598 58 9 22 
9 Q15758 Neutral amino acid transporter 
B(0) 
 
56598 58 9 18 
10 P08195 
 
Q15758 
4F2 cell-surface antigen heavy 
chain (CD98hc) 
Neutral amino acid transporter 
B(0) 
 
57909 
 
56598 
77 
 
58 
14 
 
9 
27 
 
18 
11 P08195 
 
P05362 
 
Q96PK2 
 
4F2 cell-surface antigen heavy 
chain (CD98hc) 
Intercellular-adhesion 
molecule 1 (ICAM-1) 
Microtubule-actin  
crosslinking factor 4 
57909 
 
57825 
 
670151 
   110 
 
     89 
 
     63 
13 
 
10 
 
38 
27 
 
20 
 
9 
12 P08195 4F2 cell-surface antigen heavy 
chain (CD98hc) 
57909 83 14 28 
13 P08195 
 
Q9UPN3 
 
4F2 cell-surface antigen heavy 
chain (CD98hc) 
Microtubule-actin  
crosslinking factor 1 
57909 
 
620418 
111 
 
70 
14 
 
36 
30 
 
9 
14 P08195 4F2 cell-surface antigen heavy 
chain (CD98hc) 
 
57909 99 16 35 
15 P08195 4F2 cell-surface antigen heavy 
chain (CD98hc) 
 
57909 60 12 24 
16 O60449 Lymphocyte antigen 75 
 (DEC-205) 
198271 81 20 13 
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from the elution fractions. In order to prevent contaminating proteins from masking 
glycoproteins, and to eliminate the problems associated with in-gel analysis, 
glycoproteins purified on GalMBP were identified using a solution-phase proteomic 
approach. Elution fractions were digested with trypsin in solution and peptides were 
purified by liquid chromatography. Individual peptides were then identified by MALDI 
TOF MS and sequenced by collision-induced dissociation followed by tandem mass 
spectrometry.  
Mass fragment data for each peptide were used to search the Mascot database 
for tryptic peptide sequences that match the fragmentation pattern observed. 
Proteins for which three or more peptides were sequenced within confidence limits 
were considered to be present at significant levels (Table 6.2). CD98hc, DEC-205 
and ICAM-1 were identified with the highest levels of confidence, agreeing well with 
the in-gel analysis and validating the in-solution digestion as a means of glycoprotein 
identification. Several other glycoproteins were also identified in the elution fractions. 
The cell-surface receptors CD70, CD86, CD147 and the MHC class II receptor HLA-
DR were all identified in the elution fractions at levels that could not be detected by 
the in-gel analysis. 
The biological functions of many of the glycoproteins purified on GalMBP 
involve the presentation of antigens and the activation of lymphocytes. For example, 
DEC-205 captures antigens and directs them to antigen-processing compartments 
(Jiang et al., 1995) while HLA-DR is responsible for presenting antigenic peptides on 
the cell surface for identification by T cell receptors on T lymphocytes (Watts, 1997). 
CD147, CD70, CD86, CD98hc and ICAM-1 have all been implicated in providing 
essential co-stimulatory signals following T cell receptor binding, leading to T 
lymphocyte activation (Diaz et al., 1997; Lebedeva et al., 2005; Nolte et al., 2009; 
Woodhead et al., 2000). 
.  
6.3.5 Identification of common GalMBP ligands on HRS cell lines 
Identification of glycoproteins containing Lewisx from the HRS cell line L-428 
showed that GalMBP could be a useful tool for identifying proteins commonly 
expressing Lewisx in Hodgkin's lymphoma. To investigate this application further, 
GalMBP was used to purify glycoproteins from a panel of five further HRS cells. 
Proteins were purified from all five cell lines and the major components were 
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Table 6.2 Analysis of GalMBP ligands from Hodgkin’s Lymphoma cell lines. 
Analysis of GalMBP ligands on HRS cell lines by in-solution digestion followed by liquid 
chromatography and tandem mass spectrometry. Proteins listed contain three or more 
peptides with ion scores higher than 29, which indicates identity or extensive sequence 
similarity (p<0.05), are displayed. Total ion scores and the total number of peptides 
matched are shown.  
 
HDLM-2 Cells 
 
Protein  Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total 
Ion 
Score 
4F2_HUMAN CD98 heavy chain  8 429 
K2C1_HUMAN Keratin, type II cytoskeletal 1 5 281 
    BASI_HUMAN Basigin (CD147) 4 188 
CALX_HUMAN Calnexin 4 164 
      AAAT_HUMAN      Neutral amino acid transporter B(0)  3 161 
SCRB2_HUMAN Lysosome membrane protein 2 3 153 
    LAMP2_HUMAN 
Lysosome-associated membrane protein-
2 
LAMP2 
3 138 
K1C10_HUMAN Keratin, type I cytoskeletal 10 3 113 
ICAM1_HUMAN ICAM-1 (CD54) 3 111 
 
KMH-2 Cells 
 
 
 
 
Protein 
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total Ion 
Score 
ICAM1_HUMAN ICAM-1 (CD54) 8 616 
4F2_HUMAN CD98 heavy chain  7 444 
2B1B_HUMAN HLA class II DRB1 beta chain 6 434 
2DRA_HUMAN HLA class II DR alpha chain 6 376 
LY75_HUMAN                DEC-205 (CD205) 6 361 
CD45_HUMAN Leukocyte common antigen CD45 6 248 
GRP78_HUMAN 78 KDa glucose-regulated protein 5 244 
CD70_HUMAN CD70  4 231 
K2C1_HUMAN Keratin, type II cytoskeletal 1 4 219 
1B35_HUMAN HLA Class I, B 3 207 
1C12_HUMAN HLA Class I, C 3 186 
CLC4M_HUMAN DC-SIGNR (CD299) 3 165 
PRG4_HUMAN Proteoglycan 4 3 160 
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L-428 cells 
 
Protein  
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total Ion 
Score 
4F2_HUMAN CD98 heavy chain  16 1104 
LY75_HUMAN DEC-205 (CD205) 12 568 
ICAM1_HUMAN Intercellular adhesion molecule 1 ICAM-1 (CD54) 7 389 
TBA1B_HUMAN 
 
Tubulin alpha chain 
 6 317 
TBA1C_HUMAN Tubulin alpha chain  6 303 
CD70_HUMAN CD70 5 298 
2DRA_HUMAN HLA class II DR alpha chain 5 235 
S4A7_HUMAN Sodium bicarbonate cotransporter 3 5 230 
TBB5_HUMAN Tubulin beta chain 4 209 
    BASI_HUMAN Basigin (CD147) 3 241 
    LAMP2_HUMAN 
Lysosome-associated membrane protein-2 
(LAMP2) 
 
3 171 
2B32_HUMAN HLA class II DRB3-2 beta chain 3 140 
CD86_HUMAN  CD86 (B7.2) 3 127 
 
L-1236 Cells 
 
Protein Accession
Number 
(Swissprot) 
Protein Name Peptides matched 
Total Ion 
Score 
PECA1_HUMAN Platelet endothelial cell adhesion molecule PECAM-1 (CD31) 8 601 
ICAM1_HUMAN ICAM-1 (CD54) 7 454 
4F2_HUMAN CD98 heavy chain  7 436 
DPP4_HUMAN Dipeptidyl peptidase 4 7 388 
CD45_HUMAN       Leukocyte common antigen (CD45) 6 342 
K1C10_HUMAN Keratin, type I cytoskeletal 10 6 329 
K2C1_HUMAN Keratin, type II cytoskeletal 1 5 397 
LY75_HUMAN DEC-205 (CD205) 5 224 
TBA1A_HUMAN 
TBA1B_HUMAN 
TBA1C_HUMAN 
Tubulin alpha-1A chain 
Tubulin alpha-1B chain 
Tubulin alpha-1C chain 
4 281 
      AAAT_HUMAN      Neutral amino acid transporter B(0)  4 241 
ADA_HUMAN Adenosine deaminase 4 224 
1A02_HUMAN HLA class I, A 4 180 
TBB5_HUMAN Tubulin beta chain 3 167 
SLAF1_HUMAN Signalling lymphocytic activation molecule (CD150) 3 136 
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UHO-1 Cells 
 
Protein  
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total Ion 
Score 
LY75_HUMAN DEC-205 (CD205) 30 1869 
4F2_HUMAN CD98 heavy chain  12 818 
LCAP_HUMAN Leucyl-cystinyl aminopeptidase 10 641 
ICAM1_HUMAN ICAM-1 (CD54) 10 535 
PPBT_HUMAN Alkaline phosphatase, tissue non-specific isozyme 8 432 
LAMP1_HUMAN 
Lysosome-associated membrane protein-
1 
LAMP1 
6 405 
CD70_HUMAN CD70 6 357 
TBA1A_HUMAN 
TBA1B_HUMAN 
TBA1C_HUMAN 
Tubulin alpha-chain 
 4 278 
     ATA1_HUMAN Na/K-transporting ATPase subunit alpha-1 4 181 
MRP1_HUMAN Multidrug resistance-associated protein 1 4 161 
    LAMP2_HUMAN 
Lysosome-associated membrane protein-
2 
LAMP2 
3 179 
SCRB2_HUMAN Lysosome membrane protein 2 3 171 
IL3RA_HUMAN Interleukin-3 receptor subunit alpha IL3RA 3 159 
CD86_HUMAN CD86 (B7.2) 3 144 
    
 L-540 Cells 
 
Protein  
Accession 
Number 
(Swissprot) 
Protein Name Peptides matched 
Total Ion 
Score 
S4A7_HUMAN Sodium bicarbonate cotransporter 3 9 412 
B3A2_HUMAN Anion exchange protein 2 7 316 
DPP4_HUMAN Dipeptidyl peptidase 4 7 309 
4F2_HUMAN CD98 heavy chain  4 213 
      AAAT_HUMAN      Neutral amino acid transporter B(0)  4 187 
CD45_HUMAN Leukocyte common antigen CD45 4 172 
LAMP1_HUMAN Lysosome-associated membrane protein-1 LAMP1 3 203 
    LAMP2_HUMAN Lysosome-associated membrane protein-2 LAMP2 3 169 
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identified by solution-phase trypsin digestion followed by liquid chromatography and 
tandem mass spectrometry. 
 The analysis showed a pattern of commonly-expressed proteins in the majority 
of the cell lines (Table 6.2), with a series of potential subgroups among the cell lines 
investigated (Figure 6.4). Although each cell line appears to have some unique 
characteristics, all contain one common protein, CD98hc. All cell lines with the 
exception of one contain ICAM-1 and four of the six contain DEC-205. These results 
suggest that these proteins commonly present Lewisx structures and may indicate a 
potential role for the glycan structure in the function of these proteins on HRS cells. 
For example, identification of ICAM-1 and CD98hc as major carriers of Lewisx 
structures may explain in part why antibodies specific to Lewisx structures are able to 
activate tyrosine kinase signalling pathways in HRS cell lines (Ohana-Malka et al., 
2003), because both ICAM-1 and CD98hc have been shown to transmit activation 
signals following binding by extracellular ligands (Lawson and Wolf, 2009; Rintoul et 
al., 2002). 
 Several other proteins appear in two or more cell lines with the majority being T 
lymphocyte stimulatory and costimulatory molecules including HLA Class I, HLA 
Class II, ICAM-1, CD70, CD86, CD98hc and CD147. Many of the proteins identified, 
including CD147 and PECAM-1, are also associated with myeloid cells such as 
neutrophils and macrophages (Newman, 1997; Yurchenko et al., 2001). The 
lysosome-associated membrane proteins LAMP1 and LAMP2 from both HRS and 
breast cancer cell lines bind to the GalMBP columns. These heavily glycosylated 
proteins predominantly reside in lysosomes, but have also been implicated in 
adhesion of activated lymphocytes to endothelial cells (Kannan et al., 1996). The 
presence of Lewis-type structures has been previously reported for these proteins in 
human colon cancer cells (Saitoh et al., 1992) and they may therefore also be 
involved in mediating cell-cell adhesion.  
The purification of CD98hc from many breast cancer cell lines and from all HRS 
cell lines investigated suggests that CD98hc commonly carries cancer-associated 
glycans and that it is a particularly good ligand for GalMBP. As GalMBP retains the 
spacing requirements required for binding by MBP-A, a protein projecting glycans 
containing high affinity GalMBP ligands such as Lewisx structures and also meeting 
the spacing requirements of mannose-binding protein could be an extremely high 
affinity ligand. The structure of the extracellular domain of CD98hc has been 
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Figure 6.4 Glycoproteins found in multiple HRS cell lines. Proteins present in at least two 
cell lines in Table 5.2 are indicated by dots. Coloured boxes are used to highlight possible 
subgroups within the panel of cell lines.
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determined and mapping of the asparagine residues that contain N-linked glycans 
shows that three are approximately equidistant from each other, with a mean 
distance of 26 Å (Figure 6.5A). Modeling three asialo, galactosyl, bi-antennary 
glycans with the same distances at their non-reducing ends reveals that the distance 
between terminal galactose residues is approximately 50 Å (Figure 6.5B). This value 
is in close agreement with the position of the binding sites in a GalMBP trimer, 
calculated by measuring the distance between Ca2+ ions in the carbohydrate-binding 
site (Figure 6.5C). The high affinity binding of GalMBP to CD98hc is thus potentially 
due to both the expression of GalMBP ligands and the fulfillment of the spacial 
requirements of mannose-binding protein. This observation suggests that CD98hc 
molecules carrying cancer-associated glycan structures are likely to represent a 
good target for GalMBP in any therapeutic approach.  
Many C-type lectins form trimers in a similar manner to MBP, including the 
endothelial receptor SRCL (Coombs et al., 2005). High affinity binding of SRCL to 
Lewisx structures suggests that CD98hc molecules presenting glycans containing 
Lewisx are likely to be extremely high affinity ligands for this receptor, which has been 
shown to bind to CD98hc from MCF7 cells (Section 4.3.1). Although much is known 
about the involvement of CD98hc in integrin-type adhesion and signalling, the ligands 
responsible for activating CD98hc have yet to be elucidated. These findings suggest 
that interactions between trimeric C-type lectin receptors and N-linked glycans 
projected by CD98hc could be responsible for CD98hc activation. 
 
 
6.4 Discussion 
GalMBP has identified a common set of proteins that are the major carriers of 
Lewisx among the HRS cell lines investigated. In addition to this, the ability of 
GalMBP to purify minor populations of Lewisx-containing glycoproteins has revealed 
differences in the panel of proteins purified from each cell line. These variations 
appear to show distinct subsets among the HRS cell lines investigated and suggest 
that GalMBP could be used to classify HRS cell lines into subgroups that present 
Lewisx on the same protein scaffolds (Figure 6.4). 
Glycoproteins identified in HRS cells by GalMBP affinity chromatography 
provide potential clues about the role of Lewisx-containing glycans in the pathology of 
Hodgkin's lymphoma. Many of these proteins function in presentation of antigens, in 
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Figure 6.5 Analysis of GalMBP binding to CD98hc. A, Three glycosylation sites on CD98hc 
(highlighted in purple) are approximately 25 Å apart. B, Modelling these sites with three asialo 
bi-antennary glycans shows that some of the distances between terminal galactose residues 
are approximately 50 . C, Distance between the three sugar-binding sites of GalMBP trimers 
is approximately . This figure was prepared using entries 2DH2 (CD98hc) and 1AFA  
(GalMBP) from the Protein Databank. The structure of an asialo bi-antennary glycan was 
downloaded from glycosciences.de (Linucs ID 4265) and was modelled so that terminal 
GlcNAc residues from three structures were spaced the same distances apart as the terminal 
amide groups of asparagine residues on CD98hc. Figures were prepared using PyMOL 
version 0.99.
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immune cell activation and in mediating cell adhesion. For example, DEC-205, HLA-
class I and HLA-class II are all cell-surface glycoproteins designed to present antigen 
to T cells (Jiang et al., 1995; Watts, 1997). Other proteins identified, such as ICAM-1, 
CD70, CD86, CD98hc, and CD147, can all provide essential costimulatory signals 
required for T cell activation (Diaz et al., 1997; Lebedeva et al., 2005; Nolte et al., 
2009; Woodhead et al., 2000). 
A peculiar feature of Hodgkin's lymphoma is the relatively small number of HRS 
cells present in tumour tissue (Kuppers, 2009). The majority of cells in the tumour 
are reactive haematopoietic cells, including T lymphocytes, B lymphocytes, dendritic 
cells and macrophages (Brauninger et al., 2006). HRS cells produce a variety of 
cytokines and cell-surface molecules that are responsible for attracting immune cells 
into the tumour tissue and activating cells within the tissue (Skinnider and Mak, 
2002). These activated immune cells then generate essential stimulatory signals 
required for HRS cell survival. Although many different activated immune cells are 
present within Hodgkin’s lymphomas, CD4+ T cells comprise the major species 
present (Kuppers, 2009). HRS cells are often completely surrounded by CD4+ T 
cells, forming distinctive rosette structures (Kuppers, 2009). HRS cells can activate 
subsets of CD4+ T cells into T regulatory cells (Tanijiri et al., 2007) and also direct 
activated CD4+ T cells toward the humoral Th2 response (Kuppers, 2009; Kuppers 
et al., 2002). The activation of a Th2 response is important for maintaining an 
inflammatory microenvironment within the tumour and also for suppressing the 
activation of Th1 cells, which could result in anti-tumour activity.  
 In addition to providing costimulatory signals to immune cells, two of the major 
ligands identified, CD98hc and ICAM-1, have well defined roles in mediating cell-cell 
adhesion by integrins, and in activating signalling pathways following adhesion (Feral 
et al., 2005). The need for HRS cells to interact with many different immune cells 
probably requires the expression of a many surface proteins associated with cell-cell 
adhesion and immune cell activation. The presence of Lewisx glycans on the surface 
of adhesion molecules such as CD98hc and ICAM-1 on HRS cells may aid their 
binding to counter-receptors on lymphocytes or myeloid cells through initial binding 
by lectins on the lymphocyte or myeloid cell surface. This initial binding could bring 
the adhesion molecules in close proximity to their ligands, facilitating binding. Lewisx-
containing glycans can act as ligands for DC-SIGN, a C-type lectin expressed on 
dendritic cells (Guo et al., 2004), which could act in this fashion.   
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Many of the glycoproteins identified in this analysis are directly involved in the 
presentation of HLA class II antigens and the costimulation of CD4+ T cells. The 
presence of Lewisx-type sugars on the surface of HRS cells may enhance T cell 
presentation and costimulation. Lewisx structures could facilitate initial binding of T 
cells to HRS cells through interactions with endogenous lectins on the T cell surface, 
including L-selectin, although Lewisx is not a high affinity ligand for this protein. The 
association of Lewisx glycans on HRS cells with lectins present on CD4+ T cells may 
help to protect HRS cells from reactive cytotoxic T cells.  
Lewisx-containing glycoproteins on HRS cells could also be involved in directing 
activated T cells towards a Th2 response. Expression of glycoproteins bearing 
Lewisx structures by parasitic organisms such as Schistosoma mansoni has been 
shown to induce a Th2 response in a Lewisx-specific manner (Okano et al., 1999; 
Okano et al., 2001), and there is growing evidence to suggest that C-type lectin 
receptors are important in this response (Geijtenbeek and Gringhuis, 2009). The 
interaction of DC-SIGN with glycoproteins containing Lewisx structures has been 
shown to induce a Th2 response against several pathogens (Bergman et al., 2004; 
van Liempt et al., 2007). DC-SIGN ligation activates specific signalling pathways 
within the dendritic cell which result in the release of cytokines that promote the 
induction of a Th2 response (Caparros et al., 2006). Interactions between DC-SIGN 
on dendritic cells and Lewisx-containing glycoproteins on HRS cells could act in an 
analogous manner to help promote the differentiation of CD4+ T cells into Th2 cells 
and Treg cells. Elevated levels of soluble ICAM-1 (sICAM-1) in Hodgkin’s lymphoma 
(Uchihara et al., 2006), provide a potential source of extracellular Lewisx-containing 
glycoprotein that could bind to DC-SIGN without the need for direct interactions 
between the HRS cell and the dendritic cell.  
. 
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Chapter 7 
 
General discussion 
 
The work presented in this thesis represents an investigation of the potential of 
engineered glycan-binding proteins to act as novel reagents for analysis and 
targeting of cancer cells. Increased expression of glycan structures containing 
terminal galactose residues in many cancers suggested that altering the glycan 
specificity of mannose-binding protein (MBP), a molecule that is able to activate the 
innate immune system, to bind galactosyl ligands might specifically target the protein 
toward cancer cells. This concept was tested by creating the galactose-binding 
mutant GalMBP, incorporating key residues from the carbohydrate-binding site of the 
galactose-binding asialoglycoprotein receptor into the carbohydrate-binding site of rat 
MBP-A. Although predicted to have a general specificity for terminal galactose and 
GalNAc, analysis of carbohydrate binding by GalMBP revealed a more specific 
preference for two subsets of galactose-terminated glycans that are commonly 
present on cancer cells. This finding led to the evaluation of GalMBP as a novel 
reagent for targeting and killing cancer cells.  
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7.1 Evaluation of GalMBP as a glycoproteomic tool for the analysis of cancer 
cell glycosylation 
Purification of glycoprotein ligands from breast cancer cells has illustrated the 
use of GalMBP as a novel analytical tool for glycoproteomic investigations. GalMBP 
has many advantages over other affinity reagents such as plant lectins and 
monoclonal antibodies that bind specific carbohydrate epitopes. Minimal sample 
preparation was required prior to GalMBP affinity chromatography and the relatively 
high yields, coupled with the sensitivity of mass spectrometry, allowed 
characterisation of both protein and glycan components without requiring 
radiolabelling or immunoprecipitation. The bacterial expression system for the C-
terminal fragment of GalMBP allows easy production of large quantities of trimeric 
protein with clusters of binding sites, which contributes to the successful purification 
of minor populations of proteins carrying cancer-associated glycan structures. 
GalMBP is a stable molecule, so GalMBP affinity columns can be re-used many 
times. The Ca2+-dependent binding of GalMBP allows the easy release of ligands 
bound to GalMBP columns by incubating in buffers containing EDTA. Because all 
ligands bound to the GalMBP column are released in the presence of EDTA, levels 
of ligands in different cell lines can be quantitatively compared. The relatively broad 
specificity of GalMBP has the advantage of selecting a large panel of proteins 
expressing cancer-associated glycan structures. Plant lectins and monoclonal 
antibodies have preference for more specific structures, often showing requirements 
for their presentation on specific molecular scaffolds. 
The use of GalMBP as a glycoproteomic tool for rapid characterisation of 
glycoproteins containing Lewisx structures has been demonstrated using a panel of 
Hodgkin’s Reed/Sternberg (HRS) cell lines, the neoplastic cells of Hodgkin’s 
lymphoma, for which cell-surface Lewisx is used as a diagnostic marker. The 
isolation of common glycoproteins from multiple HRS cell lines using columns of 
GalMBP may indicate a conserved role for Lewisx in the pathology of Hodgkin’s 
lymphoma. Because most proteins purified on immobilised GalMBP are involved in 
presentation of antigen to T cells or in the costimulation of T cells, the analysis 
suggests that Lewisx may be important in mediating initial interactions between HRS 
cells and T cells present in tumour tissue. Identification of ICAM-1 and CD98hc as 
major carriers of Lewisx among HRS cell lines suggests that activation signals 
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reported to occur in HRS cells following incubation with anti-Lewisx antibodies are 
likely to represent the activation of integrin-associated signalling pathways.  
Purification of CD98hc from many breast cancer cell lines and from all HRS cell 
lines investigated has identified a previously undescribed cancer cell marker that 
commonly carries cancer-associated glycans. High affinity GalMBP ligands on 
CD98hc in the correct spacing for binding by GalMBP trimers enhanced the targeting 
of GalMBP to cancer cells and this observation suggests that endogenous lectins 
with similar oligomeric structures may act as natural ligands for CD98hc. Although 
several glycoproteins, including CD98hc, were isolated from multiple breast cancer 
cell lines, a detailed glycoproteomic characterisation of GalMBP ligands from a panel 
of breast cancer cell lines has shown that there are significant variations in the 
expression levels and the protein carriers of cancer-associated glycan structures. 
These findings illustrate the diversity of breast cancer cell lines and show the 
importance of studying multiple cell lines in order to accurately reflect breast cancer 
pathology. Proteomic analysis of GalMBP ligands suggested that glycoproteins 
bound by GalMBP are predominantly presenting N-linked glycans. However, proteins 
that present O-linked glycans are typically large and heavily glycosylated, which 
makes them difficult to identify using trypsin digestion followed by mass 
spectrometry. In addition, the use of 15% SDS-polyacrylamide gels to separate 
proteins is ideally suited for separating N-linked glycoproteins but will not resolve 
large O-linked glycoproteins as effectively. The glycomic analysis of GalMBP ligands 
revealed O-linked glycans were purified from all breast cancer cell lines investigated, 
and high levels of MUC1 were detected in the elution fractions from many cell lines 
when analysed using low percentage polyacrylamide gels followed by detection with 
anti-MUC1 antibodies. These findings suggest that the relative role of O-linked 
glycoproteins in GalMBP binding to breast cancer cells may be underestimated in 
the proteomic analysis. 
A large body of structural information about how C-type CRDs bind specific 
glycan structures is available, enabling the engineering of further glycan-binding 
proteins. Whilst GalMBP has glycan specificity useful in the analysis of cancer-
associated glycosylation, it does not share the high level of selectivity observed in 
some C-type lectins. The generation of engineered glycan-binding proteins with 
specificity for more distinct glycan structures would provide further proteomic tools to 
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complement GalMBP. An increase in specificity might also be important in the 
successful development of a therapeutic reagent.  
 
7.2 Evaluation of GalMBP as a novel reagent for cancer cell targeting. 
The ability of GalMBP to target cancer-associated glycans on cells has been 
demonstrated on neuraminidase-treated erythrocytes. The finding that GalMBP 
initiated complement-dependent cell lysis on the bound erythrocytes suggested that 
it might have potential use as a therapeutic reagent. Targeting of GalMBP to cancer 
cells has been shown through binding to breast cancer cell lines. However, GalMBP 
did not initiate complement-dependent cell lysis of breast cancer cells to which it is 
bound. 
 A therapeutic role for GalMBP will be dependent on its ability to selectively 
target cancer cells. It will therefore be necessary to investigate GalMBP binding to 
cells that have not undergone oncogenic transformation. A low level of reactivity 
toward normal cells would confirm that GalMBP targets cancer cells due to the 
presence of cancer-associated glycan structures. It will be particularly important to 
analyse GalMBP binding to non-cancerous cells that may present high affinity 
ligands for GalMBP. Many leukocytes, including neutrophils and granulocytes, 
present glycans bearing Lewis structures. Interactions between GalMBP and these 
cells may have deleterious consequences in any therapeutic approach. High levels 
of GalMBP binding to non-cancerous cells would sequester the protein and reduce 
the levels available to target cancer cells. Binding to immune cells may also lead to 
more serious side effects, such as the generation of an autoimmune response. 
The anti-tumour activity of GalMBP is unlikely to be clearly resolved without the 
use of an in vivo model, where GalMBP could activate immune molecules using 
complement-independent mechanisms such as interactions with collectin receptors 
on the surface of phagocytes. Should GalMBP still fail to stimulate clearance of the 
cancer cells that it binds, it could still be useful therapeutically as a delivery agent for 
cytotoxic compounds to which it could be conjugated. A further potential therapeutic 
mechanism for GalMBP could be as a competitive inhibitor for in vivo interactions. By 
competing with endogenous lectins for binding to cancer-associated glycan 
structures GalMBP would act to reduce the ability of cancer cells to metastasise. 
Analysis of the anti-tumour activities of GalMBP will require development of an 
experimental system using animal models such as mice. This could involve the 
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induction of GalMBP expression in human tumours grown in immune-deficient mice 
or on mouse tumours grown in immune-sufficient mice. The latter case is likely to 
better represent the anti-tumour activity of GalMBP but would require prior 
demonstration that GalMBP binds to mouse cancer cell lines to validate them as 
GalMBP targets. The demonstration of a reduction in tumour size or increase in 
survival time could lead to further evaluation of GalMBP as a therapeutic reagent. 
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GalMBP is a fragment of serum mannose-binding protein
that has been modified to create a probe for galactose-
containing ligands. Glycan array screening demonstrated
that the carbohydrate-recognition domain of GalMBP se-
lectively binds common groups of tumor-associated glycans,
including Lewis-type structures and T antigen, suggesting
that engineered glycan-binding proteins such as GalMBP
represent novel tools for the characterization of glycopro-
teins bearing tumor-associated glycans. Blotting of cell ex-
tracts and membranes from MCF7 breast cancer cells with
radiolabeled GalMBP was used to demonstrate that it binds
to a selected set of high molecular weight glycoproteins that
could be purified from MCF7 cells on an affinity column
constructed with GalMBP. Proteomic and glycomic anal-
ysis of these glycoproteins by mass spectrometry showed
that they are forms of CD98hc that bear glycans displaying
heavily fucosylated termini, including Lewisx and Lewisy
structures. The pool of ligands was found to include the tar-
get ligands for anti-CD15 antibodies, which are commonly
used to detect Lewisx antigen on tumors, and for the en-
dothelial scavenger receptor C-type lectin, which may be
involved in tumor metastasis through interactions with this
antigen. A survey of additional breast cancer cell lines re-
veals that there is wide variation in the types of glycosylation
that lead to binding of GalMBP. Higher levels of binding are
associated either with the presence of outer-arm fucosylated
structures carried on a variety of different cell surface gly-
coproteins or with the presence of high levels of the mucin
MUC1 bearing T antigen.
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Introduction
The normal processes of glycosylation are often severely
altered during oncogenic transformation of animal cells
(Hakomori 1996). These changes can affect interactions be-
tween tumor cell-surface glycans and endogenous lectins, which
may determine the metastatic potential of the tumor cell. Several
common structural changes occur in tumor glycans, including
increases in the level of truncation and branching of structures as
well as an increased expression of unusual terminal sequences
(Kim and Varki 1997). These three changes often result in in-
creased exposure of terminal galactose residues, such as those
found in the cancer-associated T antigen (Gal β1-3 GalNAc)
and the Lewisx trisaccharide (Galβ1-4(Fucα1-3)GlcNAc). One
potential role of galactose ligands in tumor cell metastasis is
highlighted by the correlation between increased expression of
the galectin family of galactose-binding proteins and the ability
of many tumor cell types to metastasize (Takenaka et al. 2004).
Galectins are thought to facilitate binding of circulating tumor
cells to cells of the vascular endothelium by binding to galactose-
containing carbohydrate ligands on tumor cell surfaces (Glinsky
2000).
Monoclonal and polyclonal antibodies have proved to be use-
ful tools in the identification of tumor-specific glycosylation
(Dube and Bertozzi 2005). For example, the CD15 epitope,
which corresponds to the Lewisx trisaccharide, is a useful di-
agnostic marker for Reed-Sternberg cells of Hodgkin’s lym-
phoma (Dorfman et al. 1986) and an antibody specific to sialyl-
Lewisa is used in diagnostic tests for progression of colon cancer
(Macdonald 1999). Characterization of human cell glycosyla-
tion with antibodies has been complemented by structural com-
parison of glycans on normal and tumor cells and by analysis
of changes in the complement of enzymes involved in glycan
biosynthesis in tumor cells (Kobata and Amano 2005). How-
ever, establishing how changes in glycosylation affect the prop-
erties of tumor cells requires a more detailed understanding
of how glycans are presented at the cell surface. Specifically,
identification of proteins that carry tumor glycans is vital to
describing the cellular adhesion and subsequent processes that
enable the tumor cell to adhere to the endothelium (Hakomori
1996; Kim and Varki 1997; Takenaka et al. 2004). New tools are
needed because it is often difficult to identify protein carriers
of glycan epitopes. For individual cell-surface glycoproteins,
the nature of the glycans bearing particular epitopes is largely
unknown.
Sugar-binding receptors of the C-type lectin family contain
structurally related carbohydrate recognition domains (CRDs)
but display a diversity of carbohydrate-binding specificities
(Weis et al. 1998). Some receptors that contain C-type CRDs,
such as the selectins, interact with tumor cells and facilitate tu-
mor dissemination (Kim et al. 1998). Structural knowledge of
how C-type CRDs bind selectively to specific sugars has made
C© 2009 The Author(s)
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Fig. 1. Screening of a glycan array with GalMBP. Immobilized glycans were probed with fluorescein-labeled GalMBP. Glycans bearing terminal galactose are
highlighted in red, except those that also contain fucose, which are colored green, and those linked via a β1,3 linkage to GalNAc, which are colored dark blue.
Glycans bearing terminal GalNAc are indicated in light blue. The level of fluorescence was normalized to glycan 138. A full list of glycans present on the array is
included in supplementary Table I.
it possible to modify the sugar-binding characteristics of these
domains (Iobst and Drickamer 1994), raising the possibility of
creating CRDs with novel specificities for tumor glycans.
The results reported in this manuscript demonstrate that
GalMBP, an engineered variant of serum mannose-binding pro-
tein (MBP-A) that selectively binds to glycans bearing termi-
nal galactose, is an effective tool for identifying and purify-
ing tumor-specific glycans. This glycoproteomic approach has
allowed identification of the heavy chain of the cell-surface
receptor CD98 as the primary bearer of Lewisx and Lewisy/b
tumor glycans on the MCF7 breast cancer cell line, including a
large population of novel, heavily fucosylated, multi-antennary
tumor-associated glycans. The ability of tumor cell lines of dif-
ferent origins to bind GalMBP varies widely and reflects hetero-
geneity in the levels of terminally fucosylated N-linked glycans
and mucin MUC1 bearing O-linked glycans with exposed ter-
minal galactose residues.
Results
GalMBP binding to tumor-associated glycans
A trimeric C-terminal fragment of rat MBP-A, consisting of the
CRD and an adjacent α-helical region, can be modified to bind
to galactose-related sugars by three single amino acid changes
and the insertion of a five-amino-acid glycine-rich loop to cre-
ate GalMBP (mutant QPDWG in Iobst and Drickamer (1994)).
In order to assess the ability of this engineered CRD to bind
specific sets of galactose-containing ligands, the carbohydrate-
binding characteristics of fluorescently labeled GalMBP were
examined by probing a glycan array consisting of 285 natural
and synthetic oligosaccharides covalently linked to a chemi-
cally modified glass slide. The results show that GalMBP se-
lectively binds to glycans bearing terminal galactose residues,
with little binding to other glycans, even those containing termi-
nal N-acetylgalactosamine residues (Figure 1). Glycan 157, the
one ligand that does not contain a terminal galactose residue,
ends with a galactose that is modified with an α1,6-linked N-
acetylglucosamine residue. Thus, GalMBP can tolerate limited
substitution of the 6-position of galactose, although the presence
of 2–6-linked sialic acid prevents binding.
GalMBP shows preference for two distinct subsets of the 78
glycans bearing terminal galactose residues. One subset con-
sists of glycans in which a terminal α1,3- or α1,4-linked fucose
residue is adjacent to a terminal galactose residue, including
8 of the 20 ligands that give the strongest signals and con-
tain either the Lewisa (Galβ1-3(Fucα1-4)GlcNAc) or the Lewisx
(Galβ1-4(Fucα1-3)GlcNAc) trisaccharides. Little binding is ob-
served to glycans containing terminal fucose in α1,2 linkage
(glycans 95–99 and 108). This observation is consistent with
the fact that the primary binding site in GalMBP binds galac-
tose and not fucose (Iobst and Drickamer 1994), so although
both native MBP and GalMBP can bind the Lewisx structure,
they must do so in very different ways, with fucose in the pri-
mary binding site of MBP and galactose in the primary bind-
ing site of GalMBP. Another 8 of the 20 best ligands contain
Galβ1-3GalNAc. A requirement for GalNAc as the subterminal
residue in this disaccharide is indicated by the lack of bind-
ing to glycans containing Galβ1-3GlcNAc (glycans 131–134)
or Galβ1-3Gal (glycan 130). The disaccharide Galβ1-3GalNAc
is the core 1 structure of mucin-type O-linked glycans, which
in an unmodified form is commonly referred to as the cancer-
associated Thomsen–Friedenreich antigen (T antigen). The abil-
ity of GalMBP to bind to the T antigen is also indicated by its
binding to glycan 278, where Galβ1-3GalNAc is presented on
a threonine linker.
Detection of GalMBP ligands on MCF7 cell surfaces
The selectivity of GalMBP for structures such as the T anti-
gen and Lewisx trisaccharide, which are expressed at increased
levels in a variety of cancerous tissues such as carcinomas, in-
dicated that the modifications made to create GalMBP might
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Fig. 2. GalMBP binding to MCF7 cells and glycoproteins. (A) Binding of GalMBP or wild-type MBP-A to MCF7 cells was detected using a rabbit polyclonal
antibody to MBP-A, followed by a goat anti-rabbit secondary antibody conjugated to horseradish peroxidase. Experimental data (symbols) are shown together with
curves fitted to the data using a direct binding equation. The concentration of protein required for 50% of maximal binding was approximately 0.1 μg/mL for
GalMBP and 20 μg/mL for wild-type MBP-A. (B) Total cell lysates and biotinylated cell-surface proteins purified on avidin-conjugated beads were analyzed by
SDS–polyacrylamide gel electrophoresis followed by Coomassie blue staining or blotting onto nitrocellulose followed by probing with 125I-GalMBP. The
experiment was performed with low (L) and high (H) densities of MCF7 cells.
target it selectively to cancer cells. Binding studies with the hu-
man breast cancer cell line MCF7, which is known to express
Lewisx (Elola et al. 2007), showed that GalMBP binds to MCF7
cells with 200-fold greater affinity than wild-type MBP-A does,
confirming that GalMBP is able to detect high affinity ligands
on these cells (Figure 2A). Specific glycoprotein ligands in the
MCF7 cell membranes were detected on nitrocellulose blots
probed with radioiodinated GalMBP (Figure 2B). The two ma-
jor glycoprotein ligands, migrating at approximately 75 kDa and
100 kDa, were also detected when MCF7 cell surface proteins
were biotinylated and purified on avidin-conjugated agarose
beads. Thus, GalMBP interacts specifically with a restricted
set of cell surface glycoproteins that are potential carriers of
tumor-specific glycans.
Identification of glycoprotein ligands for GalMBP
Columns of immobilized GalMBP were used to enrich GalMBP
ligands in detergent extracts of MCF7 cells for further character-
ization. SDS–polyacrylamide gels of ligands bound to GalMBP
and released with EDTA revealed that the major Coomassie
blue-stained proteins retained on the column correspond to the
two bands of 75 kDa and 100 kDa identified in the blotting
experiments (Figure 3A). Probing with 125I-GalMBP confirmed
that these bands are ligands for GalMBP, while the absence
of significant binding of 125I-GalMBP to proteins in the flow-
through and wash fractions demonstrated that the majority of
ligand was bound to the column. When the elution fractions
were pooled and repurified on the GalMBP column, which was
washed with high and low salt buffers before ligands were again
eluted with EDTA, only two Coomassie-blue stained bands that
were not recognized by 125I-GalMBP remained, at 35 kDa and
25 kDa (Figure 3B).
Proteomic analysis of the major bands in the repurified ligand
pool by trypsin digestion and mass spectrometry demonstrated
that both high-molecular-weight GalMBP ligands comprise the
heavy chain of the cell-surface glycoprotein CD98 (CD98hc)
(Figure 3 and supplementary Table II). No other proteins were
identified across a range of search conditions. CD98hc con-
sists of a 58-kDa polypeptide backbone with four potential
N-glycosylation sites (Deves and Boyd 2000). The heterogene-
ity of CD98hc purified from MCF7 cells is presumably due to
variation in the number and the size of N-linked glycans, with
two dominant populations being evident. The 35-kDa band was
identified as the large neutral amino-acid transporter LAT1, one
of six light chains (CD98lc) that form disulfide-linked dimers
with CD98hc (Deves and Boyd 2000). The molecular weight
of the LAT1 polypeptide is 55 kDa, but the protein migrates
anomalously on SDS gels due to its hydrophobic composition
(Deves and Boyd 2000). The 25-kDa band was derived from
GalMBP, presumably as a result of limited proteolytic degrada-
tion of the column.
CD98 was originally identified as a surface antigen in lym-
phocytes and subsequently was found to be expressed in most
tissues and virtually all tumor cells (Deves and Boyd 2000).
CD98hc is required for cell-surface expression of the CD98lc
amino acid transporter (Nakamura et al. 1999). High-level ex-
pression of CD98hc therefore may be required for MCF7 cells
to produce large amounts of amino-acid transporter necessary
for sustained growth. At the same time, the CD98hc projects
an extensive array of glycans that could mediate adhesion to
the vascular endothelium and facilitate invasion of tissues. A
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Fig. 3. Purification of GalMBP ligands from MCF7 cell lysates by affinity
chromatography on immobilized GalMBP. (A) Solubilized MCF7 cells were
passed over a column containing immobilized GalMBP, which was washed in
the presence of calcium and eluted with EDTA. Fractions were analyzed by
SDS–polyacrylamide gel electrophoresis followed by staining with Coomassie
blue or blotting onto nitrocellulose followed by probing with 125I-GalMBP.
(B) GalMBP ligands were repurified on the GalMBP column and analyzed by
SDS–polyacrylamide gel electrophoresis followed by staining with Coomassie
blue. Bands from the elution fractions were excised and digested with trypsin.
Proteins identified by mass spectrometry in each band are indicated.
direct role of CD98hc in tumor-cell activation and adhesion
is suggested by the finding that crosslinking of CD98hc with
monoclonal antibodies specific to the CD98hc protein or car-
bohydrate blocks the proliferation of tumor cells (Yagita et al.
1986) and the demonstration that overexpression of CD98hc in-
duces malignant transformation of fibroblasts (Hara et al. 1999).
Glycans on CD98hc
The proteomic experiments indicate that the heavy chain of
CD98 is the predominant ligand for GalMBP in MCF7 cells
and suggest that this glycoprotein may be the carrier for tumor-
specific glycans. The preference of GalMBP for Lewis-type
structures, coupled with previous reports of Lewisx expres-
sion on MCF7 cells (Elola et al. 2007), suggested that gly-
cans on CD98 that are recognized by GalMBP may con-
tain Lewisx. This idea was confirmed by matrix-assisted laser
desorption-ionization time-of-flight (MALDI-TOF) mass spec-
trometry analysis of N-glycans on CD98hc. The MALDI-TOF
profile shows that the majority of molecular ions correspond
to large, complex-type N-glycans composed of 5–11 hexose
residues, 4–10 N-acetylhexosamine residues, and 1–6 fucose
residues (Figure 4). MS/MS analysis of the major molecular
ions coupled with the knowledge of the biosynthetic pathway of
N-linked glycosylation was used to predict the structures of the
main glycans present (Dell 1994). Many of the glycans identi-
fied are tetra-antennary, with bi- and tri-antennary structures also
present at lower levels. There is evidence of substantial termi-
nal fucosylation but very limited terminal sialylation and some
high mannose oligosaccharides are also present. Sequences
predicted to be O-glycosylated are not found in CD98hc and
O-glycosylation of the protein has not been reported, so the
most likely ligands for GalMBP would be the N-linked glycans.
MS/MS analysis provided evidence that Lewisa/x, Lewisy/b,
and core fucose are present in all molecular ion peaks contain-
ing two or more fucose residues (Figure 5). All of the peaks
analyzed produced fragment ions at m/z 660, corresponding to
Lewisa/x. Diagnostic fragments corresponding to elimination of
fucose from the 3-position of GlcNAc indicate that Lewisx is
the predominant singly fucosylated terminal structure, although
some Lewisa termini may also be present. For example, the
dominant species at m/z 2591 consists of a bi-antennary glycan
with both of the antennae terminating in Lewisx (Figure 5A).
Similarly, a fragment at m/z 834 is present in multiply fucosy-
lated peaks, indicating the presence of Lewisy/b (Figure 5A–C).
Analysis of larger molecular ions revealed the presence of two-
and three-repeat poly-N-acetyllactosamine extensions bearing
one or two fucose residues, which have the potential to form
repeated Lewisx/a structures (Figure 5C–D).
Glycans on CD98hc as targets for cell adhesion
The detection of heavily fucosylated structures on CD98hc ex-
plains the selective binding of GalMBP to this protein and in-
dicated that it may provide a scaffold for interactions of MCF7
cells with endothelia (Elola et al. 2007). This suggestion was
supported by the fact that CD98hc is bound by the scavenger
receptor C-type lectin (Figure 6). This endothelial receptor rec-
ognizes Lewisx selectively and has been proposed to function
in adhesion of tumor cells during metastasis (Coombs et al.
2005; Elola et al. 2007). In previous studies, in which whole
cell extracts were blotted with scavenger receptor C-type lectin,
two lower-molecular-weight bands were detected (Elola et al.
2007). These bands, which appear to be proteolytic fragments
of CD98hc, were not observed when more stringent steps were
taken to prevent proteolysis during sample preparation.
Survey of GalMBP ligands on breast cancer cell lines
Based on the ability of GalMBP to bind glycans characteristic
of tumor cell surfaces, probing of additional breast cancer cell
lines was undertaken. Direct binding assays revealed that cells
of different origins differ in their capacity for binding GalMBP,
with higher affinity binding observed for MCF7 and SKBR3
cells compared to ZR75-1 and T47D cells (Figure 7A and
B). As a control, little binding was observed for MDA-MB-
231 cells, which are not believed to be of epithelial origin. The
differences in binding correlate partially with variations in the
levels of Lewisx epitopes on glycoproteins from these cells as
detected with two monoclonal anti-CD15 antibodies, with high-
est binding observed for MCF7 and SKBR3 cells (Figure 7C).
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Fig. 4. Mass spectrometric analysis of N-glycans from CD98hc. Glycans released from purified GalMBP ligands were permethylated and subjected to MALDI MS
profiling. All labeled molecular ions corresponding to complex-type glycans were subjected to MS/MS analysis. The assignment for each ion represents the most
likely structure based on the precise fit between the calculated composition and the m/z value, taking into account the biosynthetic pathways of N-glycosylation in
addition to the MS and MS/MS data. Values (m/z) listed correspond to 12C throughout. Satellite peaks surrounding major signals are either artifacts of the
permethylation process or are minor glycans with one or more sialylated antennae. The symbols are defined in Figure 1.
Analysis of the N-linked glycans purified on GalMBP from
the additional cell lines confirmed that SKBR3 cells display
multiple glycans with outer arm fucosylation, including tri- and
tetra-antennary structures, although the degree of fucosylation is
reduced compared to the MCF7 cells and glycans from ZR75-1
and T47D cells bear even fewer such structures (supplementary
Figure 1).
The relatively paucity of CD15 antigens and related epitopes
on the glycoproteins from ZR75-1 and T47D cells indicated
that there might be other GalMBP ligands on these cells that ac-
count for some of the binding observed. The ability of GalMBP
to interact with the T antigen suggested that O-linked glycans
displayed on cell surface mucins such as MUC1 could be addi-
tional targets (Burchell et al. 2001). The presence of such mucins
would not easily be detected by mass spectrometry because few
tryptic peptides can be released from the core polypeptide of
the mucin, so the presence of MUC1 was demonstrated by us-
ing a monoclonal antibody to probe gels of the GalMBP lig-
ands (Figure 7D). The blot reveals the presence of MUC1 in
the material purified from MCF7, SKBR3, and ZR75-1 cells.
Mass spectrometry of the O-linked glycans on glycoproteins
purified from the cells lines confirmed the presence of T anti-
gen as the predominant O-linked glycan from all but the T47D
cells, in which the T antigen is mostly sialylated (supplementary
Figure 2).
These results demonstrate that the relative contributions of
fucosylated N-linked structures and O-linked T antigen vary be-
tween different breast cancer cell lines. In addition to differences
in the relative contributions of these two classes of glycans, the
different molecular weights of glycoproteins bearing CD15 anti-
gens on the different cell lines suggested that these are carried
on different protein scaffolds. This conclusion was confirmed
by proteomic analysis, which demonstrated extensive variabil-
ity in the glycoproteins purified on GalMBP (supplementary
Table III). Although CD98hc, the predominant carrier on MCF7
cells, is also detected in the extracts from SKBR3 and T47D
cells, it is not the predominant protein present in these cases
and it is not detected in the case of the ZR75-1 cells. These
results suggest that the extent of tumor-specific glycosylation in
different cell lines may depend on the abundance of different
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Fig. 6. Demonstration of GalMBP ligands from MCF7 cells binding to the
scavenger receptor C-type lectin. Purified MCF7 ligands were analyzed by
SDS–polyacrylamide gel electrophoresis. Parallel lanes were stained with
Coomassie blue or blotted onto nitrocellulose membranes and probed with
125I-GalMBP or 125I-scavenger receptor C-type lectin (SRCL).
target proteins as well changes in the expression of components
of the glycosylation machinery of the cell.
Discussion
The results described here demonstrate that breast cancer
cells vary widely in the nature of their glycosylation in spite
of their similar origins and phenotypes, with two classes of
tumor-associated glycosylation present: branched, outer arm-
fucosylated N-linked glycans, and O-linked glycans bearing the
T antigen. However, the most abundant protein carriers of the
N-linked glycans vary dramatically between different cell lines,
with MCF7 cells being unusual in that a single glycoprotein is
the predominant carrier of the heavily fucosylated structures.
These results emphasize the importance of looking at more than
one breast cancer cell line when examining glycosylation differ-
ences. They also provide a molecular explanation of variability
in the response of breast cancers to treatments with antibodies
directed against carbohydrate epitopes (Mordoh et al. 1995) and
they suggest that screening may help to identify tumors more
likely to respond to treatment with anti-CD15 antibodies. In ad-
dition to providing an important tool for such analysis, GalMBP
can be used as a surrogate for endogenous receptors, such as the
endothelial scavenger receptor C-type lectin, that may interact
with tumor cell glycans during metastasis but which are much
more difficult to obtain in quantities sufficient for use as affinity
reagents.
The fact that GalMBP binds two subsets of galactose-
terminating glycans that are commonly present on tumor cells
makes it a powerful tool for identifying and analyzing glycopro-
teins present on tumor cell lines. Purification of glycoproteins by
affinity chromatography on GalMBP requires minimal sample
preparation prior to affinity chromatography and the high yields,
coupled with the sensitivity of mass spectrometry, allowed char-
acterization of both protein and glycan components without re-
quiring radiolabeling or immunoprecipitation. The bacterial ex-
pression system for the C-terminal fragment of GalMBP allows
easy production of large quantities of trimeric protein with
clusters of binding sites and will facilitate creation of further
variants with modified selectivity for different sets of glycans.
In a recent study, isolation of ligands for wild-type MBP from
SW1116 human colon tumor cells by affinity chromatography
revealed that unmodified rabbit MBP binds to heavily fuco-
sylated glycans, including those present on CD26 (Kawasaki
et al. 2009). The recognition mechanism of this wild-type pro-
tein is different from GalMBP because fucose would be the
principal sugar interacting with the binding site, but the best
ligands bear multiple fucosylated N-acetyllactosamine repeats
and thus would overlap with those bound by GalMBP. It is in-
teresting that this approach leads to identification of a pattern
of glycoprotein ligands different to any of the breast cancer cell
lines, with CD26 and CD98hc identified as the major carriers of
glycans that react with wild-type MBP.
The glycan array profile of GalMBP reveals a preference
for galactose-terminating glycans that either bear terminal fu-
cose residues or terminate in galactose-linked β1-3 to GalNAc.
GalMBP makes primary interactions with terminal galactose
residues (Iobst and Drickamer 1994; Kolatkar and Weis 1996).
The glycan array results indicate that this binding is enhanced
through secondary interactions with an adjacent terminal fucose
residue. The preference for terminal fucose shows some simi-
larity to that of the macrophage galactose receptor (Coombs
et al. 2006), but the selectivity of GalMBP for Galβ1-3GalNAc
has not been observed in other galactose-binding receptors. The
glycan array results demonstrate that, in the context of gly-
cans, GalMBP binds preferentially to galactose-terminated lig-
ands, which is distinct from the preferential binding to GalNAc
observed for the asialoglycoprotein receptor and the roughly
equal binding of galactose- and GalNAc-containing ligands
to the macrophage galactose receptor (Coombs et al. 2006).
These results indicate that further targeting to novel sets of gly-
cans may be achieved by additional engineering of the binding
site, employing the large body of information on the struc-
tural basis for ligand recognition by various C-type lectins
(Drickamer 1999; Feinberg et al. 2007) in conjunction with
rapid characterization of the specificities developed using the
glycan array.
In the presence of complement, full-length GalMBP binds to
and lyses erythrocytes pretreated with neuraminidase to expose
terminal galactose in the form of the Thomsen–Friedenreich
antigen (T antigen) on red blood cell glycans (Bray et al.
1981) (unpublished observations). The ability of GalMBP to
lyse neuraminidase-treated red blood cells highlights a poten-
tial therapeutic role for the protein either through complement-
dependent lysis, by complement-mediated phagocytosis by
leukocytes, or by a complement-independent mechanism that
has been referred to as MBP-dependent cell cytotoxicity (Ma
et al. 1999).
Material and methods
Preparation of proteins
The C-terminal fragment of GalMBP was expressed by inducing
bacteria in the presence of Ca2+ as described for the scavenger
receptor C-type lectin (Coombs et al. 2005). Protein released by
sonication was purified on galactose-Sepharose by the method
used previously (Iobst and Drickamer 1994). Full-length wild-
type MBP-A was prepared following the published procedure
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Fig. 7. Binding of GalMBP to a panel of breast cancer cell lines and purification of glycoprotein ligands. (A and B) Binding of GalMBP was assayed as described
in Figure 2A. (C and D) Gel electrophoresis of GalMBP ligands from multiple tumor cell lines purified by affinity chromatography on immobilized GalMBP. (C)
Gels (17.5%) were stained with Coomassie blue or blotted onto nitrocellulose and probed with monoclonal anti-Lewisx antibodies followed by the
peroxidase-conjugated goat anti-mouse secondary antibody. (D) Gels (5%) were blotted on nitrocellulose and probed with the monoclonal anti-MUC1 antibody
followed by the peroxidase-conjugated goat anti-mouse secondary antibody.
(Wallis and Drickamer 1999). A version of GalMBP correspond-
ing to full-length MBP-A was expressed in Chinese hamster
ovary cells following the same strategy used for wild-type MBP-
A (Wallis and Drickamer 1997), except that the protein was pu-
rified on galactose-Sepharose. The truncated form of GalMBP
was labeled with fluorescein isothiocyanate in the bicine buffer
(Powlesland et al. 2006) or with [125I]Bolton-Hunter reagent
(Coombs et al. 2005). The glycan array developed by the Con-
sortium for Functional Glycomics was screened using the stan-
dard buffer conditions (www.functionalglycomics.org). Scav-
enger receptor C-type lectin was prepared and labeled as previ-
ously described (Coombs et al. 2005).
Binding of GalMBP to cells
MCF7 cells were grown as previously described (Elola et al.
2007). Cell lines MDA-MB-231, T47D, and ZR-75-1 were
obtained from the European Collection of Cell Cultures, and
SKBR3 cells were purchased from the American Type Culture
Collection. Cells were grown in the media recommended by the
suppliers. Confluent cells in 96-well plates were washed twice
with 250 μL of medium without phenol red, incubated with
wild-type MBP-A or GalMBP in medium for 30 min at room
temperature, washed four times with medium, incubated for
60 min at room temperature with a 1:800 dilution of anti-
MBP-A antibody in medium containing 5% bovine serum al-
bumin, washed again four times with medium, incubated for
60 min at room temperature with a 1:800 dilution of goat
anti-rabbit antibody conjugated to horseradish peroxidase (30
μg/mL) (MP Biomedicals, Illkirch, France), and washed four
times with medium and incubated with 100 μL of peroxi-
dase substrate (Pharmingen, BD Biosciences, San Jose, CA)
for 10 min at room temperature in the dark. Reactions were
terminated with 50 μL of 2 M HCl and were centrifuged at
250 × g for 5 min. Supernatants were transferred to a 96-
well ELISA plate and the absorbance at 450 nm was read
using a Victor3 plate reader from Perkin Elmer (Waltham,
MA).
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Cell surface biotinylation
MCF7 cells grown to 80% and 40% confluence in 100 mm plates
were washed twice with PBS supplemented with 0.1 mM CaCl2
and 1 mM MgCl2 and incubated with gentle shaking for 20 min
at 4◦C in supplemented PBS containing 1 mg/mL sulfo-NHS-
biotin (Perbio Science, Cramlington, UK). Cells were washed
twice and incubated with gentle shaking for a further 40 min
at 4◦C with supplemented PBS containing 100 mM glycine,
and washed twice with supplemented PBS and harvested by
scraping into supplemented PBS and centrifugation at 450 × g
for 2 min. Each pellet was dissolved in the biotinylation lysis
buffer (150 mM NaCl, 100 mM Tris-Cl, pH 7.4, 1 mM EDTA,
1% Triton X-100) containing protease inhibitors, sonicated for
5 s, and incubated at 4◦C for 10 min with end-over-end mix-
ing. Solubilized pellets were centrifuged at 14,000 × g for 5
min and portions of the supernatants were reserved for analy-
sis of total protein content. The remaining supernatants were
incubated with a 50% suspension of avidin-conjugated agarose
beads (Perbio Science) for 60 min at 4◦C with end-over-end
mixing. Beads were pelleted by centrifugation at 14,000 × g for
5 min. The pellets were washed four times with the biotinyla-
tion lysis buffer, and bound proteins were eluted by boiling at
100◦C for 5 min in the SDS–polyacrylamide gel sample buffer
containing 2-mercaptoethanol.
Affinity purification of ligands on immobilized GalMBP
The C-terminal fragment of GalMBP, 5 mg in 2 mL of 150 mM
NaCl, 100 mM HEPES, pH 8.0, 50 mM CaCl2, was coupled to
2 mL of Affigel 10 (BioRad Laboratories, Hercules, CA) at 4◦C
for 4 h following the manufacturer’s directions and equilibrated
in the loading buffer (150 mM NaCl, 25 mM Tris-Cl, pH 7.8,
25 mM CaCl2). Cells (2 × 225 cm2 flasks) were grown to
confluence, washed in PBS, harvested by scraping into PBS
followed by centrifugation at 450 × g for 2 min, resuspended
in the cell lysis buffer (150 mM NaCl, 25 mM Tris-Cl, pH
7.8, 2 mM CaCl2) containing 1% Triton X-100 and protease
inhibitors, sonicated for 10 s and incubated on ice for 30 min.
Following centrifugation at 3500 × g for 5 min, lysate was
passed over the GalMBP affinity column, which was washed
with the cell lysis buffer containing 0.1% Triton X-100. Bound
proteins were eluted with the elution buffer (150 mM NaCl, 25
mM Tris-Cl, pH 7.8, 2.5 mM EDTA) containing 0.1% Triton
X-100. For repurification, elution fractions were pooled, CaCl2
was added to 25 mM, and the protein was again passed over
the GalMBP affinity column. The column was washed with the
high salt loading buffer, in which the NaCl concentration was
increased to 1.25 M, and with the loading buffer, both containing
0.1% Triton X-100, and ligands were eluted in the elution buffer
containing 0.1% Triton X-100.
Western blot analysis of GalMBP ligands
Samples dissolved in the sample buffer containing 1%
2-mercaptoethanol and boiled at 100◦C for 5 min were an-
alyzed by SDS–polyacrylamide gel electrophoresis and elec-
troblotted onto Protran nitrocellulose membranes (Whatman,
Maidstone, UK) (Burnette 1981). For probing with radiola-
beled receptors, blots were blocked overnight at 4◦C with 2%
hemoglobin in the loading buffer, incubated with 125I-GalMBP
or 125I-scavenger receptor C-type lectin for 2 h at room tem-
perature with gentle shaking and washed four times with Tris-
buffered saline. Radioactivity was detected using a Phosphorim-
ager SI from Molecular Dynamics (Sunnyvale, CA). Probing
with anti-Lewisx antibodies was performed as previously de-
scribed (Elola et al. 2007). Blots were probed for MUC1 by in-
cubating overnight with hybridoma cell culture supernatant con-
taining monoclonal antibody HMFG2, provided by Joy Burchell
and Joyce Taylor-Papadimitriou (Kings College London), fol-
lowed by alkaline phosphatase-conjugated goat anti-mouse IgG
from Jackson ImmunoResearch (West Grove, PA).
Analysis of purified ligands by mass spectrometry
Solvents, acetic acid, and trifluoroacetic acid were purchased
from Romil (Cambridge, UK). Proteins present in elution frac-
tions from the GalMBP-agarose column were precipitated in
10% trichloroacetic acid and analyzed by SDS–polyacrylamide
gels. For proteomic analysis (Abu-Qarn et al. 2007), bands
were excised, stain was removed by incubation in acetoni-
trile, and gel pieces dried in a vacuum centrifuge. Proteins
present were reduced with 10 mM dithiothreitol and alky-
lated with 55 mM iodoacetic acid, prior to digestion with se-
quencing grade-modified trypsin (E.C.3.4.21.4 Promega, Madi-
son, WI). Peptides were extracted from gel pieces by incuba-
tion with 0.1% trifluoroacetic acid for 10 min, followed by
the addition of acetonitrile for 15 min. The extraction pro-
cess was repeated once. Peptides were reduced in volume us-
ing a vacuum centrifuge and spotted onto a MALDI stainless
steel plate with α-cyano-4 hydroxycinnamic acid used as a
matrix.
Peptides were subjected to MALDI MS profiling, comple-
mented with MS/MS sequencing of the 10 most abundant
ions in each sample, on an Applied Biosystems 4800 MALDI-
TOF/TOF mass spectrometer. For peptide mass fingerprint data,
peak picking was conducted using GPS Explorer software ver-
sion 3.6 (Applied Biosystems, Foster City, CA). A signal-
to-noise threshold of 10 was used, sequazyme peptide mass
standards were used as external standards for calibration and
no contaminant ions were excluded. For MS/MS experiments,
peak list generation and database searching were conducted us-
ing GPS Explorer software version 3.6 (Applied Biosystems)
with the default parameters. Both MS and MS/MS data were
used to search 283,454 entries in release 54.2 of the SwissProt
database with version 2.2 of the Mascot database search algo-
rithm (www.matrixscience.com) with the following parameters:
peptide masses were fixed as monoisotopic, partial oxidation of
methionine residues was considered, partial carboxymethyla-
tion of cysteine residues was considered, the mass tolerance
was set at 75 ppm for precursor ions and 0.1 Da for fragment
ions, and tryptic digests were assumed to have no more than one
missed cleavage. Peptide matches from both MS and MS/MS
data were used to generate probability-based Mowse protein
scores. Scores greater than 55 were considered significant
(P < 0.05) (Perkins et al. 1999). In order to broaden the search
for other possible proteins in the GalMBP-binding fractions
from MCF7 cells, the mass tolerance for precursor ions was
increased to 100 ppm, taxonomy was broadened to include
all species, and the possibility of two missed cleavages was
allowed.
For glycan analysis, proteins eluted from GalMBP were
precipitated trichloroacetic acid and subjected to glycan re-
lease and permethylation as previously described (Sutton-Smith
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and Dell 2005). Samples were redissolved in 10 μL of
methanol:water (4:1), mixed with an equal volume of 10 mg/mL
2,5-dihydroxybenzoic acid matrix and subjected to MALDI MS
profiling, with selected ions further analyzed by MS/MS. The
MALDI profile of glycans in the major elution fraction from
the reverse phase cartridge is shown. Both MALDI MS and
MS/MS data were acquired on an Applied Biosystems 4800
MALDI-TOF-TOF mass spectrometer.
Analysis of GalMBP ligands by liquid chromatography and
tandem mass spectrometry
GalMBP ligands were precipitated with trichloroacetic acid,
lyophilized, dissolved in 25 μL of 8 M urea containing
10 mM HEPES, pH 8.0, reduced with dithiothreitol, alkylated
with iodoacetic acid, and digested in solution with sequenc-
ing grade modified trypsin (Promega) (Foster and Mann 2005).
Tryptic peptides were dried on a vacuum centrifuge, resus-
pended in 80 μL 0.1% trifluoroacetic acid, desalted, and pu-
rified by nano-liquid chromatography using an Ultimate 3000
(LC Packings, Dionex) fitted with a Pepmap analytical C-18
nanocapillary. After loading in 2% acetonitrile containing 0.1%
trifluoroacetic acid, the column was eluted with a gradient from
8–45% acetonitrile over 60 min at a flow rate of 0.3 μL/min.
Samples were spotted directly onto a MALDI steel target plate
using a Probot (LC Packings, Dionex, Sunnyvale, CA) with α-
cyano-4 hydroxycinnamic acid as a matrix. Samples were sub-
jected to MALDI-MS profiling with major peaks selected for
collision-induced dissociation and sequencing by tandem mass
spectrometry.
Fragment ions detected in the MS/MS spectra was used to
search the SwissProt database with the Mascot database search
algorithm (www.matrixscience.com) for peptide sequences con-
sistent with the ion fragments observed. For each search, the
parameters used were: peptide masses fixed as monoisotopic,
partial oxidation of methionine residues considered, partial car-
boxymethylation of cysteine residues considered, mass toler-
ance 100 ppm, fragment ion tolerance 0.3 Da, tryptic digests
assumed to have no more than one missed cleavage, and taxon-
omy group searched Homo sapiens. Probability-based Mowse
scores were generated for each peptide sequence identified and
only values of greater than 95% significance were considered
(Perkins et al. 1999). Positive identification of a protein required
identification of three or more unique peptide sequences identi-
fied with ions scores of greater than 95% significance. CD98hc
was screened for potential O-glycosylation sites using the Ne-
tOGlyc 3.1 server (www.cbs.dtu.dk/services/NetOGlyc).
Supplementary data
Supplementary data for this article are available online at
http://glycob.oxfordjournals.org/.
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B. T47D N-glycans
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C. ZR-75-1 N-glycans
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Supplementary Figure 1. (A) (B) (C)Analysis of N-linked glycans from SKBR3, T47D, and ZR75-1 cells.
MALDI/TOF mass spectra of the major elution fractions from the Sep-Pak purifications are shown.All labeled
ions were subjected to MS/MS analysis.
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Supplementary Figure 2. (A) (B) (C) (D)Analysis of O-linked glycans from MCF7, SKBR3, T47D, and ZR75-1
cells. The MALDI/TOF spectra of the major elution fractions from the Sep-Pak purifications are shown.
Supplementary Table I. Glyans on glycan array.
Glycan Glycan structure Average Standard 
number fluorescence deviation
7 α-D-Gal–Sp8 2635 1443
8 α-D-Glc–Sp8 738 378
9 α-D-Man–Sp8 509 1151
10 α-GalNAc–Sp8 4595 1896
11 α-L-Fuc–Sp8 1291 582
12 α-L-Fuc–Sp9 1333 596
13 α-L-Rhα–Sp8 438 160
14 α-Neu5Ac–Sp8 678 335
15 α-Neu5Ac–Sp11 804 448
16 β-Neu5Ac-Sp8 576 322
17 β-D-Gal–Sp8 2260 1475
18 β-D-Glc–Sp8 976 311
19 β-D-Man–Sp8 425 697
20 β-GalNAc–Sp8 1043 624
21 β-GlcNAc–Sp0 514 175
22 β-GlcNAc–Sp8 383 214
23 β-GlcN(Gc)-Sp8 613 317
24 (Galβ1-4GlcNAcβ)2-3,6-GalNAcα–Sp8 1222 543
25 GlcNAcβ1-3(GlcNAcβ1-4)(GlcNAcβ1-6)GlcNAc-Sp8 375 247
26 [3OSO3][6OSO3]Galβ1-4[6OSO3]GlcNAcβ-Sp0 3905 524
27 [3OSO3][6OSO3]Galβ1-4GlcNAcβ-Sp0 1861 1132
28 [3OSO3]Galβ1-4Glcβ-Sp8 1822 643
29 [3OSO3]Galβ1-4(6OSO3)Glcβ–Sp0 2250 957
30 [3OSO3]Galβ1-4(6OSO3)Glcβ–Sp8 3185 568
31 [3OSO3]Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 1361 404
32 [3OSO3]Galβ1-3GalNAcα–Sp8 815 450
33 [3OSO3]Galβ1-3GlcNAcβ–Sp8 1511 552
34 [3OSO3]Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 737 159
35 [3OSO3]Galβ1-4[6OSO3]GlcNAcβ-Sp8 2561 938
36 [3OSO3]Galβ1-4GlcNAcβ–Sp0 1180 476
37 [3OSO3]Galβ1-4GlcNAcβ-Sp8 974 349
38 [3OSO3]Galβ–Sp8 1705 1440
39 [4OSO3][6OSO3]Galβ1-4GlcNAcβ-Sp0 1633 518
40 [4OSO3]Galβ1-4GlcNAcβ-Sp8 1351 453
41 6-H2PO3Manα–Sp8 511 252
42 [6OSO3]Galβ1-4Glcβ–Sp0 2256 1217
43 [6OSO3]Galβ1-4Glcβ–Sp8 2742 1060
44 [6OSO3]Galβ1-4GlcNAcβ–Sp8 2604 1243
45 [6OSO3]Galβ1-4[6OSO3]Glcβ-Sp8 7262 2333
46 NeuAcα2-3[6OSO3]Galβ1-4GlcNAcβ–Sp8 694 427
47 [6OSO3]GlcNAcβ–Sp8 2103 690
48 9-O-AcNeu5NAcα-Sp8 489 183
49 9-O-AcNeu5NAcα2-6Galβ1-4GlcNAcβ-Sp8 597 198
50 Manα1-3(Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 738 543
51 GlcNAcβ1-2Manα1-3(GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 564 147
52 Galβ1-4GlcNAcβ1-2Manα1-3(Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 2076 459
53 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Gly 1263 780
54 Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-3(Neu5Acα2-6Galβ1-4GlcNAcβ1-2Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-Sp8 1355 591
55 Fucα1-2Galβ1-3GalNAcβ1-3Galα-Sp9 636 164
56 Fucα1-2Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp9 704 246
57 Fucα1-2Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 307 178
58 Fucα1-2Galβ1-3GalNAcα–Sp8 867 661
59 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 847 273
60 Fucα1-2Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp9 1289 370
61 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp10 370 267
62 Fucα1-2Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp8 404 300
63 Fucα1-2Galβ1-3GlcNAcβ–Sp0 424 248
64 Fucα1-2Galβ1-3GlcNAcβ–Sp8 211 106
65 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 444 61
66 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 607 371
67 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 389 243
68 Fucα1-2Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 383 152
69 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAc–Sp0 450 283
70 Fucα1-2Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 546 187
71 Fucα1-2Galβ1-4GlcNAcβ–Sp0 449 332
72 Fucα1-2Galβ1-4GlcNAcβ–Sp8 339 150
73 Fucα1-2Galβ1-4Glcβ–Sp0 282 97
74 Fucα1-2Galβ–Sp8 1707 575
75 Fucα1-3GlcNAcβ-Sp8 642 633
76 Fucα1-3GlcNAcβ-Sp8 416 271
77 Fucα1-4GlcNAcβ–Sp8 397 238
78 Fucβ1-3GlcNAcβ-Sp8 814 1172
79 GalNAcα1-3(Fucα1-2)Galβ1-3GlcNAcβ-Sp0 542 346
80 GalNAcα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 443 150
81 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp0 426 164
82 GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ–Sp8 398 128
83 GalNAcα1-3(Fucα1-2)Galβ1-4Glcβ-Sp0 715 463
84 GalNAcα1-3(Fucα1-2)Galβ–Sp8 6005 14001
85 GalNAcα1-3GalNAcβ–Sp8 331 161
86 GalNAcα1-3Galβ–Sp8 695 380
87 GalNAcα1-4(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 459 142
88 GalNAcβ1-3GalNAca–Sp8 228 123
89 GalNAcβ1-3(Fucα1-2)Galβ-Sp8 4340 1928
90 GalNAcβ1-3Galα1-4Galβ1-4GlcNAcβ-Sp0 1745 475
91 GalNAcβ1-4(Fucα1-3)GlcNAcβ-Sp0 339 250
92 GalNAcβ1-4GlcNAcβ–Sp0 669 265
93 GalNAcβ1-4GlcNAcβ–Sp8 470 148
94 Galα1-2Galβ–Sp8 459 217
95 Galα1-3(Fucα1-2)Galβ1-3GlcNAcβ-Sp0 357 244
96 Galα1-3(Fucα1-2)Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 340 197
97 Galα1-3(Fucα1-2)Galβ1-4GlcNAc-Sp0 300 89
98 Galα1-3(Fucα1-2)Galβ1-4Glcβ-Sp0 331 166
99 Galα1-3(Fucα1-2)Galβ–Sp8 400 167
100 Galα1-3(Galα1-4)Galβ1-4GlcNAcβ-Sp8 4983 2540
101 Galα1-3GalNAcα-Sp8 510 66
102 Galα1-3GalNAcβ–Sp8 258 191
103 Galα1-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 413 194
104 Galα1-3Galβ1-3GlcNAcβ-Sp0 525 398
105 Galα1-3Galβ1-4GlcNAcβ–Sp8 879 175
106 Galα1-3Galβ1-4Glcβ–Sp0 363 229
107 Galα1-3Galβ–Sp8 608 342
108 Galα1-4(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 573 141
109 Galα1-4Galβ1-4GlcNAcβ–Sp0 1173 353
110 Galα1-4Galβ1-4GlcNAcβ–Sp8 1760 1164
111 Galα1-4Galβ1-4Glcβ–Sp0 1004 494
112 Galα1-4GlcNAcβ–Sp8 2245 462
113 Galα1-6Glcβ-Sp8 1012 442
114 Galβ1-2Galβ–Sp8 624 493
115 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 27645 3827
116 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 2362 413
117 Galβ1-3(Fucα1-4)GlcNAc–Sp0 11544 3156
118 Galβ1-3(Fucα1-4)GlcNAc–Sp8 25937 4145
119 Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 13755 11332
120 Galβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcα-Sp8 16480 6923
121 Galβ1-3(GlcNAcβ1-6)GalNAcα-Sp8 3983 818
122 Galβ1-3(Neu5Acα2-6)GalNAcα-Sp8 4411 2011
123 Galβ1-3(Neu5Acβ2-6)GalNAcα-Sp8 5998 3514
124 Galβ1-3(Neu5Acα2-6)GlcNAcβ1-4Galβ1-4Glcβ-Sp10 1480 342
125 Galβ1-3GalNAcα-Sp8 6720 3221
126 Galβ1-3GalNAcβ–Sp8 14254 3225
127 Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp0 27047 8778
128 Galβ1-3GalNAcβ1-4(Neu5Acα2-3)Galβ1-4Glcβ-Sp0 22770 3463
129 Galβ1-3GalNAcβ1-4Galβ1-4Glcβ–Sp8 20665 12510
130 Galβ1-3Galβ–Sp8 3457 1537
131 Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 723 310
132 Galβ1-3GlcNAcβ1-3Galβ1-4Glcβ–Sp10 1439 252
133 Galβ1-3GlcNAcβ–Sp0 1270 830
134 Galβ1-3GlcNAcβ–Sp8 1900 277
135 Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 11018 3525
136 Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 17675 2294
137 Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 10200 1390
138 Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ1-4Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 47546 5464
139 Galβ1-4[6OSO3]Glcβ–Sp0 3820 1199
140 Galβ1-4[6OSO3]Glcβ–Sp8 8256 2780
141 Galβ1-4GalNAcα1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 35253 5429
142 Galβ1-4GalNAcβ1-3(Fucα1-2)Galβ1-4GlcNAcβ-Sp8 38753 5948
143 Galβ1-4GlcNAcβ1-3(Galβ1-4GlcNAcβ1-6)GalNAcα-Sp8 1883 225
144 Galβ1-4GlcNAcβ1-3GalNAcα–Sp8 603 530
145 Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 2284 384
146 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 430 178
147 Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 2497 970
148 Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ–Sp0 933 468
149 Galβ1-4GlcNAcβ1-3Galβ1-4Glcβ–Sp8 1820 787
150 Galβ1-4GlcNAcβ1-6(Galβ1-3)GalNAcα–Sp8 7136 5663
151 Galβ1-4GlcNAcβ1-6GalNAcα–Sp8 22993 5394
152 Galβ1-4GlcNAcβ–Sp0 757 482
153 Galβ1-4GlcNAcβ–Sp8 644 396
154 Galβ1-4Glcβ–Sp0 938 557
155 Galβ1-4Glcβ–Sp8 2556 4729
156 GlcNAcα1-3Galβ1-4GlcNAcβ-Sp8 311 286
157 GlcNAcα1-6Galβ1-4GlcNAcβ-Sp8 16641 2363
158 GlcNAcβ1-2Galβ1-3GalNAcα–Sp8 230 305
159 GlcNAcβ1-3(GlcNAcβ1-6)GalNAcα–Sp8 285 237
160 GlcNAcβ1-3(GlcNAcβ1-6)Galβ1-4GlcNAcβ–Sp8 738 481
161 GlcNAcβ1-3GalNAcα–Sp8 189 143
162 GlcNAcβ1-3Galβ-Sp8 336 181
163 GlcNAcβ1-3Galβ1-3GalNAcα-Sp8 298 118
164 GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 327 157
165 GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 302 134
166 GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 551 259
167 GlcNAcβ1-3Galβ1-4Glcβ–Sp0 305 181
168 GlcNAcβ1-4MDPLys 304 175
169 GlcNAcβ1-4(GlcNAcβ1-6)GalNAcα-Sp8 203 117
170 GlcNAcβ1-4Galβ1-4GlcNAcβ-Sp8 573 510
171 (GlcNAcβ1-4)6β-Sp8 640 390
172 (GlcNAcβ1-4)5β-Sp8 997 374
173 GlcNAcβ1-4GlcNAcβ1-4GlcNAcβ–Sp8 2040 552
174 GlcNAcβ1-6(Galβ1-3)GalNAcα–Sp8 2459 2410
175 GlcNAcβ1-6GalNAcα–Sp8 2300 761
176 GlcNAcβ1-6Galβ1-4GlcNAcβ-Sp8 941 272
177 Glcα1-4Glcβ–Sp8 175 92
178 Glcα1-4Glcα–Sp8 519 387
179 Glcα1-6Glcα1-6Glcβ-Sp8 549 699
180 Glcβ1-4Glcβ-Sp8 300 172
181 Glcβ1-6Glcβ-Sp8 348 286
182 Sorbitol-Sp8 564 355
183 GlcAα-Sp8 626 386
184 GlcAβ-Sp8 384 263
185 GlcAβ1-3Galβ-Sp8 614 462
186 GlcAβ1-6Galβ-Sp8 3500 2173
187 KDNα2-3Galβ1-3GlcNAcβ–Sp0 340 296
188 KDNα2-3Galβ1-4GlcNAcβ–Sp0 451 215
189 Manα1-2Manα1-2Manα1-3Manα-Sp9 524 94
190 Manα1-2Manα1-3(Manα1-2Manα1-6)Manα-Sp9 295 56
191 Manα1-2Manα1-3Manα-Sp9 456 288
192 Manα1-6(Manα1-2Manα1-3)Manα1-6(Manα2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 298 188
193 Manα1-2Manα1-6(Manα1-3)Manα1-6(Manα2Manα2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 432 269
194 Manα1-2Manα1-2Manα1-3(Manα1-2Manα1-3(Manα1-2Manα1-6)Manα1-6)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 381 400
195 Manα1-3(Manα1-6)Manα–Sp9 503 311
196 Manα1-3(Manα1-2Manα1-2Manα1-6)Manα-Sp9 481 192
197 Manα1-6(Manα1-3)Manα1-6(Manα2Manα1-3)Manβ1-4GlcNAcβ1-4GlcNAcβ-N 466 133
198 Manα1-6(Manα1-3)Manα1-6(Manα1-3)Manβ1-4GlcNAcβ1-4 GlcNAcβ-N 894 742
199 Man5_9mix N 634 414
200 Manβ1-4GlcNAcβ-Sp0 288 222
201 Neu5Acα2-3(Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ-Sp0 29741 6517
202 Neu5Acα2-3Galβ1-3GalNAcα-Sp8 457 277
203 NeuAcα2-8NeuAcα2-8NeuAcα2-8NeuAcα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 846 402
204 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ-Sp0 1292 512
205 Neu5Acα2-8Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ–Sp0 454 262
206 Neu5Acα2-8Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ–Sp0 3261 4473
207 Neu5Acα2-8Neu5Acα2-8Neu5Acα-Sp8 222 126
208 Neu5Acα2-3(6-O-Su)Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 479 384
209 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp0 612 270
210 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4GlcNAcβ-Sp8 404 156
211 Neu5Acα2-3(GalNAcβ1-4)Galβ1-4Glcβ–Sp0 757 272
212 NeuAcα2-3(NeuAcα2-3Galβ1-3GalNAcβ1-4)Galβ1-4Glcβ-Sp0 412 141
213 Neu5Acα2-3(Neu5Acα2-6)GalNAcα–Sp8 419 222
214 Neu5Acα2-3GalNAcα–Sp8 481 281
215 Neu5Acα2-3GalNAcβ1-4GlcNAcβ-Sp0 510 469
216 Neu5Acα2-3Galβ1-3(6OSO3)GlcNAc-Sp8 464 601
217 Neu5Acα2-3Galβ1-3(Fucα1-4)GlcNAcβ–Sp8 450 428
218 NeuAcα2-3Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ Sp0 725 305
219 Neu5Acα2-3Galβ1-3(Neu5Acα2-3Galβ1-4)GlcNAcβ-Sp8 507 221
220 Neu5Acα2-3Galβ1-3[6OSO3]GalNAcα-Sp8 1075 736
221 Neu5Acα2-3Galβ1-3(Neu5Acα2-6)GalNAcα–Sp8 444 215
222 Neu5Acα2-3Galβ-Sp8 797 501
223 NeuAcα2-3Galβ1-3GalNAcβ1-3Galα1-4Galβ1-4Glcβ-Sp0 411 371
224 NeuAcα2-3Galβ1-3GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 529 220
225 Neu5Acα2-3Galβ1-3GlcNAcβ–Sp0 406 239
226 Neu5Acα2-3Galβ1-3GlcNAcβ–Sp8 344 147
227 Neu5Acα2-3Galβ1-4[6OSO3]GlcNAcβ-Sp8 828 630
228 Neu5Acα2-3Galβ1-4(Fucα1-3)(6OSO3) GlcNAcβ –Sp8 1394 329
229 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3) GlcNAcβ–Sp0 790 425
230 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp0 713 520
231 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ–Sp8 456 280
232 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ-Sp8 380 271
233 Neu5Acα2-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp8 1446 269
234 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAc-Sp0 519 291
235 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ–Sp0 966 329
236 Neu5Acα2-3Galβ1-4GlcNAcβ–Sp0 428 430
237 Neu5Acα2-3Galβ1-4GlcNAcβ–Sp8 606 458
238 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 620 734
239 Neu5Acα2-3Galβ1-4Glcβ–Sp0 715 553
240 Neu5Acα2-3Galβ1-4Glcβ–Sp8 270 167
241 Neu5Acα2-6(Galβ1-3)GalNAcα–Sp8 4542 2836
242 Neu5Acα2-6GalNAcα–Sp8 545 601
243 Neu5Acα2-6GalNAcβ1-4GlcNAcβ-Sp0 388 90
244 Neu5Acα2-6Galβ1-4[6OSO3]GlcNAcβ-Sp8 2798 1633
245 Neu5Acα2-6Galβ1-4GlcNAcβ–Sp0 385 289
246 Neu5Acα2-6Galβ1-4GlcNAcβ–Sp8 353 157
247 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 951 349
248 Neu5Acα2-6Galβ1-4GlcNAcβ1-3Galβ1-4GlcNAcβ-Sp0 785 442
249 Neu5Acα2-6Galβ1-4Glcβ–Sp0 601 192
250 Neu5Acα2-6Galβ1-4Glcβ–Sp8 450 352
251 Neu5Acα2-6Galβ–Sp8 1147 365
252 Neu5Acα2-8Neu5Acα-Sp8 615 610
253 Neu5Acα2-8Neu5Acα2-3Galβ1-4Glcβ–Sp0 945 529
254 Neu5Acβ2-6GalNAcα–Sp8 203 212
255 Neu5Acβ2-6Galβ1-4GlcNAcβ-Sp8 483 236
256 Neu5Acβ2-6(Galβ1-3)GalNAcα–Sp8 2480 2916
257 Neu5Gcα2-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 437 335
258 Neu5Gcα2-3Galβ1-3GlcNAcβ-Sp0 714 206
259 Neu5Gcα2-3Galβ1-4(Fucα1-3)GlcNAcβ-Sp0 880 582
260 Neu5Gcα2-3Galβ1-4GlcNAcβ–Sp0 647 212
261 Neu5Gcα2-3Galβ1-4Glcβ–Sp0 712 253
262 Neu5Gcα2-6GalNAcα–Sp0 365 116
263 Neu5Gcα2-6Galβ1-4GlcNAcβ–Sp0 748 200
264 Neu5Gcα–Sp8 243 237
265 [3OSO3]Galβ1-4(Fucα1-3)(6OSO3)Glc-Sp0 1598 452
266 [3OSO3]Galβ1-4(Fucα1-3)Glc-Sp0 514 260
267 [3OSO3]Galβ1-4[Fucα1-3][6OSO3]GlcNAc-Sp8 1995 366
268 [3OSO3]Galβ1-4[Fucα1-3]GlcNAc-Sp0 394 303
269 Fucα1-2[6OSO3]Galβ1-4GlcNAc-Sp0 1381 985
270 Fucα1-2Galβ1-4[6OSO3]GlcNAc-Sp8 1305 1220
271 Fucα1-2[6OSO3]Galβ1-4[6OSO3]Glc-Sp0 2156 1083
272 Fucα1-2-(6OSO3)-Galβ1-4Glc-Sp0 1701 2480
273 Fucα1-2-Galβ1-4[6OSO3]Glc-Sp0 1359 559
274 Galβ1-3(Fucα1-4)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 4469 2914
275 Galβ1-3-(Galβ1-4GlcNacβ1-6)GalNAc-T 12027 8153
276 Galβ1-3(GlcNacβ1-6)GalNAc-T 8636 2146
277 Galβ1-3-(Neu5Aα2-3Galβ1-4GlcNacβ1-6)GalNAc-T 3835 1833
278 Galβ1-3GalNAc-T 10274 5772
279 Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 160 91
280 Galβ1-4[Fucα1-3][6OSO3]GlcNAc-Sp0 3319 3394
281 Galβ1-4[Fucα1-3][6OSO3]Glc-Sp0 2356 1641
282 Galβ1-4(Fucα1-3)GlcNAcβ1-3Galβ1-3(Fucα1-4)GlcNAcβ-Sp0 2981 1602
283 Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0 373 213
284 Neu5Acα2-3Galβ1-3GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0       472 201
285 Neu5Acα2-3Galβ1-4GlcNAcβ1-3Galβ1-3GlcNAcβ-Sp0          437 293
Supplementary Table II. MALDI TOF/TOF mass spectrometry of tryptic fragments of MCF7 cell 
glycoproteins purified on GalMBP.  
 
 
 
Band 
Number 
 
SwissProt 
Accession 
number 
 
 
Protein name 
 
Precursor 
mass 
 
Protein 
score 
 
Peptides 
matched 
 
Sequence 
Coverage 
(%) 
1 P19999 Mannose-binding protein A (precursor) 25292 63 9 34 
2 Q01650 
Large neutral amino 
acids transporter small 
subunit 1 (CD98lc) 
54974 111 7 17 
3 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 375 23 47 
4 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 349 22 43 
5 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 204 19 37 
6 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 190 18 38 
7 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 89 14 25 
8 P08195 4F2 cell-surface antigen heavy chain (CD98hc) 57909 58 9 17 
 
Supplementary Table III. Glycoprotein ligands identified by proteomic analysis. 
  
Cell line Accession number Protein Peptides matched 
Total Ion 
Score 
     
MCF7 4F2_HUMAN CD98 heavy chain (CD98hc) 18 1077 
 LAT1_HUMAN CD98 light chain (LAT1) 4 253 
 CD166_HUMAN Activated leukocyte adhesion molecule (ALCAM) 4 188 
     
SKBR3 SUSD2_HUMAN Sushi domain-containing protein 2 6 335 
 AAAT_HUMAN Neutral amino acid transporter B(0) 4 232 
 LG3BP_HUMAN Galectin-3-binding protein precursor (LG3BP) 4 171 
 GTR1_HUMAN Solute carrier family 2, facilitated glucose 
transporter member 1 (GLUT1) 
3 157 
 SC5A6_HUMAN Sodium-dependent multivitamin transporter 3 155 
 4F2_HUMAN CD98 heavy chain (CD98hc) 3 154 
 AT1A1_HUMAN Na/K-transporting ATPase subunit alpha-1 3 130 
     
ZR75-1 LAMP1_HUMAN Lysosome-associated membrane protein-1 
(LAMP1) 
6 293 
 ADT2_HUMAN ADP/ATP translocase 2 5 238 
 ANO1_HUMAN Anoctamin-1 5 180 
 LAMP2_HUMAN Lysosome-associated membrane protein-2 
(LAMP2) 
3 175 
 AT1A1_HUMAN Na/K-transporting ATPase subunit alpha-1 3 142 
 CD166_HUMAN Activated leukocyte adhesion molecule (ALCAM) 3 118 
     
T47D MUC1_HUMAN MUC1 6 438 
 LAMP1_HUMAN Lysosome-associated membrane protein-1 
(LAMP1) 
6 369 
 LCAP_HUMAN Leucyl-cystinyl aminopeptidase 4 269 
 4F2_HUMAN CD98 heavy chain (CD98hc) 5 261 
 LAMP2_HUMAN Lysosome-associated membrane protein-2 
(LAMP2) 
3 168 
 CBPD_HUMAN Carboxypeptidase D precursor 3 149 
 FPRP_HUMAN Prostaglandin F2 receptor negative regulator 
precursor 
3 141 
 
